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O.01: THE FIRST INVESTIGATOR-INITIATED MULTICENTER 
RANDOMIZED PHASE III TRIAL IN BRAZIL: SINGLE AGENT 
PEMETREXED (P) VS. CARBOPLATIN AND PEMETREXED (CP) IN 
PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER 
(NSCLC) AND PERFORMANCE STATUS (PS) OF 2
Carlos Gil M. Ferreira, C. Barrios, Jr Pereira, R. Ribeiro,  
C. Beato, Y. Neron, A. Murad, F. Franke, Lh De Lima Araujo,  
Cs Baldotto, Fm Alencar, P. Trovatti, M. Precivale, Ia Small,  
M. Zukin, R. Lilenbaum  
Coordenação De Pesquisa Clínica E Incorporação Tecnológica, Instituto 
Nacional De Câncer, Rio De Janeiro/BRAZIL
Background: Despite strong participation in international 
industry-sponsored trials, most Latin American countries have 
no established mechanism to conduct investigator-initiated 
multicenter clinical trials in cancer. We report the first such trial 
in Brazil.
Methods: A collaboration of 8 selected research sites was 
organized under the auspices of INCA (Brazilian National 
Cancer Institute), which served as the coordinating center. 
One site in the US was also included. Partial support from the 
pharmaceutical company, Eli Lilly, and funds from INCA and 
Fundação do Câncer were used to oversee the conduct of the 
trial and monitor the sites. Patients with advanced NSCLC, PS 
2, and no prior chemotherapy were randomized to P alone (500 
mg/m2) or CP (AUC 5 + same P) administered every 3 weeks for 
4 cycles. The primary endpoint was overall survival (OS). The 
statistical analysis was independently performed and supported 
by INCA.
Results and Conclusion: Results: The protocol was developed 
between 2005 and 2006 and approved by the Brazilian 
regulatory agencies in 2007. A total of 217 patients were 
enrolled from April 2008 to July 2011. Twelve patients were 
ineligible and excluded. Enrollment was uneven among the 
sites, with about 60% of patients enrolled at INCA. There was 
significant improvement in survival for patients treated with 
the combination compared to single agent (median OS 9.1 
months vs. 5.6 months (HR=0.57, 95% CI 0.41; 0.79, p=0.001). 
Conclusions: Combination chemotherapy significantly improves 
survival and represents a new standard in patients with 
advanced NSCLC and PS 2. This trial demonstrates the feasibility 
of an independent mechanism to conduct cancer trials in Latin 
America and represents a paradigm shift for clinical research 
in the region. This experience was the basis for the Brazilian 
Network for Cancer Clinical Research, launched in 2010 by INCA 
and the Ministry of Health. 
Disclosure: No significant relationships.
ORAL SESSION - July 26, 2012 08:00 – 09:15
O.02: LUX-LUNG 3: A RANDOMIZED, OPEN-LABEL, PHASE 
III STUDY OF AFATINIB VS. PEMETREXED AND CISPLATIN AS 
FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED 
ADENOCARCINOMA OF THE LUNG HARBORING EGFR 
ACTIVATING MUTATIONS
Ken O’Byrne1, Martin Schuler2, Nobuyuki Yamamoto3, Vera 
Hirsh4, Tony Mok5, Dan Massey6, Victoria Zazulina7, Mehdi 
Shahidi7, Lecia Sequist8, James Yang9  
1St. James’ Hospital, Dublin, Ireland, Dublin/IRELAND, 2West German 
Cancer Center, University Duisburg-Essen, /GERMANY, 3Shizuoka Cancer 
Center/JAPAN, 4Mcgill University/CANADA, 5Prince Of Wales Hospital/HONG 
KONG, 6Boehringer Ingelheim Limited/UNITED KINGDOM, 7Boehringer 
Ingelheim Limited/UNITED KINGDOM, 8Massachusetts General Hospital/
UNITED STATES OF AMERICA, 9National Taiwan University Hospital/TAIWAN
Background: Afatinib is a novel, selective, orally bioavailable, 
ErbB Family Blocker, irreversibly blocking EGFR (ErbB1), HER2 
(ErbB2) and HER4 (ErbB4). In a Phase II, single-arm study 
(LUX-Lung 2), progression-free survival (PFS) was 13.7 months 
and the response rate was 66% in afatinib-treated, lung 
adenocarcinoma patients with EGFR exon 19 deletion and 
L858R mutations. In this study, the efficacy and safety of 
afatinib compared with pemetrexed and cisplatin as first-line 
treatment in patients with advanced adenocarcinoma of the 
lung harboring an EGFR activating mutation was investigated. 
This is the first study comparing EGFR mutation directed 
therapy to pemetrexed and cisplatin.
Methods: This was an open-label, randomized, global, 
Phase III trial with an accrual target of 330 patients, enrolling 
chemotherapy-naïve adult patients with pathologically 
confirmed Stage IIIB/IV lung adenocarcinoma and EGFR 
activating mutations (detected by central analysis; therascreen 
EGFR RGQ PCR Kit), and an ECOG performance status of 0 or 
1. Patients were randomized (2:1) to receive daily, continuous, 
oral afatinib 40 mg, until progression or unacceptable adverse 
events, or intravenous pemetrexed 500 mg/m2 and cisplatin 75 
mg/m2 on Day 1 of each 21-day cycle for up to 6 cycles. Patients 
were prospectively stratified according to EGFR mutation 
(L858R vs. EGFR exon 19 deletion vs. other) and ethnicity (Asian 
vs. other). The primary endpoint was PFS, evaluated by RECIST 
1.1 (independent review and investigator assessment). Response 
was assessed every 6 weeks until Week 48, then every 12 
weeks. A stratified log-rank test will be used to compare the 
PFS of afatinib and chemotherapy. Secondary endpoints include 
objective response rate, disease control rate, overall survival 
and safety.
Results and Conclusion: The trial has completed accrual and 
analysis of the primary endpoint (PFS) is expected during the 
first quarter of 2012.
Disclosure: Ken O’Byrne: Compensated consultant for 
Boehringer Ingelheim, Lilly Oncology, compensated honoraria 
for Boehringer Ingelheim, Lilly Oncology, Research Funding as 
an investigator for this study, LUX-Lung 3 1200.32 study. Other 
remuneration for myself Ke
ORAL SESSION - July 26, 2012 08:00 – 09:15
O.03: NON INVASIVE NSCLC DIAGNOSIS: MULTIPLE MARKER 
DETECTION IN PERIPHERAL BLOOD
Paola Ulivi1, Laura Mercatali1, Gian Luca Casoni2, Emanuela 
Scarpi3, Lauro Bucchi4, Rosella Silvestrini1, Stefano Sanna2, Marco 
Monteverde2, Wainer Zoli1, Venerino Poletti2, Dino Amadori5  
1Biosciences Laboratory, I.R.S.T., Meldola/ITALY, 2Thoracic Diseases, 
Morgagni-Pierantoni Hospital, Forlì/ITALY, 3Biostatistics And Clinical Trials, 
I.R.S.T., Meldola/ITALY, 4Romagna Cancer Registry, I.R.S.T., Meldola/ITALY, 
5Medical Oncology, I.R.S.T., Meldola/ITALY
Background: Non-invasive early detection of lung cancer 
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would help to reduce the number of patients diagnosed with 
advanced disease, which is associated with a grim prognosis. 
The availability of a non-invasive test, performed on peripheral 
blood, capable of discriminating between subjects with or 
without lung cancer, in theory could have two potential 
uses: 1) could be used as a preliminary screening method to 
select individuals at high risk of NSCLC, warranting further 
investigation with spiral CT; 2) it might help to discriminate 
between non-neoplastic disease and malignancies in subjects 
with suspect nodules detected by CT scans, thereby eliminating 
the need for serial CTs or invasive biopsy. We analyzed the 
diagnostic accuracy of a panel of peripheral blood markers in 
detecting non small cell lung cancer (NSCLC). 
Methods: 100 healthy donors and 100 patients with NSCLC 
were enrolled onto this study. Free circulating DNA was 
determined in serum and mRNA expression of peptidylarginine 
deiminase type 4 (PAD4/PADI4), pro-platelet basic protein 
(PPBP) and haptoglobin was evaluated in peripheral blood 
using a Real-Time PCR-based method. The most efficient cut 
off values to discriminate between healthy donors and cancer 
patients were identified using receiver operating characteristic 
(ROC) curve analysis. All P values were based on two-sided 
testing and statistical analyses were carried out using SAS 
Statistical software version 9.1 (SAS Institute) 
Results and Conclusion: Free circulating DNA, PADI4, PPBP and 
haptoglobin levels were all significantly higher in NSCLC patients 
than in healthy donors (P<0.0001, P<0.0001, P=0.0002 and 
P=0.0001, respectively). The fitted logistic regression model 
demonstrated a significant direct association between marker 
expression and lung cancer risk. The odds ratios of individual 
markers were 6.93 (95% CI 4.15-11.58; P<0.0001) for free DNA, 
6.99 (95% CI 3.75-13.03; P<0.0001) for PADI4, 2.85 (95% 
CI 1.71-4.75; P<0.0001) for PPBP and 1.16 (95% CI 1.01-1.33; 
P=0.031) for haptoglobin. Combined analysis revealed that free 
DNA in combination with PPBP and PADI4 gave an area under 
the ROC curve of 0.932, 95% CI = 0.896-0.967, with sensitivity 
and specificity over 90%. Free circulating DNA analysis 
combined with PPBP and PADI4 expression determinations 
would appear to accurately discriminate between healthy 
donors and NSCLC patients. This non-invasive multi marker 
approach warrants further studies to assess its potential role in 
the diagnostic or screening workup of patients with suspected 
lung cancer. 
Disclosure: No significant relationships.
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O.04: ROLE OF STEREOTACTIC ABLATIVE RADIOTHERAPY 
(SABR) IN STAGE I NSCLC
Ben Slotman, Frank Lagerwaard, Niels Haasbeek, Naomi 
Verstegen, Max Dahele, Suresh Senan  
Radiation Oncology, VU University Medical Center, Amsterdam/
NETHERLANDS
Background: SABR has a definite role in the treatment of 
inoperable patients with NSCLC and it might become an 
alternative for surgery in operable patients. Based on our 
experience with stereotactic ablative radiotherapy (SABR) for 
early NSCLC in >900 treated patients, the prognostic factors 
will be discussed. 
Methods: Between 2003 and 2009, 676 Stage I NSCLC patients 
were treated at VU University medical center. Patients treated 
for double or recurrent tumors were excluded from this analysis. 
Evaluations before and regularly after SABR included CT-scans 
and QoL evaluation. There were 378 T1N0 (56%) and 298 T2N0 
(44%) tumors. The mean age was 74 years (range 41-91). All 
except four patients underwent 18FDG-PET staging; 496 (73%) 
of patients were medically inoperable and 180 (27%) refused 
surgery or had a preference for SBRT. Pathological confirmation 
of malignancy was obtained in 245 patients (36%). All others 
had new and/or growing FDG-PET-positive lesions and CT-
characteristics of malignancy. In the Dutch population, the risk 
of malignancy is more than 90% in these patients. The following 
risk-adapted SABR schemes were used: 3x20 Gy (n=246; 36%) 
for T1 tumors, 5x12 Gy (n=288; 43%) for T1 tumors adjacent 
to the thoracic wall/mediastinum or T2 tumors, and 8x7.5 Gy 
(n=142; 21%) for lesions adjacent to the pericardium, hilus or 
brachial plexus. After the introduction of volumetric modulated 
arc therapy (RapidArc,) which uses a more modern treatment 
planning algorithm, for SABR, doses were modified to 3x18 Gy, 
5x11 and 8x7.5 Gy, respectively.
Results and Conclusion: Median survival was 37 months. 
5-year survival was 27%. Local failure was seen in 29 patients), 
with an actuarial local failure-free survival rate of 91% at 3 
years. The actuarial regional-free survival rate at 3 years was 
91% and the actuarial distant failure free survival rate at 3 years 
was 83 %. Acute and late toxicity was limited with few patients 
experiencing grade 3 or higher toxicity. Chest wall pain was 
seen in 4% of patients, and rib fractures and pneumonitis each 
in 2%. There was no significant difference in tumor control 
and survival between patients with and without pathologically 
proven disease. In a subgroup analysis of 177 potentially 
operable patients treated with SABR, we found a 2-years 
survival of 88% and a median survival of 62 months. These 
results support ongoing randomized trials comparing surgery 
and SABR in these patients. In the absence of clinical trials, 
we recently published the results of a population based study, 
demonstrating that the introduction of SABR resulted in a 16% 
absolute increase in the use of radiotherapy in elderly patients 
in the Netherlands that this resulted in improved survival. 
Disclosure: Speaker honorarium Varian medical systems
ORAL SESSION - July 26, 2012 08:00 – 09:15
O.05: MOLECULAR EVENTS IN LUNG SQUAMOUS CELL 
CARCINOMAS ASSOCIATED WITH ARSENIC EXPOSURE
Daiana D. Becker-Santos, Roland Hubaux, Emily A. Vucic, 
Stephen Lam, Wan Lam, Victor D. Martinez  
Integrative Oncology, British Columbia Cancer Research Centre, Vancouver/
CANADA
Background: Naturally occurring arsenic contaminated water 
is a global threat, currently affecting ~100 million people. If 
arsenic-related health effects occur at levels below the currently 
considered safe threshold (10µg/L), this number rises to several 
hundred million worldwide. Both genetic and epigenetic 
changes drive arsenic-induced carcinogenesis and lung 
cancer (LC) is one of the main consequences of this process. 
Interestingly, lung squamous cell carcinomas (SqCC) occur at 
higher rates than other subtypes following exposure, even in 
never smokers. Here, we have analyzed a panel of lung tumors 
from a population with chronic arsenic exposure (including a 
rare set of lung SqCC from never smokers) to identify whole 
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genome arsenic associated copy-number alterations (CNAs), 
copy-number variations (CNVs) and DNA methylation changes. 
Also, we have studied changes bronchial epithelial cell lines 
exposed to different arsenic metabolites, in order to elucidate 
key genomic and epigenomic changes.
Methods: Arsenic-exposed lung SqCC cases were investigated 
by whole-genome tiling path comparative genomic 
hybridization for CNAs. Additionally, non-exposed cases 
were also analyzed as controls. In addition, blood samples 
from arsenic-exposed individuals from Northern Chile (with 
no cancer diagnosed) were examined to identify naturally 
occurring germline CNVs. DNA methylation analyses for 
independent arsenic-exposed cases from never smokers were 
also performed. Human bronchial epithelial cell lines exposed to 
different arsenic compounds (non-methylated and methylated 
species) were used in order to evaluate functional genetic and 
epigenetic changes.
Results and Conclusion: We identified arsenic related changes 
occurring in lung SqCC, both at genetic and epigenetic level. 
The most recurrent events were represented by DNA losses at 
chromosomes 1q21.1, 7p22.3, 9q12, and 19q13.31. Intriguingly, 
we observed a single arsenic-associated DNA gain at 19q13.33, 
which encompasses genes related to key functions for 
oncogenic transformation, such as DNA repair. Additionally, 
distinctive DNA methylation patterns were associated to arsenic 
related lung SqCC, indicating these changes can have an impact 
on carcinogenic mechanisms for this subgroup of lung tumors.
Our study provides insights into the molecular pathways 
involved in arsenic-promoted malignant transformation in 
lungs. Findings specifically associated to lung SqCC cases 
among never smokers contribute to understand key events 
distinguishing this rare subgroup of lung cancer. Elucidation of 
mechanisms underlying the initiation and promotion of arsenic-
driven lung carcinogenesis will be paramount for the design 
more effective and rationale-based strategies for prevention, 
monitoring and/or treatment of different types of cancer caused 
by this metalloid. 
Disclosure: No significant relationships.
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MO.01: ASSOCIATION OF CYP1A1, NAT2, GSTT1 GENE 
POLYMORPHISM WITH LUNG CANCER PATIENTS IN 
NORTHERN INDIA POPULATION
Rajni K. Shukla1, Surya Kant1, Sandeep Bhattacharya2,  
Balraj Mittal3  
1Pulmonary Medicine, Csmmedical University, (Erstwhile King George’s 
Medical College), Lucknow/INDIA, 2Physiology, Csmmedical University/
INDIA, 3Genetics, Sanjay Gandhi Post Graduate Institute Of Medical 
Sciences, Lucknow/INDIA
Background: Lung cancer poses a major threat to human 
survival and health; both the incidence and death rate of lung 
cancer are in the first place among cancers worldwide. The 
rapid development of medical technology greatly improved 
health care quality, however, the recent situation in the 
diagnosis and treatment of lung cancer is far beyond what we 
have expected. Other previous studies have shown that lung 
cancer is affected comprehensively by smoking, environment 
pollution, individual genetic factors and so on. Xenobiotic 
metabolic enzyme genes, whose genetic polymorphism are 
considered to be predisposition factors to lung cancer. Thus, in 
our study, we look association of GSTT1, GSTM1, CYP1A1, and 
NAT2 gene polymorphism with the northern India lung cancer 
patients.
Methods: This is case control study; we were included 218 
histological confirmed lung cancer patients and 238 control 
subjects. The lung cancer patients were recruited from Dept 
of Pulmonary Medicine, C.S.M.Medical University, (Erstwhile 
King Geroge’s Medical College), INDIA. We applied the PCR & 
RFLP to explore the genetic polymorphism of the CYP1A1, NAT2 
gene, and GSTT1 genetic polymorphism. The logistic regression 
analysis was carried out to estimate the association between 
genetic polymorphisms of these gene and lung cancer risk 
which was manifested by Odds Ratio (OR) and 95% confidential 
interval (95%CI)
Results and Conclusion: Results: The frequency of homozygous 
GSTT1 null was found to be significantly higher in Lung 
cancer patients as compared with healthy controls (OR=1.95; 
95%CI=1.18-3.21; P=0.009), but there were no significant 
differences in the distribution of genotypes polymorphisms 
of GSTT1 and CYP1A1 msp1 between lung cancer patients 
and healthy controls. GSTT1 null genotype were significant 
associated with the smoker lung cancer patients, with odds 
ratio [OR] = 1.76; 95% confidence interval [CI] = 1.17-2.66; p= 
0.007.But NAT2 fast acetylator genotype frequency of slow or 
fast acetylator genotypes was not significant in lung cancer 
patients alone (OR = 1.18, 95% CI: 0.69 - 2.03, p value = 
0.583).in non-smoker (OR = 1.06, 95% CI: 0.43 - 2.64, p value 
= 0.899) and smoker (OR = 1.32, 95% CI: 0.59 - 2.93, p value = 
0.494) when compared with controls.
Conclusion: Our study suggested null polymorphisms of the 
GSTT1 is associated with of the northern Indian lung cancer 
patients, but other polymorphism demonstrate that the CYP1A1 
and NAT2 fast or slow acetylators genotype did not associated 
with the risk of developing lung cancer in North Indian 
population when compared with controls.
Disclosure: No significant relationships.
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MO.02: CLINICAL AND PATHOLOGICAL CHARACTERISTICS, 
OUTCOME AND MUTATIONAL PROFILES REGARDING NON-
SMALL CELL LUNG CANCER RELATED TO WOOD-SMOKE 
EXPOSURE
Oscar Arrieta1, Alma Delia Campos-Parra2, Carlos Zuloaga1, 
Alejandro Avilés1, Roberto Sánchez-Reyes1, María Eugenia 
Vázquez Manríquez3, Emilia Covián-Molina1, Luis Martínez-
Barrera3, Abelardo Meneses4, Andrés Cardona5, José R Borbolla-
Escoboza6  
1Clinica De De Oncología Torácica Y Laboratorio De Oncología 
Experimental, Instituto Nacional De Cancerología/MEXICO, 2Clinica De De 
Oncología Torácica Y Laboratorio De Oncología Experimental, Instituto 
Nacional De Cancerología, México, Df/MEXICO, 3Instituto Nacional 
De Enfermedades Respiratorias, México Df/MEXICO, 4Laboratorio De 
Medicina Translacional, Insituto Nacional De Cancerología, México Df/
MEXICO, 5Clinical And Traslational Oncology Group, Institute Of Oncology, 
Fundación Santa Fe De Bogotá/COLOMBIA, 6Boehringer Ingelheim, México 
Df/MEXICO
Background: Although smoking is the major risk factor for non-
small cell lung cancer (NSCLC), other factors are also associated 
with lung carcinogenesis such as wood-smoke exposure (WSE). 
This article has been aimed at suggesting that lung cancer 
related to cigarette-smoking and WSE-related lung cancer has 
different clinical and genetic characteristics. 
Methods: A cohort of 914 lung cancer patients was 
prospectively studied; they had been treated at Mexico’s 
National Cancer Institute between 2007 and 2010. WSE and 
cigarette-smoking association with clinical characteristics, 
mutation profile, response to chemotherapy and EGFR-TKIs 
was analyzed, as well as overall survival (OS) rate. The trial was 
registered with ClinicalTrials.gov: NCT01023828. 
Results and Conclusion: Results — 95.1% of the lung cancer 
patients studied were classified as coming within the NSCLC 
histology subtype; 58% of the patients smoked cigarettes, 35% 
had a background of WSE (exposure to both cigarette smoke 
and wood smoke was documented in 12.1% of all patients) 
and 19.4% patients had no smoke exposure background. WSE 
was associated with NSCLC and adenocarcinoma histology 
and was more frequently associated with EGFR- mutations 
than cigarette-smoking (50.0% cf 19.4%), whereas KRAS 
mutations were less common in WSE patients (6.7%) than in 
smokers (21%). WSE patients had a higher EGFR-TKI response 
rate (RR) (39.7%) than smokers (18.8%). The NSCLC patient 
WSE group’s OS was longer (22.7 months) than that for smokers 
(13.8 months). Conclusion — NSCLC patients who smoked 
tobacco/cigarettes differed from those having a background of 
WSE regarding tumor histology, mutation profile, RR and OS, 
indicating that different carcinogenic mechanisms were induced 
by these two types of smoke exposure. 
Disclosure: No significant relationships.
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MO.03: PHASE II TRIAL OF THE AKT INHIBITOR MK-2206 PLUS 
ERLOTINIB (ERL) IN PATIENTS (PTS) WITH ADVANCED NON-
SMALL CELL LUNG CANCER (NSCLC) WHO HAVE PROGRESSED 
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AFTER PRIOR BENEFIT (RESPONSE OR STABLE DISEASE) 
FROM ERL: INTERIM RESULTS FROM PHII-108 (NCI 8698), A 
CALIFORNIA CANCER CONSORTIUM TRIAL 
Primo Lara1, Jeffrey Longmate2, Philip C. Mack3, Karen Kelly3, 
Tianhong Li3, Mariana Koczywas2, Karen Reckamp2, David 
Gandara3  
1UC Davis Comprehensive Cancer Center, Sacramento/UNITED STATES 
OF AMERICA, 2City Of Hope/UNITED STATES OF AMERICA, 3UC Davis 
Comprehensive Cancer Center/UNITED STATES OF AMERICA
Background: Although EGFR tyrosine kinase inhibitors such 
as ERL are active in NSCLC, notably in tumors with EGFR 
activating mutations, resistance is universal and uniformly 
fatal. New agents that modulate ERL resistance are thus 
needed. Preclinical modeling in NSCLC lines demonstrated 
that in ERL-sensitive cells, stimulation with HGF (the ligand for 
cMET) reverses cytotoxic & cytostatic effects of ERL. Inhibitors 
targeting AKT also mitigated HGF-mediated resistance, partially 
restoring ERL activity. Elevated HGF plasma levels were seen in 
pts who progressed on ERL, suggesting that HGF contributes to 
ERL resistance in WT-EGFR tumors. MK-2206 is a novel, highly 
selective allosteric inhibitor of AKT. We developed a phase II 
trial of MK-2206 plus ERL in pts with advanced NSCLC who have 
progressed after previous benefit from ERL, stratified by EGFR 
mutation status. Here we present interim results of this ongoing 
trial. 
Methods: Eligible pts must have progressive disease (PD) 
following prior response (or stable disease, SD) to ERL for at 
least 12 weeks prior to PD. Treatment: ERL 150 mg QD + MK-
2206 45 mg po QOD. Cycle length is 28 days. Pts are stratified 
into 2 groups: (1) presence of an EGFR activating mutation; and 
(2) EGFR wild-type. Primary endpoints: Response rate >30% 
(stratum 1) and disease control rate at 12 weeks (stratum 2). 
Accrual was by a 2-stage design. In stratum 1, if at least 2 of the 
first 21 pts have a response, the study accrues to a final sample 
size of 41. In stratum 2, if 2 or more have disease control at 12 
weeks, the study continues to 41 pts. 
Results and Conclusion: As of 3/27/12, 42 pts have been 
accrued. Pt characteristics: median age (range) – 63 years 
(44-86); Sex – 11M/31F; KPS 90-100% - 28 pts; Presence of 
activating EGFR mutation: 24 (57%); Median number of cycles 
- 3 (range, 0-14). In stratum 1, four of 24 pts (17%) had a partial 
response, 7 (29%) had SD, 8 (33%) had PD, while 5 (21%) 
are not yet assessable. The first stage of accrual continues in 
stratum 2. Of 16 pts in this stratum, none had PR, four (25%) 
had SD, 7 (44%) had PD, and 5 not yet assessable. Treatment 
thus far has been tolerable with no grade 4 toxicities. Most 
common grade 3 toxicities are fatigue, decreased lymphocytes, 
and rash. Only one on-study death was seen; this was due 
to PD. Conclusions: To date, MK2206 plus ERL is feasible and 
active in ERL pre-treated NSCLC, with responses seen in the 
EGFR mutated stratum. Accrual is continuing in both strata. 
Updated results will be presented. 
Disclosure: No significant relationships.
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MO.04: IRINOTECAN COMPARED TO ETOPOSIDE IN 
COMBINATION WITH PLATINUM ANALOG IN EXTENSIVE 
DISEASE SMALL CELL LUNG CANCER: SYSTEMATIC REVIEW AND 
META-ANALYSIS WITH GEOGRAPHIC ORIGIN SUB-ANALYSIS
João Paulo D.S.N. Lima, Lucas V. Dos Santos, Emma C. Sasse, 
André D. Sasse  
Oncologia Clínica, Hospital De Câncer De Barretos, Barretos/BRAZIL
Background: Superiority of irinotecan regimens over etoposide 
- both combined with platinum analogs - in extensive disease 
small cell lung cancer (ED-SCLC) has been extensively debated, 
with contradictory results in randomized trials worldwide. 
Ethnic and pharmacogenomical issues were hypothesized as 
major causes of these divergent findings. A systematic review 
was sought to elucidate this confounding scenario. 
Methods: Randomized controlled trials comparing first-line 
irinotecan-platinum doublets (IP) versus etoposide-platinum 
doublets (EP) in ED-SCLC patients were searched in MEDLINE, 
EMBASE, and CENTRAL databases, ESMO, ASCO, and IASLC 
meeting proceedings. Meta-analyses were performed using 
random-effects model. Subgroup analyses were undertaken 
comparing the geographical area of study and interaction test 
were used to compare subgroups. The outcomes of interest 
were overall survival (OS), Survival at one year (S1), survival at 
two years (S2), progression-free survival (PFS), and response 
rate (RR).
Results and Conclusion: Seven studies (1967 patients) 
were included. OS, S1, and S2 meta-analysis demonstrated 
superiority of IP over EP (OS HR = 0.88; 95% CI 0.80-0.95; 
P=0.002; I²=0%; table 1). PFS meta-analysis was not feasible 
due to impending heterogeneity (I²=86%), not related 
to geographical origin; RR was similar between IP and EP 
groups, absolute rates: IP 52%, EP 50%, P-value=0.31). The 
analyses according to geographical area demonstrated that 
patients around the world experienced similar benefit from IP, 
excepting for S2, where Asian and European patients derived 
larger benefits of IP (table 2). Meta-analysis Patients HR 95% 
CI P-value OS analysis 1967 0.87 [0.80 - 0.95] 0.002 1-year 
survival 1967 0.74 [0.60 – 0.91] 0.004 2-year survival 1967 
0.80 [0.66 - 0.98] 0.049 Geographic analysis Patients HR 
95% CI P-value Interaction test OS Western trials 1813 0.89 
[0.81 – 0.98] 0.02 Reference OS Japanese trial 154 0.80 [0.66 – 
0.98] 0.03 NS 2-year survival – America 933 1.05 [0.65 – 1.69] 
0.91 0.009 2-year survival – Europe 792 0.41 [0.24 – 0.69] 
0.003 Reference 2-year survival – Asia 154 0.23 [0.07 – 0.72] 
0.01 0.36 Conclusions: This meta-analysis demonstrates that 
IP improved OS for both Western and Eastern patients. The 
survival at 2 years may vary according geographical origin of 
patients. The present findings corroborate the role of ethnic 
background in cancer therapy and demand further confirmation 
in a pharmacogenomic context. 
Disclosure: No significant relationships.
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MO.05: SENSITIVITY OF EGFR EXON 20 INSERTION MUTATIONS 
TO EGFR INHIBITORS IS DETERMINED BY THEIR LOCATION 
WITHIN THE TYROSINE KINASE DOMAIN OF EGFR
Hiroyuki Yasuda, Lorena L.D. Figueiredo-Pontes, Daniel G. 
Tenen, Susumu Kobayashi, Daniel B. Costa 
Division Of Hematology/Oncology, Beth Israel Deaconess Medical Center, 
Harvard Medical School, Boston/UNITED STATES OF AMERICA
Background: Epidermal growth factor receptor (EGFR)
mutations define an important subgroup of non-small-cell lung 
cancer (NSCLC). Most patients whose tumors harbor exon 19 
deletions or L858R EGFR have responses to reversible ATP-
mimetic EGFR tyrosine kinase inhibitors (TKIs), gefitinib and 
erlotinib. Exon 20 insertion mutations comprise ~5% of EGFR 
mutations, mostly occur at the N-lobe of EGFR after its C-helix 
and nearly all NSCLCs with EGFR exon 20 insertion mutations 
display lack of responses to EGFR TKIs. 
Methods: We have compiled genotype-clinical outcomes 
of EGFR exon 20 insertion mutations NSCLCs to EGFR TKIs, 
generated a comprehensive panel of exon 20 EGFR mutation 
constructs using site-directed mutagenesis for in vitro analysis, 
compared NSCLC cell lines with EGFR mutations to a novel 
malignant pleural effusion-derived cell line (BID007), and 
defined the pattern of response to EGFR TKIs of different exon 
20 insertion mutations.
Results and Conclusion: The disease control rate of gefitinib 
or erlotinib was significantly higher in EGFR exon 20 insertion 
mutations located within the C-helix when compared to 
mutations following the C-helix (p=0.0017) and two patients 
with EGFR A763—Y764insFQEA (located within the C-helix 
of EGFR) mutated NSCLC had partial responses to erlotinib. 
Most other exon 20 insertion mutation-positive NSCLCs 
did not respond (p=0.0119). Seven representative exon 20 
insertion mutations and more common EGFR mutations 
were studied (including EGFR-delL747—P753insS, delL747—
P753insS+T790M, A763—Y764insFQEA, Y764—765insHH, 
M766—A767insAI, A767—V769dupASV, D770—N771insNPG, 
D770—N771insSVD, H773—V774insH, L858R and L858R+T790M). 
All, but A763—Y764insFQEA and the known EGFR TKI-
sensitive delL747—P753insS and L858R, were resistant to 
micromolar concentrations of erlotinib. Ba/F3 cells with 
EGFR-A763—Y764insFQEA underwent apoptosis upon exposure 
to nanomolar concentrations of erlotinib. Cell line BID007 
with EGFR-A763—Y764insFQEA was inhibited by siRNAs 
against EGFR and had phosphorylated EGFR, ERK and AKT 
inhibited by nanomolar concentrations of erlotinib whist 
undergoing apoptosis. The enzymatic kinetic behavior of A763—
Y764insFQEA, A767—V769dupASV and  
D770—N771insNPG is being studied and will be compared to 
wild-type EGFR. Structural models of representative EGFR exon 
20 insertion mutations are being generated. Conclusion: Most 
EGFR exon 20 insertion mutations are resistant to EGFR TKIs 
and enzymatic and crystal structure of representative mutations 
are ongoing to determine their mechanism of resistance 
to gefitinib/erlotinib. However, EGFR-A763—Y764insFQEA 
is an EGFR TKI-sensitive mutation and can be inhibited by 
clinically-achievable doses of gefitinib/erlotinib. These findings 
have clinical implications for the 10,000 cases of EGFR exon 
20 insertion mutated NSCLC diagnosed yearly plus point 
towards the need to define the molecular mechanisms that 
underlie differential responses to EGFR TKIs and the need for 
development of novel EGFR inhibitors specific for the more 
prevalent exon 20 insertion mutations. 
Disclosure: Pfizer (consultant 2011, compensated) Roche 
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MO.06: EFFICACY AND SAFETY OF CRIZOTINIB IN ADVANCED 
ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) 
RESULTS FROM A PHASE II GLOBAL TRIAL
Carlos G. Ferreira1, C Barrios2, Alice T. Shaw3, Yuankai Shi4, 
Tommaso M. De Pas5, Pan C. Yang6, Greg J. Riely7, Lucio Crinò8, 
Shrividya Iyer9, Anna Polli10, Silvana Lanzalone10,  
Dong W. Kim11  
1Division Of Clinical And Translational Research, Instituto Nacional Do 
Câncer (Inca), Rio De Janeiro/BRAZIL, 2Department Of Medicine, Pucrs 
School Of Medicine, Porto Alegre/BRAZIL, 3Medical Oncology, Department 
Of Thoracic Oncology, Massachusetts General Hospital, Boston/MA/
UNITED STATES OF AMERICA, 4Department Of Medical Oncology, Chinese 
Academy Of Medical Sciences(Cams), Beijing/CHINA, 5Medical Oncology 
Unit Of Respiratory Tract And Sarcomas, European Institute Of Oncology, 
Milan/ITALY, 6National Taiwan University College Of Medicine, Taipei/
TAIWAN, 7Memorial Sloan-Kettering Cancer Center, New York/UNITED 
STATES OF AMERICA, 8S. Maria Della Misericordia Hospital, Perugia/ITALY, 
9Oncology, Pfizer, New York/UNITED STATES OF AMERICA, 10Oncology, 
Pfizer, Milan/ITALY, 11Department Of Internal Medicine, Seoul National 
University Hospital, Seoul/KOREA
Background: In NSCLC approximately 3–5% of patients harbor 
an ALK gene rearrangement. The EML4-ALK fusion gene is 
a known oncogenic driver in a subset of NSCLC patients. 
Crizotinib is a first-in-class, oral, ATP-competitive, small-
molecule ALK inhibitor with anti-MET activity.
Methods: An ongoing global, multicenter, open-label, single-
arm, phase II study (PROFILE 1005) is evaluating the safety 
and efficacy of crizotinib (250 mg BID in 3-week cycles) in 
patients with advanced ALK-positive NSCLC who progressed 
after ≥1 chemotherapy for recurrent/advanced/metastatic 
disease. Tumor response was evaluated every 6 weeks (RECIST 
1.1). Efficacy assessments included response rate, duration of 
response, disease control rate, and progression-free survival 
(PFS). Patient-reported outcomes and global quality of life (QOL) 
using the EORTC QLQ-C30 and LC-13 at baseline, day 1 each 
cycle and at end of treatment were assessed.
Results and Conclusion: 439 patients were evaluable for safety 
and 255 patients for tumor response (as of June 2011). Median 
age was 53 years. The majority of patients were female (53%), 
never smokers (65%), and had adenocarcinoma (92%), ECOG 
PS 0–1 (83%) and ≥2 prior chemotherapy regimens (85%). Of 
evaluable patients, median treatment duration was 25 weeks 
(77% of patients still ongoing). ORR was 53% (95% CI: 47–60), 
disease control rate was 85% (95% CI: 80–89) at 12 weeks, 
median duration of response was 43 weeks (96% CI 36–50) 
and median PFS was 8.5 months (95% CI: 6.2–9.9). Common 
treatment-related AEs included visual effects (50%), nausea 
(46%), vomiting (39%), and diarrhea (35%), mostly grade 1–2. 
Treatment-related SAEs were reported in 29 patients (6.6%) 
and included dyspnea and pneumonitis (4 patients each; 0.9%), 
and febrile neutropenia and renal cyst (2 patients each; 0.5%). 
Statistically significant (p<0.05) and clinically meaningful (≥ 
10 points) improvement from baseline was noted for patient-
reported overall pain, pain in chest, cough, dyspnea, insomnia, 
fatigue and global QOL. Crizotinib demonstrated a 53% 
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response rate, durable PFS, a favorable tolerability profile and 
improvement in patient-reported symptoms. These findings 
are consistent with earlier reports and results provide strong 
support for crizotinib as a standard of care for advanced ALK-
positive NSCLC. 
Disclosure: CG Ferreira, Y Shi, P-C Yang, and TM De Pas have 
no conflicts of interest to disclose. C Barrios has received 
honoraria and research funding from Pfizer Inc. AT Shaw has 
had a consultancy or advisory role for which compensation was 
received for Ariad, Chu
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MO.07: STAGING IMPLICATIONS OF INTRAOPERATIVE 
ULTRASOUND GUIDED MEDIASTINAL LYMPADENECTOMY IN 
NSCLC SURGERY
Nenad Ilic, Josko Juricic, Josip Banovic, Dragan Krnic, Nives 
Frleta Ilic, Darko Ilic 
Thoracic Surgery Dept., University Surgical Hospital, Split/CROATIA
Background: The extend of lymph node involvement in patients 
with non-small cell lung cancer (NSCLC) is the cornerstone of 
staging and influences both multimodality treatment and final 
outcome. We studied safety, accuracy and characteristics of 
intraoperative ultrasound (US) guided systematic mediastinal 
nodal dissection in patients with resected NSCLC. 
Methods: Prospective randomized trial of intraoperative 
surgical staging after radical surgery for NSCLC was carried 
out. Intraoperative hand held ultrasound probe was used in 
systematic mediastinal nodal dissection in 124 patients after 
radical surgery for NSCLC and compared with 120 patients who 
underwent lung resections and standard systematic mediastinal 
nodal dissection. Mapping of the lymph nodes by their number 
and station followed by histopathologic evaluation was 
performed. Patients data were statistically analyzed. 
Results and Conclusion: The surgical procedure used 
depended on the extent of the disease, as well as the 
cardiopulmonary reserve of the patients and was comparable 
in both groups of patients. Operating time was prolonged for 12 
(6 – 20) minutes in patients with US guided mediastinal nodal 
dissection, but number and stations of evaluated lymph nodes 
was significantly higher (p>0.001) at the same group of patients. 
Skip nodal metastases were found in 24% of patients without 
N1 nodal involvement. We upstaged 22 (10%) patients using US 
guided mediastinal lymphadenectomy. Median follow-up was 
38 (range, 10 - 52) months. Standard staging system seemed 
to be improved in US guided mediastinal lymphadenectomy 
patients. Complications rate showed no difference between 
analyzed groups of patients. Conclusion: Higher number and 
location of analyzed mediastinal nodal stations in patients with 
resected NSCLC using hand held ultrasound probe suggested 
to be of great oncology significance. Procedure showed 
absolute safety and high accuracy. Our results indicated that 
intraoperative US may have important staging implication. 
Further clinical studies should be carried out in order to improve 
intraoperative staging in NSCLC patients. 
Disclosure: No significant relationships.
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MO.08: ANALYSIS OF PPGALNAC-T13 ENZYME AND ITS 
RELATIONSHIP WITH CLINIC, HISTOLOGIC AND BIOMARKERS 
PROFILE IN PATIENTS WITH NON-SMALL-CELL LUNG CANCER 
(NSCLC).
Diego Touya1, Carmen Behrens2, Luisa Solis2, Ping Yuan2, Rafael 
Alonso3, Mario Varangot1, Eduardo Osinaga4, Ignacio Wistuba2, 
Nora Berois4  
1Departament Of Oncology, School Of Medicine, University Of The 
Republic, Montevideo/URUGUAY, 2Departments Of Thoracic/Head & Neck 
Medical Oncology, Md Anderson, Houston/UNITED STATES OF AMERICA, 
3Departament Of Quantitative Methods, School Of Medicine, University 
Of The Republic, Montevideo/URUGUAY, 4Laboratory Of Glycobiology And 
Tumor Inmunology, Institut Pasteur, Montevideo/URUGUAY
Background: O-gylcosylation alterations occur in most 
carcinomas, resulting in the expression of molecules which 
may constitute useful targets for diagnostic and therapy. 
ppGalNAc-T13 enzyme catalyzes a key step in the initiation 
of O-glycosylation. It is overexpressed in metastatic 
neuroblastoma, and has been correlated with the prognosis 
of patients with this tumor. In resected lung cancer specimens 
there is no information about ppGalNAc-T13 expression.
Aim: To study the frequency of expression of the ppGalNAc-T13 
enzyme in a large set of surgically resected NSCLC tumor 
tissues, and its association with clinical, pathological and 
molecular characteristics including patients’s recurrence-free 
survival (RFS) and overall survival (OS).
Methods: We used tumor tissue microarrays containing 
443 NSCLCs, including 249 adenocarcinomas (ADCA) 
and 122 squamous cell carcinomas (SCC). We performed 
immunohistochemistry using a monoclonal antibody specific 
against ppGalNAc-T13. The cytoplasmic expression of the enzyme 
was quantified using a four-value intensity score (0, 1+, 2+, and 
3+) and the percentage (0-100%) of the extent of reactivity in 
each tissue core. The final score was then obtained by multiplying 
the intensity and reactivity extension values (range, 0-300). 
The patients were divided into 2 groups: with (n=72, WNA) and 
without neoadjuvant (n=371, WONA) chemotherapy.
Results and Conclusion: Results: We found frequent 
ppGalNAc-T13 expression in NSCLC, without significant differences 
between WNA and WONA (p=0,20) groups. ADCAs expressed 
higher levels of the enzyme than SCCs in both groups (WNA, 
p=0.02; and, WONA, p<0.0001). In the ADCA patients, with 
or without neoadyuvant, ppGalNAc-T13 expression is different 
according histology pattern (WNA: p = 0.002 and WONA: p = 
0.044) showed higher value with the presence of solid histology 
pattern and lower in lepidic histology pattern. Using Spearman 
Correlation test, ppGalNAc-T13 correlated significantly with 
EpCAM (p<0.001) and TTF-1 (p<0.01) expression, In ADCAs, we 
found no correlation between ppGalNAc-T13 expression and EGFR 
and KRAS mutation status and the presence of EML4-ALK fusion 
gene. Interestingly, in the ADCA-WNA subset, high ppGalNAc-T13 
expression level was associated with worse OS (p<0.01 , HR=5.2), 
not significative in RFS (p= 0.15, HR=1.8). In contrast, we did 
not find any association between ppGalNAc-T13 expression and 
outcome in the ADCA-WONA subset of patients. Conclusions: 
ppGalNAc-T13 is frequently expressed in NSCLC and associates 
with worse prognosis in patients with ADCA who received 
neoadjuvant chemotherapy. Our data suggest that ppGalNAc-T13 
is a novel marker associated to chemoresistance in NSCLC. 
Disclosure: No significant relationships.
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MO.09: CONTEXT-DEPENDENT CONSEQUENCES OF AKT 
INHIBITION IN NSCLC CELL LINES
Philip C. Mack1, William S. Holland2, Nichole Mahaffey2, Danielle 
Chinn2, Primo Lara2, David Gandara2  
1UC Davis Comprehensive Cancer Center, Sacramento/UNITED STATES OF 
AMERICA, 2UC Davis Comprehensive Cancer Center/UNITED STATES OF 
AMERICA
Background: MK2206 is a selective, allosteric inhibitor of 
AKT, a key signal transduction intermediary. AKT is active in 
NSCLC, as indicated by elevated phosphorylation in tumor cells 
and is considered a critical component of signal transduction 
mediated by receptor tyrosine kinases (RTKs) such as EGFR and 
MET. However, mutations in factors immediately upstream 
of AKT, such PTEN and PI3K, are not a common pathology 
in NSCLC. Preclinical and early clinical investigations are 
underway to define optimal treatment strategies, identify target 
subpopulations, and elucidate biomarkers predictive of MK2206 
activity. We evaluated the signal transduction, cytotoxic and 
cytostatic effects of AKT inhibition via MK2206 with or without 
the EGFR inhibitor erlotinib in a panel of 10 NSCLC with different 
oncogenic abnormalities in the presence or absence of HGF-
induced Met activation.
Methods: Cell growth, cell cycling and apoptotic effects were 
evaluated by the MTT assay, PARP cleavage and flow cytometry. 
Changes in phosphorylation of signal transduction mediators 
and RTKs were evaluated by multiplex kinase arrays and 
Western analysis. Drug interactions were tested for synergy 
using Median Effect Analysis. Met activation was stimulated 
through exogenous addition of HGF (25ng/ul).
Results and Conclusion: In all cell lines tested, single-agent 
MK2206 ablated pAKT (T308 and S473) and showed additive-
to-synergistic interactions between erlotinib and MK2206. 
Addition of the MET ligand HGF prevented erlotinib-induced 
cytotoxic and cytostatic effects in erlotinib-sensitive lines, 
coinciding with induction of both pERK1/2 and pAKT. MK2206, 
which ablated pAKT regardless of HGF treatment, could restore 
cytostatic activity to erlotinib. Of note, single-agent MK2206 
resulted in compensatory upregulation in Erk1/2 and, in the 
presence of HGF, marked upregulation of pMET; however, these 
effects were mitigated by erlotinib. Conclusion: AKT inhibition 
by MK2206 resulted in significant compensatory effects, 
including upregulation of MET and ERK activity, when used 
as a single agent. However, the combination of erlotinib plus 
MK2206 showed additive-to-synergistic activity in all NSCLC 
cell lines tested, regardless of EGFR or KRAS status. Exogenous 
addition of HGF prevented erlotinib activity, and induced 
both pERK1/2 and pAKT. MK2206 could override this pAKT 
induction, restoring cytostatic activity of erlotinib. A California 
Cancer Consortium clinical trial (NCI 8698) is underway to test 
MK2206 plus erlotinib in patients who previously benefited 
from erlotinib. 
Disclosure: No significant relationships.
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MO.10: EVALUATION OF ALK IN NON-SMALL CELL LUNG CANCER 
USING FISH AND RT-PCR
Kenneth J. Bloom, Paul Choppa  
Pathology, Clarient, A Ge Healthcare Company, Aliso Viejo/UNITED STATES 
OF AMERICA
Background: Translocations involving the kinase domain of the 
anaplastic lymphoma kinase (ALK) gene have been identified 
in a number of different malignancies including non-small cell 
lung cancer (NSCLC). Although ALK has been demonstrated 
to fuse with a number of different genes, the echinoderm 
microtubule-associated protein-like 4 (EML4) gene is commonly 
associated with ALK in NSCLC. Crizotinib was recently approved 
for the treatment of ALK positive NSCLC patients as determined 
by the presence of an ALK gene rearrangement based on a 
companion diagnostic FISH assay. The frequency of ALK related 
NSCLC reported in the literature varies widely ranging from 
approximately 2 -12%. Part of this variability is likely due to the 
testing method. We sought to compare FISH with an RT-PCR 
reaction capable of detecting the 10 most common EML4-ALK 
variants.
Methods: 1133 formalin fixed paraffin embedded lung 
samples were assessed using the Vysis LSI ALK break apart 
rearrangement FISH probe and a variant specific RT-PCR 
which is capable of detecting the 10 most common EML4-
ALK variants. For FISH, 50 tumor cells were enumerated for 
the presence of a break apart signal which was considered as 
present when at least one set of orange and green signals were 
2 or more signal diameters apart or when a single orange signal 
without a corresponding green signal was observed in more 
than 15% of tumor cells. The RT-PCR reaction uses one-step 
chemistry and is capable of detecting each of the 10 fusion 
transcripts at a sensitivity of approximately 1%.
Results and Conclusion: Of the 1133 cases, 28 (2.47%) samples 
had a detectable break apart by the FISH assay. Nineteen of 
these samples were confirmed as a form of EML4-ALK by the 
RT-PCR while the other 9 did not generate a signal from any 
of the 10 EML4-ALK variant specific reactions. The 19 samples 
that were confirmed by RT-PCR consisted of 9 variant one, 4 
variant two, 4 variant three and 2 variant five. The samples 
that were not confirmed by the RT-PCR suggest the possibility 
of an ALK translocation partner other than EML4. In addition 
to alternative ALK rearrangements, the FISH test identified 26 
(2.3%) samples as having ALK gene amplification. FISH detected 
a break apart signal in 2.47% of samples, consistent with the 
reported literature. Attempting to detect the specific EML4-
ALK variant by RT-PCR failed to identify 9 (32%) of the 28 ALK 
positive tumors identified by FISH suggesting that this method 
should not be used as the sole means of identifying patients 
who may benefit from Crizotinib therapy. 
Disclosure: No significant relationships.
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P1.01: A MATHEMATICAL MODEL FOR PREDICTING MALIGNANCY 
OF SOLITARY PULMONARY NODULES
Yun Li, Jun Wang  
Department Of Thoracic Surgery, People’s Hospital Of Peking University, 
Beijing/CHINA
Background: Detecting and diagnosing SPNs are critical since 
early identification of malignant nodules is crucial to the 
chance for successful treatment. SPNs, however, are usually 
small, located deep in the pulmonary parenchyma, and often 
yield atypical imaging findings. While researchers are seeking 
advanced image technique, more and more clinicians stressed 
that in addition to the radiographic and image characteristics. 
Confronting such massive data, clinical experience and 
judgment may not be reproducible or reliable, while a 
quantitative model might have its advantages in accuracy, 
reproducibility, uninfluenced by personal judgment, and 
outcome exchange ability. Researches began to suggest that a 
clinical prediction equation has the potential to facilitate clinical 
decision making.
To improve the accuracy of the model, a systematic and 
comprehensive clinical and imaging data with specific diagnosis 
is needed.. In this paper, we aimed to develop a prediction 
model for patients with SPN based on a comprehensive data 
collection and thorough analysis. 
Methods: Records from 371 patients (197 male, 174 female) 
with SPN between Jan 2000 and Sep 2009 were reviewed 
(Group A). Clinical data were collected to estimate the 
independent predictors of malignancy of SPN with multivariate 
logistic regression analysis. And a clinical prediction model 
was subsequently developed. Between Oct 2009 and May 
2011, data from additional 145 patients with SPN were used 
to validate this new clinical prediction model (Group B). The 
same dada were also estimated using two previously published 
models in order to compare with our new model.
Results and Conclusion: Results: Median patient age was 57.1 
years in group A. 54% of the nodules were malignant and 46% 
were benign. Logistic regression analysis identified six clinical 
characteristics (age, diameter, border, calcification, spiculation, 
and family history of tumor) as independent predictors of 
malignancy in patients with SPN. The area under the ROC curve 
for our model (0.874 ± 0.028) was higher than those generated 
using another two reported models. In our model, sensitivity 
= 94.5%, specificity = 70.0% positive predictive value = 
87.8%, negative predictive value = 84.8%). Conclusions: Age, 
diameter, border, calcification, spiculation, and family history 
of tumor were independent predictors of malignancy in patients 
with SPN. Our prediction model was sufficient to estimate 
malignancy in patients with SPN and proved to be more 
accurate than the two existing models.
Disclosure: No significant relationships.
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P1.02: MOLECULAR MECHANISM OF CIGARETTE SMOKE 
INDUCED UNREGULATED PROLIFERATION OF HUMAN LUNG 
CELLS AND ITS PREVENTION.
Neekkan Dey, Shinjini Ganguly, Dhrubajyoti Chattopadhyay, 
Indu B. Chatterjee  
Department Of Biotechnology And Dr B. C. Guha Centre For Genetic 
Engineering And Biotechnology., University Of Calcutta, Kolkata/INDIA
Background: Lung cancer is the leading cause of cancer-deaths 
throughout the World. Cigarette smoking is the strongest 
risk factor for developing lung cancer. Hyper-proliferation of 
cells occurs in response to cigarette smoke (CS) exposure. 
Unregulated cell proliferation together with suppressed 
apoptosis is a contributory factor for lung-carcinogenesis. 
However, the carcinogenic mechanism of cigarette smoking 
is not well understood. This is particularly because cigarette 
smoke is a complex mixture of about 4000 compounds and 
identifying the risk factor in CS is essential for achieving this 
goal.
Methods: Cytotoxicity was evaluated by the MTT assay. Cell 
cycle analysis was performed by propidium iodide (PI) staining 
followed by flow-cytometry. Apoptosis was assessed by 
AnnexinV- PI staining followed by flow-cytometry. Reactive 
Oxygen Species (ROS) production was detected by 2’, 
7’-dichlorodihydrofluorescein diacetate (H2DCFDA) fluorescence 
using confocal laser scanning microscope. Cell proliferation 
was assessed using “In Situ Cell Proliferation Kit, FLUOS” 
(Roche Applied Science, Germany). DNA double strand break 
was detected using “OxiSelect DNA Double Strand Break (DSB) 
Staining Kit” (CELL BIOLABS, INC.).
Results and Conclusion: We have identified p-benzoquinone 
(p-BQ) as a major risk factor that is produced from 
p-benzosemiquinone, which is present in high concentration 
(100-200 µg/cigarette) in CS. Using MTT assay, flow-cytometric 
analysis after AnnexinV-PI staining, cell cycle analysis and 
BrdU-incorporation assay we have observed that p-BQ has a 
biphasic-nature. Low concentration of p-BQ mimics CS-induced 
proliferation of cultured lung cells (A549). The proliferation is 
not restricted to A549 cells; it also occurs in other cell lines. 
However, under the experimental conditions the benzo[a]
pyrene and nitrosamines (e.g. NNK and NNN) do not induce 
proliferation. In contrast, higher concentrations of CS/p-BQ 
result in cell death caused by oxidative stress and apoptosis. 
The oxidative stress has been evidenced by the formation of 
ROS and apoptosis by the AnnexinV-PI assay, phosphorylation 
of p53 and activation (cleavage) of caspase 3. No such oxidative 
stress or apoptosis was observed with low concentration of 
CS/p-BQ. Coimmunoprecipitation and immunoblot experiments 
indicate that p-BQ-induced proliferation is mediated via 
aberrant phosphorylation of EGFR that lacks c-Cbl mediated 
ubiquitination and degradation. This results in prolonged 
EGFR signaling leading to persistent activation of Ras (potent 
oncoprotein that play a major role in lung cancer), the 
downstream survival and proliferative signaling molecules Akt 
and ERK1/2, as well as the transcription factors c-Myc and 
c-Fos. In addition, p-BQ causes hyper-acetylation of histones, 
thereby enhancing transcription of proliferation-inducing genes. 
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Whereas, repeated p-BQ exposure generate high levels of DNA 
double strand breaks and induce cultured lung cells to evade 
the cell cycle checkpoints, that may cause mutation of different 
proto-oncogenes and tumor suppressor genes which ultimately 
lead to cancer. Both anti-p-BQ antibody and vitamin C (a strong 
reductant of p-BQ) prevent CS/p-BQ-induced activation of 
EGFR and proliferation of lung cells. Despite major advances in 
the treatment and management of lung cancer, most patients 
eventually die. Consequently, newer approaches such as 
chemoprevention(s) are necessary in the battle against lung 
cancer. We consider that prevention of CS-induced proliferation 
of lung cells by vitamin C and/or anti-p-BQ antibody may 
provide a novel intervention for preventing initiation of CS-
induced lung cancer.
Disclosure: No significant relationships.
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P1.03: REFERRAL OF LUNG CANCER PATIENTS TO SPECIALIZED 
CLINICAL ONCOLOGY CARE: INSTITUTO DO CANCER DO ESTADO 
DE SAO PAULO 2010-2011.
Rafael Caires-Lima, Tiago K. Takahashi, Milena P. Mak, Felipe 
S.R. Roitberg, Carlos H.A. Teixeira, Cristiane S. Mesquita, 
Andrea M. Marini, Renata E. Martins, Tereza Y. Takagaki, Pedro 
N. Araújo, Olavo Feher, Paulo M. Hoff, Gilberto De Castro Junior  
Clinical Oncology, Instituto Do Cancer Do Estado De Sao Paulo, São Paulo/
BRAZIL
Background: Lung cancer is the leading cause of death from 
malignancy in Western countries. To achieve better outcomes 
and improve quality of care, it is essential to know both 
patients and disease characteristics. Here we aim to describe 
epidemiological and tumor characteristics and their impact on 
survival outcomes, of patients admitted at Instituto do Câncer 
de Estado de São Paulo (ICESP) between January 2010 and July 
2011. 
Methods: It is a retrospective, descriptive, and uninstitutional 
study, of patients diagnosed histologically with lung cancer, 
consecutively admitted at ICESP between January 2010 and July 
2011. Overall survival was the main endpoint. Frequencies were 
compared using chi-square test. Survival was estimated using 
the Kaplan-Meier methods, and the curves were compared by 
the log-rank test. This study was approved by the local IRB. 
Results and Conclusion: 232 patients (pts) were included in 
this analysis: median age 65y (24-91), 57% male, 56% ECOG 
0 - 1, and 83% previous or current smokers. Non small cell lung 
cancer (NSCLC) was the most common histologic type (213 pts, 
92%). Small cell lung cancer (SCLC) was diagnosed in 18 pts 
(7.6%) and only one (0.4%) was a case of a carcinoid tumor. 
Regarding NSCLC histologic subtypes, adenocarcinoma was 
the most common (130 pts, 61%), followed by squamous cell 
carcinoma (63 pts, 30%) and large cell carcinoma (5 pts, 2%). 
In 17 pts (7%), it was not possible to determine the subtype, 
even with immunohistochemistry. In terms of staging, 155 
pts (71%) with NSCLC presented metastatic disease (stage IV) 
at diagnosis, 27 pts (12%) were staged as IIIB, 15 pts (10%) 
IIIA, 8 pts (3.5%) II and 8 pts (3.5%) I. Among patients with 
SCLC, six (33%) had localized disease (LD) and 12 (67%) had 
extensive disease (ED). Analyzing only stage IV NSCLC pts, 123 
(79%) were treated with first line chemotherapy, 56 (36%) 
with second line and 13 (8%) with third line systemic therapies; 
ECOG 0 - 2 NSCLC pts were more likely to be exposed to 
second-line therapies (46% vs 36%; p = 0.0002). In a median 
follow-up of 9.5 mo, median overall survival (mOS) was 9 mo 
for all pts in this analysis. Regarding NSCLC, in patients with 
stage I and II mOS was not reached (100% and 68% in 2 years 
for stage I and II, respectively). In patients with stage IIIA, IIIB 
and IV, the median OS was 15.2, 11.4 and 7 mo, respectively 
(p-trend = 0.0002). According to ECOG-PS, mOS was 11.3, 
6.3, 4.1, and 2.2 mo for NSCLC pts with ECOG 1, 2, 3 and 4, 
respectively (p-trend < 0.0001). For SCLC pts, mOS was 12.9 
mo among those with LD versus 4.9 mo in ED (HR 3.1; 95% CI 
1.1 - 8.6; p = 0.02). Lung cancer survival rate remains poor. As 
expected, clinical stage and performance status were important 
prognostic factors. Primary prevention strategies (quitting 
smoking) and early diagnosis (screening) may be useful in this 
scenario. 
Disclosure: No significant relationships.
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P1.04: SPUTUM HYALURONAN ANALYSIS AS A NEW STRATEGY 
FOR THE SCREENING AND DIAGNOSIS OF LUNG CANCER
Maristela P. Rangel1, Vanessa K. De Sá1, João Roberto M. 
Martins2, Edwin Roger P. Cuentas1, Tereza Takagaki1, Adhemar L. 
Filho3, Rui Reis3, Helena Nader2, Vera L. Capelozzi1 
1Pathology, Faculdade De Medicina Da Universidade De Sao Paulo, Sao 
Paulo/BRAZIL, 2Universidade Federal De Sao Paulo, Sao Paulo/BRAZIL, 
3Hospital De Cancer De Barretos, Barretos/BRAZIL
Background: Hyaluronic Acid (HA) concentration is elevated in 
several cancers, but there is no data regarding its concentration 
in the sputum of lung cancer patients.In this study, we 
examined the HA concentrations in the tissue and in the sputum 
of lung cancer patients and its impact on the screening and 
diagnosis of the disease.
Methods: HA was examined in 45 paired tissues samples and 
sputum samples were collected from 90 lung cancer patients. 
Twenty five COPD patients were selected to compose a high 
risk group and 15 healthy volunteers were analysed as controls. 
All the patients and controls underwent a sputum induction. 
Sputum samples were incubated with urea 7M and tissue 
samples were dehydrated with acetone prior to analysis. 
Afterwards both were incubated with a proteolytic enzyme. 
The levels of HA were measured by a noncompetitive ELISA-like 
fluorometric assay.
Results and Conclusion: A significant different concentration 
pattern of HA in the tissues was found between tumoral and 
non-tumoral samples (p<0.001). Equally significant was the 
difference found in the sputum among lung cancer, COPD and 
healthy individuals (p<0.001 Fig1A). When comparing the groups 
separately, a difference was found between sputum HA from 
LC vs.healthy volunteers (p<0.001) and LC vs.COPD patients 
(p=0.002). ROC curve between LC and healthy volunteers 
furnished an area of 0.821. Assuming a cut off value of 31,44ng/
mg, the specificity was 100% and the sensitivity was 51% 
(Fig1B). ROC curve to distinguish COPD patients from LC patients 
showed an area of 0.698 and the cut off value of 48.3ng/
mg presented 100% of specificity and 33% of sensitivity 
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(Fig1C). The results presented suggest a promising role of HA 
in the sputum as a novel screening and diagnostic marker for 
differentiating normal from LC patients. 
Disclosure: No significant relationships.
S113Copyright © 2012 by the International Association for the Study of Lung Cancer
LALCA 2012 Abstracts Journal of Thoracic Oncology  •  Volume 7, Number 7, Supplement 2, July 2012
POSTER SESSION 1 - July 26, 2012 09:00 – 17:00
Prevention, Early Detection, Epidemiology and Tobacco Control
P1.05: PEQUI FRUIT (CARYOCAR BRASILIENSE CAMB) PULP 
OIL, A NATURAL SOURCE OF ANTIOXIDANTS, REDUCE 
THE OXIDATIVE STRESS STATUS AND DNA DAMAGE IN 
EXPERIMENTAL LUNG CANCER.
Natália B.R. Colombo1, Edwin R. Parra1, César K. Grisolia2, Daniel 
P. Gelain3, Márcia Hage4, Carlos E. Schnorr3, Eduardo Kolling3, 
Denise F. Barbeiro5, Vera L. Capelozzi1  
1Pathology, Faculdade De Medicina Da Universidade De São Paulo 
(Fmusp), São Paulo/BRAZIL, 2Genetic, Universidade De Brasília, Brasília/
BRAZIL, 3Oxidative Stress, Universidade Federal Do Rio Grande Do Sul, 
Porto Alegre/BRAZIL, 4Laboratory Of Atmospheric Pollution, Faculdade 
De Medicina Da Universidade De São Paulo (Fmusp), São Paulo/BRAZIL, 
5Clinical Emergency, Faculdade De Medicina Da Universidade De São Paulo 
(Fmusp), São Paulo/BRAZIL
Background: It is well known that the endogenous antioxidant 
enzyme defense as well as an adequate ingestion of exogenous 
sources of antioxidants prevents the oxidative damage 
caused by reactive species (ROS),including DNA damage, 
and can reduce the risk of cancer, atherosclerosis and other 
degenerative diseases. The pulp of Caryocar brasiliense Camb, 
most known as pequi, is a Brazilian fruit that has high levels 
of antioxidants properties, such as vitamin C, carotenoids, 
phenolic compounds like flavonoids, saponins and tannins, 
and essential oils. The aim of this study was to estimate and to 
evaluate the antioxidant enzyme activities of catalase (CAT) and 
superoxide dismutase (SOD), as well as the ratio between then, 
and the antioxidant activity of the pequi oil, measuring lipid 
peroxidation and DNA damage in experimental model of lung 
cancer induced by urethane.
Methods: The study was performed in 18 male BALB/c mice: 
14 animals received by gavage 0,5µL/mg/day of pequi oil 
(PI0601631-6) (Control+CBCoil = 4) during 75 days. After 
15 days of the beginning of the gavage, 10 of these mices 
received two doses of 1,5g/kg intraperitoneal of urethane 
(Urethane+CBC oil=10). The other 4 animals were only 
submitted to two doses of 1,5g/kg intraperitoneal of urethane 
(Urethane group=4). After 75 days, the three groups were 
sacrificed. The antioxidant activity of pequi oil was evaluated in 
the lung tissues by the biochemical TBARS (Thiobarbituric acid-
reactive substances), CAT and SOD test. The DNA damage was 
estimated by the comet test method.
Results and Conclusion: The lung parenchyma from the 
Urethane groups without oil and with oil showed neoplasic 
formations induced by the chemical carcinogenesis in contrast 
with Control + CBC oil group. The results of the TBARS test 
showed a significant decreased of the lipid peroxidation in the 
Urethane + CBC oil, similar as values of the Control+CBC oil, 
when compared with Urethane group. The CAT and SOD test, 
as well as the ratio between then, didn’t show a significant 
difference. The image analysis of the comet assay showed a 
statistical significant decreased of the DNA damage cells in the 
Urethane + CBC oil group when compared with urethane group 
(p=0.001). The decreased DNA damage was very similar that we 
obtained in the Control + CBC oil group. We conclude that the 
different natural antioxidant components found in the pequi 
oil are efficient to diminish the oxidative stress status and the 
DNA damage in chemical carcinogenesis induced by urethane 
experimental lung cancer, suggesting that this type of strategies 
may have a greater impact in lung cancer treatment. Financial 
Support: FAPESP, CNPq
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P1.07: TOXICITY PROFILE OF FIRST LINE TREATMENT WITH 
PEMETREXED, IN PATIENTS WITH NSCLC (NON-SQUAMOUS 
HISTOLOGY) AT A PRIVATE ONCOLOGY INSTITUTION IN 
SALVADOR, BAHIA, BRAZIL.
Maria Cecília Mathias, Oddone F.M. Braghiroli, Gildete S. Lessa, 
Clarissa Mathias, Eldsamira Mascarenhas  
Oncology, Nob, Salvador/BRAZIL
Background: Lung cancer is a disease with high morbidity 
and mortality and the progress of chemotherapy has been a 
reality, also, the search for a personalized therapy has been 
the treatment goal. There are many chemotherapy regimens 
and the change in treatment according to tumor histology is a 
recent practice. Studies show that personalized treatments have 
clinical benefits with tolerable toxicity.
Methods: We performed a retrospective study evaluating 
the toxicity profile of patients with non small cell lung cancer 
(NSCLC) in our institution treated with pemetrexed and 
compared the obtained data with other already validated 
studies.
Results and Conclusion: As stated in Table 1, a tolerable 
toxicity profile was found, with few grade 3 and 4 events and 
with grade 1 and 2 fatigue as a very common finding.
Conclusion: Lung cancer treatment has made great progress 
and each day longer survival rates are achieved with an 
improved quality of life. The toxicity profile in patients treated 
with pemetrexed combined with cisplatin or carboplatin was 
acceptable and very close to results already published in other 
important studies.
Disclosure: No significant relationships.
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P1.08: BIOLOGICAL BIOMARKERS FOR SCREENING OF PRE 
NEOPLASTIC LESIONS  ASSOCIATED TO LUNG CANCER IN A RISK 
CHILEAN POPULATION
Marta Adonis1, José Díaz1, Rosana Miranda2, Marco Chahuan3, 
Alcides Zambrano4, Mónica Campos5, Hugo Benítez6, Pablo 
Avaria1, Ulises Urzúa1, Yasna Cisterna7, Lorena Contreras1, Pedro 
Marín4, Stephen Lam8, Lionel Gil1  
1Cellular And Molecular Biology, Icbm, Faculty Of Medicine, University 
Of Chile, Santiago/CHILE, 2Patología, Hospital Barros Lucos Trudeau, 
Santiago/CHILE, 3Broncopulmonar Adultos, Hospital San Borja Arriarán, 
Santiago/CHILE, 4Respiratorio, Hospital Regional De Antofagasta, 
Antofagasta/CHILE, 5Oncología, Hospital San Borja Arriarán, Santiago/
CHILE, 6Patología, Hospital Regional De Antofagasta, Antofagasta/CHILE, 
7Bionet, Clínica Portada, Antofagasta/CHILE, 8Integrative Oncology, British 
Columbia Cancer Research Centre, Vancouver/CANADA
Background: The high incidence of lung cancer (LC) has 
been associated with smoking habit, genetic diversity and 
environmental pollution, especially in those cities highly 
exposed to environmental carcinogens.
Methods: This is a report of an ongoing prospective bimodality 
cancer survillance trial for high risk LC voluntaries. Enrolment 
was based in a LC survey applied to 508 chilean voluntaries and 
364 of them were included in this study, being classified as high 
risks subjects, exposed naturally to environmental pollution in 
Antofagasta and Metropolitan regions. Antofagasta region has 
the higher LC mortality rate in the country and inhabitants were 
exposed for 12 years to arsenic in drinking water concentrations 
as high as 870ug/L. Two biomarkers, Quantitative Automatic 
Cytology (QAC) and DR70 (Onko Sure), were used as tools in the 
detection of LC preneoplasic an neoplasic lessions. The study 
has also included Autofluorescent Bronchoscopy (AFB) as an 
additional technique.
Results and Conclusion: Results: AFB identifies PNL (metaplasia 
and dysplasia) better than the WLB. Fifty % of the samples, 
classify as suspicious by AFB, were confirmed as metaplasia or 
dysplasia by histopathology. The parallel combination of DR70 
and AQC, showed a significant increased of sensitivity to 90.9% 
(95%IC: 69.4 -100) for LC and PNL with Predictive Positive 
Value (PPV) for LC and PNL of 13.2% and 20.4%, respectively 
and Negative Predictive Value (NPV) for LC and PNL of 99.5% 
and 99.6%, respectively. The prevalence for LC and PNL in 
this population was 3.74% (95% IC: 1.4 – 6.08). Conclusions: 
The combined tests can be used as complementary tools 
to identify individuals harbouring LC or PNL. This is the first 
study in Latin America to complement image techniques with 
cellular and molecular biomarkers, to detect LC and PNL. These 
results provide scientific and clinical information for Chilean 
health authorities to include early detection of LC in the AUGE 
government programme, that provide additional health services 
for patients. Supported by INNOVA-CORFO, Chile. 
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P1.09: NANOCYTOMIC BIOMARKERS FROM THE BUCCAL 
MUCOSA FOR LUNG CANCER RISK STRATIFICATION: 
OPTIMIZATION AND DIAGNOSTIC SYNERGISM WITH MICRORNA 
EXPRESSION  
Hemant K. Roy1, Hariharan Subramanian2, Dhananjay Kunte1, 
Thomas Hensing3, Sudhir Srivastava4, Vadim Backman5  
1Department Of Medicine, Northshore University Healthsystem, Evanston/
UNITED STATES OF AMERICA, 2Biomedical Engineering, Northwestern 
University, Evanston/UNITED STATES OF AMERICA, 3Medical Oncology, 
Northshore University Healthsystem, Evanston/UNITED STATES OF 
AMERICA, 4Cancer Prevention, National Cancer Institute, Bethesda/UNITED 
STATES OF AMERICA, 5Biomedcial Engineering, Northwestern University, 
Evanston/UNITED STATES OF AMERICA
Background: The “field of injury” concept posits that the 
buccal mucosa should be a surrogate marker for lung cancer 
risk by recapitulating the tissue responsive to cigarette smoke 
carcinogens (Future Oncol. 2011). Our novel optics technology, 
partial wave spectroscopic microscopy (PWS or nanocytology), 
provides heretofore unattainable insights into cellular structure 
at the nanoscale (PNAS 2008). PWS represents a powerful 
modality for detecting the micro-architectural consequences 
of the genetic/epigenetic alterations in field carcinogenesis 
(Cancer Res 2009). We recently demonstrated that PWS analysis 
of the histologically normal cheek cells discriminated smokers 
with versus without lung cancer (Cancer Res 2010). However, 
buccal cells heterogeneity (stratified squamous epithelium 
ranging from small basal cells to larger more differentiated 
superficial cells) was not assessed in this initial proof of concept 
publication. To optimize clinical performance, we now took two 
approaches: standardize the buccal cell type by size and add 
microRNA biomarkers. 
Methods: In this case-control study, we defined cases as 
having histologically confirmed but untreated and controls 
were smokers without evidence of lung cancer. Brushings from 
buccal epithelium was placed on a glass slide and ethanol fixed. 
PWS analysis was performed as previously described and the 
parameter disorder strength (Ld) was assessed (PNAS 2008, 
Gastro 2011). We dichotomized cell size at 60 µm (“small” 
versus” large” cells). MicroRNA analysis was using taqman real 
time PCR analysis. 
Results and Conclusion: For this optimization study, our cohort 
was expanded to 175 patients with no statistical differences in 
age, gender or smoking history between cases and controls. 
Despite being microscopically identical, buccal PWS parameter 
Ld was markedly elevated lung cancer patients . “Large” cell 
analysis was superior to previous unselected analysis or focusing 
on “small” cells (see table). For microRNA analysis, we used our 
initial microarray analysis to select a single miR (miR15a) in order 
to mitigate concerns regarding overfitting and showed perfect 
discriminative ability. We demonstrate the ability of buccal PWS 
to serve as a minimally-intrusive modality for lung cancer risk 
stratification. The clinical performance is improved by targeting 
the more differentiated cells. Moreover, addition of a single 
microRNA showed outstanding diagnostics. While requiring 
larger dataset validation, this underscores the promise of buccal 
analysis with PWS (±microRNA) pre-screen. We envision that 
buccal PWS with a high negative predictive value threshold 
would allow many neoplasia-free smokers to forego the 
expensive low dose CT (LDCT). Furthermore, by enriching the 
disease prevalence in the LDCT population, this will dramatically 
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decrease the false positives and mitigate concerns over the 
harms associated with lung cancer population screening. 
 Unselected cells  Cells <60µm Cells≥60 µm Cells≥60 µm 
 (initial cohort)  new cohort  new cohort  +miR15a 
 Sensitivity  78%  56%  89%  100% 
 Specificity  78%  75%  95%  100% 
 Area under 0.85  0.82  0.94  1.00 
 ROC curve  
Disclosure: Drs. Roy and Backman are co-founders/share 
holders of American BioOptics LLC and co-founders of 
Nanocytomics LCC.
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P1.10: SURGICAL PREVENTION OF DEVELOPMENT OF 
BRONCHOPLEURAL FISTULA AFTER PNEUMONECTOMY IN 
PATIENTS WITH LUNG CANCER
Shukhrat Khudaybergenov, Otabek Eshonkhodjaev, Ortikali 
Irisov  
Department Of Lungs And Mediasinum Surgery, Republican Specialized 
Center Of Surgery Named After Academician V.Vakhidov, Tashkent/
UZBEKISTAN
Background: It is known that bronchial stump fistula (BSF) and 
related to it pleural empyema are general causes of efficacy 
decrease of surgical treatment of pulmonary cancer, purulent 
destructive pulmonary diseases and other surgical pathologies 
of thoracic organs. Development of BSF after pneumonectomy 
(PE) was always related to bronchial suture failure and 
unfavorable conditions of its healing. Nowadays in oncology a 
necessity of stratification of patients with local distributed and 
disseminated cancer forms of any localization is scientifically 
proved. It allows to determine heterogenicity of patients’ 
group in relation to the nearest and remote prognosis as well 
as to work out and to implement optimal volumes of surgical 
treatment into practice.
Methods: Stratification data of risk factors of bronchial stump 
failure (BSF) development in 575 patients, who underwent 
primary pneumonectomy in this article were presented. Control 
group (CG) consisted of 477 patients, 390 patients of them 
had different tumors of the lungs and 87 patients had purulent 
diseases of the lungs. The main group (MG) consisted from 98 
patients, 72 patients of them had pulmonary tumors and 26 
patients had purulent pulmonary diseases. They underwent the 
worked out treatment tactics based on determination of risk 
groups development of bronchial failure after pneumonectomy. 
In the right sided PE minimum risk only into group of 6,7% 
patients were included (13), into group of mean risk - 70,3% 
(137) and into group of maximum risk - 23,1% (45) patients. 
In CG BSF developed in 52 (10,9%) patients, at the same time 
an incidence of this complication in patients of oncologic 
profile was 10,5% (41 patients), and in patients with purulent 
pulmonary diseases – 12,6% (11 patients). In MG BDF was 
observed in 3 (3,1%) patients, at the same time an incidence 
of this complication in patients of oncologic profile was 2,8% 
(2 patients), and with purulent pulmonary diseases – 3,8% (1 
patient). To evaluate adequate a retrospective distribution of 
patients in risk groups in CG and prospective one in MG were 
performed. 271 patients were included in group of minimum 
risk that accounted for 47,1%, 220 patients were included in 
group of mean risk, which accounted for 38,3% and in group 
of maximum risk - 84 patients that accounted for 14,6%. 
Formation of risk groups depending on localization of disease 
showed that in the planning of left sided PE minimum risk was 
determined in 258 (67,9%) patients, mean risk - in 83 (21,8%) 
and maximum risk - in 39 (10,3%) patients.
Results and Conclusion: In accordance with factor estimation 
of risk degree of development of BSF worked out an 
accomplishment of PE was conjugated with minimal risk in 
47,1% (271) patients, mean risk - in 38,3% (220) and maximal 
risk – in only 14,6% (84), at the same time depending upon a 
side of operation a 3-fold real increase of risk after PE to the 
right was registered. Thus, minimal risk of development of this 
complication reached 67,9% to the left and only 6,7% to the 
right, mean risk was 21,8% and 70,3% respectively, whereas 
maximal degree of risk was revealed in only 10,3% to the 
left and in 23,1% to the right. An incidence of BSF after PE in 
patients of CG accounted for minimal risk 1,3%, at an average – 
16,0%, and maximal – 32,3%, in its turn, an implementation of 
factor estimation of risk degree of development of BSF after PE 
in MG allowed to reduce an incidence of this complication until 
0,0%, 2,6% and 9,1% respectively. Conclusions. 1. Peculiarities 
of a tactics of surgical intervention in PE must be determined 
strong in accordance with risk degree of development of BSF 
and, depending on the latter, include various in their efficacy 
of hermetization as well as work volume of accomplishment 
methods of suturing bronchus stump and consolidation of 
suture line. 2. The right-sided PE in patients in a group of mean 
risk as well as PE to the left in patients with maximum risk 
cause a necessity to suture bronchus stump by manual method 
as the most hermetic as well as consolidation of suture line 
with pericardial flap. 3. Sternotomic approach is necessary 
for patients in a group of maximum risk for an adequate 
accomplishment of surgical intervention, and consolidation 
by a proposed method with omentum flap after suturing 
stump by manual method 5. Independence from risk degree of 
development of BSF after accomplishment of PE an incidence 
of lethality can reach 11,0% – at mean risk and 22,6% – at 
minimum risk, at the same time an introduction of tactics of 
surgical intervention based on the worked out factor estimation 
of risk degree of development of BSF after PE permitted to 
decrease an incidence of lethality from 7,1% (34 of 477 patients 
in control group) up to 3,1% (3 of 98 patients in main group).
Disclosure: No significant relationships.
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P1.11: EPIDEMIOLOGICAL AND TREATMENT OUTCOMES IN 
PATIENTS WITH METASTATIC LUNG CANCER AT AN ONCOLOGIC 
INSTITUTION IN SOUTHERN BRAZIL: UPDATED SURVIVAL 
ANALYSIS
Thais A. Almeida, Nils Skare, Ana Luiza Wiermann, Johnny 
Camargo, Rosane R. Johnsson, Fabricio A.M. Oliveira, Luciano 
S. Biela, Roger A. Shiomi, Josiane Mourão, Rodrigo J. Barbosa, 
Diogo D. Gavarrete  
Clinical Oncology, Erasto Gaertner Hospital, Curitiba/BRAZIL
Background: In Brazil lung cancer is the third most common 
malignancy with 27,630 new cases estimated for the year 
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2010, divided in 17,800 men and 9,830 women. There is an 
increasing incidence especially in females, which is attributed 
to increased smoking habit in this gender. It is important to 
document the follow-up survival data in this southern Brazilian 
population. Our epidemiological profile of patients with non-
small cell lung cancer (NSCLC) in advanced stage has been 
previously presented. We report here updated overall survival 
and progression-free survival data and confront the results of 
treatment with the data in the literature.
Methods: This retrospective study included 125 patients 
referred to the Clinical Oncology Service of our hospital with 
NSCLC in stage IIIB with pleural effusion and IV, from 2005 to 
2010. For this updated survival analysis, the data cutoff was 
January 2012. The Kaplan-Meier method was used for survival 
analysis.
Results and Conclusion: There were 103 deaths in 125 patients 
enrolled. Of 125 patients studied, 52.8% were male, median 
age was 58 years, performance status (PS) was equal or less 
than 1 in 61.3% and subtype adenocarcinoma seen in 59.2% of 
cases. Among the 104 patients assessable for response, partial 
remission rate was 31.7% and stable disease 16.3%. Patients 
were treated with carboplatin-paclitaxel in first line in 88.6% 
and docetaxel in second line in 47.1%. Median survival was 
8.3 months (95% CI 6.3 to 10.3 months) and PS continues to 
be important with a significant statistical difference in median 
survival between patients with PS equal or less than 1 versus 
those equal or greater than 2 (p = 0.0116). Progression-free 
survival was 5.0 months (95% CI 4.0 to 6.0 months). Prolonged 
follow-up of patients continues to show a survival difference 
between patients with with PS 0 or 1 versus those equal or 
greater than 2. Overall survival is still similar to that found in 
the world literature, as does the progression-free survival. This 
study shows the epidemiological profile and the treatment 
outcome of patients with lung cancer in a Southern Brazilian 
population
Disclosure: No significant relationships.
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P1.12: LUNG CANCER, CLINICAL PRESENTATION AT THE MEDICAL 
ONCOLOGY DEPARTMENT, CLINICS HOSPITAL, ASUNCION 
NATIONAL UNIVERSITY MEDICAL SCHOOL (ANUMS)
Vicente A. Villalba1, Romy M. Gomez2, Ita Yoffe2  
1Oncologia Medica, Hospital De Clinicas, Asuncion/PARAGUAY, 2Oncologia, 
Hospital De Clinicas, Asuncion/PARAGUAY
Background: Lung cancer is one of the most frequent in adults 
and is one of the main causes of cancer death in the world. 
In our country is one of the principal causes of cancer death, 
and generally the diagnosis is made when the patient is in 
an advanced stage. Objectives: To establish the clinical and 
pathologic figures of lung cancer patients seen in the Medical 
Oncology Department of the Clinics Hospital ANUMS 
Methods: We made a retrospective descriptive study using the 
clinical charts of patients who attended in our service since 
January 2001 to December 2011. 
Results and Conclusion: From January 2001 to December 2011, 
85 patients with the diagnosis of lung cancer were received 
for treatment. They were 16 females and 69 males with ages 
between 16 to 87 years old, average of 59.Sixty five(76%)were 
active smokers,one a former smoker,4 passive smokers,8 were 
no smokers and in 7 we found no data of smoking habit in the 
charts. Adenocarcinoma represented 40% of cases,followed 
by undifferentiated large cell carcinomas and only 12% of 
squamous cell carcinomas. Small cell lung cancer was the 
diagnosis in 14% of the patients. In 7% the diagnosis was 
NSCLC without other specification, 6% were carcinoid tumors. 
The majority of small cell lung cancer had an extensive disease 
71%. The TNM presentation stage of patients with NSCLC 
was ECII in five, ECIIIA in 10, ECIIIB in 26 and ECIV in 25. One 
patient came with a relapsed tumor and four patients were 
lost of follow up before the staging work up was completed. 
ECOG:8 ECOG 0;35 ECOG 1;19 ECOG 2;13 ECOG3;3 ECOG4 and 
in seven in the chart was no data of ECOG. Seventy percent 
of patients received chemotherapy,with platin containing 
regimens: 44% cisplatin and etoposide, 27% carboplatin plus 
paclitaxel,13%carboplatin and etoposide,10%gemcitabine 
and etoposide and in 6% other combinations. Eight patients 
underwent surgery and 17 radiation therapy. Twenty six 
patients died between 1 to 32 month after the admission in the 
Department with a median survival of 8,5 month.Tree are alive 
and asymptomatic with 28, 36 and 63 month of follow up, ten 
patients are in palliative treatment and 42 patients were lost 
of follow up, twelve of them with progressive disease and two 
asymptomatic with 12 and 13 month of disease free survival. 
Disclosure: No significant relationships.
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P1.13: PREVALENCE OF SMOKING AMONG MEDICAL 
PROFESSIONALS OF A PUBLIC HOSPITAL
Fátima M.M.D. Santos1, Carlos H.B.C. Gouveia2, Maria J.C. 
Passos2, Patricia M. Andrade2, Alexandre A.B.P. Guimarães2, 
Roberta I.L. Machado2  
1Dps, Ufpb, João Pessoa/BRAZIL, 2Ufpb, João Pessoa/BRAZIL
Background: Smoking is considered a serious public health 
problem and a major avoidable risk factorfor major causes of 
morbidity and mortality today, such as cancer, cardiovascular 
andpulmonary diseases. According to estimates by the World 
Health Organization (WHO), six million deaths are a result of 
that harm. Despite such information, smoking persists among 
physicians when it should be a model group of anti-smoking 
campaign, as recommended by WHO. It is shown, thus the 
importance of research to assess theprevalence of smoking 
among physicians. The objetctive of this study is to determine 
the prevalence of smokers in a sample of physicians from a 
public hospital in the city of João Pessoa in the state of Paraíba, 
characterizing the smoking profile of this sample and the 
possible relationship with respiratory symptoms such as cough 
and / or dyspnea, as well as the relationship with secondhand 
smoke in domestic living.
Methods: It was used a questionnaire designed specifically for 
our objectives in a observational cross-sectional descriptive 
study. It was applied to all doctors of the hospital in the form 
of interviews in the hospital. It was performed through an 
active search and voluntary participation. It was asked about 
smoking, how long being skoming, the number of cigarettes 
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per day, having symptoms of cough and / or dyspnea, in case 
of being a former smoker (those with one or more years of total 
abstinence) how long and usage of medications for stopping. All 
interviewed ones were asked about secondhand smoke in home 
environment.
Results and Conclusion: There is a total sample of 447 
practicing physicians in the hospital among the contracted, 
volunteers, residents and professors. In inferred results, 5.08% 
are smokers, 9.32% are former smokers and 18.64% being 
passive smokers. Thus, 66.96% of the sample behaves as 
nonsmokers. Among the 33.04 exposed to tobacco effects, 
10.75% reported cough and/or dyspnea. The universe of non-
smokers in this sample was greater than the others, however 
passive smokers constitutes a concern group similar found 
in the general population influencing the habit and exposing 
individuals to the harmful effects of smoking without offering 
them the right to choice. Similar groups have been found in the 
general population. Medical professionals in various age groups 
have shown a positive awareness about the harms of smoking.
Disclosure: No significant relationships.
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P1.14: EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION IN 
NON SMALL CELL LUNG CANCER: VENEZUELAN EXPERIENCE
George A. Oblitas1, Cristina Garcia1, Maria Fuentes1, Ernestina 
Pichelbauer1, Jose Delgado1, Maria Perez1, Juan Rodriguez1, 
Karen Kubicek2, Patricia Nuñez3  
1Oncologia Medica, Instituto Oncologico Dr Luis Razetti, Caracas/
VENEZUELA, 2Oncologia Medica, Hospital Militar, Caracas/VENEZUELA, 
3Oncologia Medica, Oncologico Padre Machado, Caracas/VENEZUELA
Background: Lung cancer is the most common cause of cancer 
related death worldwide. The current treatment strategy 
includes the identification of somatic mutations of EGFR. In 
Venezuela, frequency and type of EGFR mutation in patients 
with NSCLC are unknown. Given its importance in treatment 
decisions, it was decided to conduct this study in order to know 
the characteristics of our population regarding the status and 
type EGFR mutation.
Methods: Since November 2010 until March 2012, we collected 
samples from 395 patients with NSCLC diagnosis in the country, 
and were evaluated to determine the EGFR mutation. We 
calculated 95% confidence intervals based on the binomial 
distribution.
Results and Conclusion: Among 395 patients, 80 had 
inadequate sample,19 missing data and 296 patients for 
analysis. We obtained a mutation rate of EGFR of 11.5%, 
being more frequent in males (56%) under 65 years (66%), 
former smokers (59%) with adenocarcinoma histology (97%). 
Regarding the type of EGFR mutation, the exon 21 mutation was 
detected in 59% of positive cases, and deletion of exon 19 in 
38%. Conclusions: EGFR mutation is present in the Venezuelan 
population and shows a particular regional demographic 
behavior.
Disclosure: No significant relationships.
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P1.17: OUTCOMES OF CISPLATIN PLUS PEMETREXED AS FIRST-
LINE THERAPY FOR ADENOCARCINOMA OF THE LUNG - HOW 
AN ONCOLOGICAL CENTRE IN TAYSIDE, SCOTLAND COMPARES 
WITH THE LITERATURE
Gordon M. Buchanan, Hannah K. Lord  
Ninewells Hospital And Medical School, University Of Dundee Medical 
School/UNITED KINGDOM
Background: Evidence supports the use of cisplatin plus 
pemetrexed as first-line chemotherapy for advanced 
adenocarcinoma and large cell carcinoma of the lung. We review 
the outcomes of patients with such histologically-confirmed 
disease, treated with this regimen, in NHS Tayside, between 
June 2008 and April 2011.
Methods: Patients were identified from our departmental 
databases and patient demographics, smoking status, disease 
stage, toxicities, response to treatment and survival were 
collected,
Results and Conclusion: 16 patients were identified. 12 (75%) 
patients were male. 13 (81.3%) were 65 years or younger. 
93.8% were current or ex-smokers. 87.5% had disease stage 
lV. 75% had a performance status (PS) of 1 with 25% having 
a PS of 0. Seven patients received only 1 cycle, due to rapidly 
progressive disease (5), toxicities (1) or a dislike of overnight 
stay (1). 6 patients received 4 cycles, one patient 3 cycles 
and 2 patients 6 cycles. 6 patients had a partial response, 2 
stable disease and 6 disease progression, measured on CT. 
Grade 3 or 4 toxicities were recorded in 2 (13%) of patients (1 
neutropenic sepsis and 1 fatigue). Median survival at the time of 
data collection was 284 days (range 11-578) with 5 patients still 
being alive. These local data, of a very small sample size, show a 
very similar median survival compared with published data (10.1 
vs. 10.3 months). Our incidence of grade 3 or 4 toxicities is also 
higher than published literature (7% vs. 1% febrile neutropenia). 
Cisplatin plus pemetrexed is therefore not without toxicity and 
in our population challenges to administration exist.
Disclosure: No significant relationships.
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P1.18: METASTATIC NON SMALL CELL LUNG CANCER (NSCLC) 
WITH MORE THAN 3 YEARS SURVIVAL 
Jorge Arancibia1, Osvaldo Arén1, Rodrigo Ascui1, Humberto 
Cerda1, Cristina Fernandez2, Victor Zambrano3, Daniel Cancino3, 
Marcela Carcamo4  
1Servicio De Oncología Médica-Sección Oncología Torácica, Instituto 
Nacional Del Cáncer, Santiago/CHILE, 2Servicio De Anatomía Patológica, 
Instituto Nacional Del Cancer, Santiago/CHILE, 3Servicio De Radioterapia, 
Instituto Nacional Del Cancer, Santiago/CHILE, 4Estadistica Médica, 
Instituto Nacional Del Cancer, Santiago/CHILE
Background: Metastatic NSCLC has a poor prognosis with a 
median survival around 12 months in treated patients. The 
published evidence suggests that females have a better survival 
than men and that EGFR mutated adenocarcinoma histology 
has a significant better prognosis. In this study we describe the 
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characteristics of a subpopulation of long survivors (>3 years) in 
patients with metastatic NSCLC.
Methods: A population of 313 patients with metastatic NSCLC 
were treated with at least 2 cycles of first line platinum based 
chemotherapy in our Thoracic Oncology Unit from April 2004 to 
April 2009. Metastatic disease was staged according to the 7th 
edition IASLC staging system. An analysis of the characteristics 
of the subpopulation of patients that had an overall survival 
over 3 years was performed.
Results and Conclusion: Results: Sixteen patients (5,1%) of 
the study population had an overall survival longer than 3 
years. The characteristics of this group of long survivors were: 
94% female, 6% men, 87,5% adenocarcinoma histology, 31% 
carriers of EGFR mutation. The location of metastatic disease 
at presentation was: 50% pleural/lung, 25% central nervous 
system, 12,5% bone and 12,5% lymphatic nodes. 87% of the 
patients received second line chemotherapy and 62% received 
third line chemotherapy.
Conclusion: This study suggests a clinical, pathologic and 
molecular profile of long survivors among metastatic NSCLC 
patients. Awareness of this profile may be of help in selecting 
adequate treatment for these patients.
Disclosure: No significant relationships.
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P1.19: BEVACIZUMAB CONTAINING CHEMOTHERAPY AS THIRD 
TO FIFTH LINE OF SYSTEMIC TREATMENT FOR SELECTED 
PATIENT WITH ADVANCED LUNG ADENOCARCINOMA
Diego Marquez-Medina, Mª Teresa Taberner Bonastre, Ariadna 
Gasol Cudos, Irene Mangues Bofarull, José Miguel Durán Alamá, 
Santiago Miguelsanz García, José Antonio Schoenenberger 
Arnaiz, Antonieta Salud Salvia  
Medical Oncology, University Hospital Arnau De Vilanova, Lleida/SPAIN
Background: Non-small cell lung cancer (NSCLC) are the most 
common and lethal malignancies of developed countries. 
Conventional chemotherapy has a limited impact only on 
the course of the disease and great expectations have been 
deposed in target therapies. Bevacizumab is a monoclonal 
antibody against vascular endothelial growth factor A, that 
inhibits neoangiogenesis and increases the effect of cytotoxic 
compounds in NSCLC. In Spain, Bevacizumab associated to 
platin-based chemotherapy is approved for first line treatment 
of unresectable or advanced non-squamous NSCLC. We 
report our experience applying Bevacizumab plus platin-based 
chemotherapy as third to fifth line systemic therapy for selected 
patients with lung adenocarcinoma.
Methods: Five patients with wild type epidermal growth factor 
receptor lung adenocarcinomas were treated in third (20%), 
fourth (60%) or fifth (20%) line of therapy. Four of them were 
women and one was a man. One patient received 4 cycles of 
Bevacizumab 7.5 mg/kg plus Carboplatin AUC 5 every 21 days. 
Two patients received Bevacizumab 7.5 mg/kg plus Carboplatin 
AUC 5 plus Paclitaxel 175 mg/m2 every 21 days for 2 and 5 
cycles, respectively. And other two patients were treated with 2 
cycles of Bevacizumab plus Carboplatin plus Paclitaxel, followed 
by 4 cycles of Bevacizumab plus Carboplatin, followed by 
triweekly Bevacizumab. One of them still maintains treatment 
with single agent Bevacizumab.
Results and Conclusion: Disease stabilization was observed in 
60% of cases and partial response in 40%. Mean progression 
free survival was 5.04 months (range 1.4 to 9.8), and mean 
overall survival was 10.5 months (range 2.03 to 21.83). Three 
patients presented no relevant toxicity, grade-2 infection was 
observed in one patient, and grade-3 deep venous thrombosis 
was observed in another one. CONCLUSION: Bevacizumab 
in combination with carboplatin-based chemotherapy is 
active and secure for selected advanced patients with lung 
adenocarcinoma treated beyond the second line of therapy, and 
it could be applied in previously heavily treated patients.
Disclosure: No significant relationships.
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P1.20: ERLOTINIB IS HIGHLY ACTIVE IN SELECTED PATIENTS 
WITH NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING 
WILD TYPE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)
Diego Marquez-Medina, Ariadna Gasol Cudós, Mª Teresa 
Taberner Bonastre, Antonio Martín Marco, Silvia Gómez 
Falguera, Eugenia Ortega Izquierdo, Irene Mangues Bofarul, 
Antonieta Salud Salvia  
Medical Oncology, University Hospital Arnau De Vilanova, Lleida/SPAIN
Background: Gefitinib and Erlotinib are the only two Tyrosine 
Kinase Inhibitors of the epidermal growth factor receptor (TKI-
EGFR) approved for the treatment of advanced NSCLC. The iPass 
Trial revealed that Gefitinib is only active for NSCLC harboring 
sensitizing mutation EGFR. Selected (female, Asian, non-
smoker) patients with unknown or wild type EGFR (wtEGFR) 
does not significantly respond to Gefitinib. In the same way, 
Erlotinib has been reported to be especially active in NSCLC 
harboring sensitizing mutation EGFR. So, some physicians 
consider the administration of ITK-EGFR to mutation patients 
only. We report our experience applying Erlotinib as second, 
third or fourth line of therapy to selected stage IV wtEGFR 
NSCLC.
Methods: We retrospectively review 24 consecutive stage IV 
NSCLC patients treated with single agent Erlotinib between July, 
2006 and September, 2011. None of them harbored mutation 
EGFR (18 patients were wtEGFR, tumor samples were non-
valid in another 4, and they were not analyzed in 2). Selection 
criteria to receive Erlotinib includes female gender, and/or to be 
current or non-smoker, and/or non-squamous NSCLC histology, 
and/or to be younger than 60 years old.
Results and Conclusion: Patients’ age ranged since 31 to 
77 years old (mean 56.7 years old). Sixteen patients were 
women, and 8 were men. Non-smoker represented 62.5% 
of cases, 12.5% of patients smoked less than 5 cigarettes per 
day, and 25% were current smokers. NSCLC histology was 
adenocarcinoma in 70.8% of cases, squamous cell carcinoma in 
17.7%, non-specified NSCLC in 8.4%, and large cell carcinoma 
in 4.1%. Single agent Erlotinib was administered as second line 
therapy in 45.8% of patients, third line in 41.7%, and fourth 
line in 12.5%. Estimated mean progression free survival was 5.6 
months (29.16% progressed in the first 3 months of treatment, 
33.33% progressed between the third and sixth month of 
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treatment, and 37.5% maintained treatment for more than 
six months). Mean overall survival was 10 months. Grade III 
asthenia, skin rash, and diarrhea appeared in 8.4% of patients 
only. CONCLUSION: Single agent Erlotinib could be a highly 
active and tolerable treatment for clinically selected NSCLC 
regardless the absence of sensitizing mutation EGFR.
Disclosure: No significant relationships.
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P1.21: SALVAGE RADIOTHERAPY FOR SOLITARY FOCUS OF 
DISEASE PROGRESSION COULD ALLOW MAINTAINING THE 
EFFICACY OF ERLOTINIB IN ADVANCED NON-SMALL CELL LUNG 
CANCER
Diego Marquez-Medina1, Abraham Chachoua2, Ariadna Gasol 
Cudós1, Franco Muggia2  
1Medical Oncology, University Hospital Arnau De Vilanova, Lleida/SPAIN, 
2Medical Oncology, Nyu Cancer Institute And Langone Medical Center/
UNITED STATES OF AMERICA
Background: Incidence and lethality of non-small cell lung 
cancer (NSCLC) is high and conventional chemotherapy 
obtains limited benefits in the treatment of advanced cases. 
Accordingly, the introduction of gefitinib and erlotinib, two 
tyrosine kinase inhibitors of the epidermal growth factor 
receptor (TKI-EGFR), for the palliation of advanced NSCLC 
gave rise to great expectations. Sensitizing mutations of the 
EGFR select 16.6% of NSCLC who clearly benefit of TKI-EGFR. 
However, detection and reversal of acquired resistances to 
these TKI-EGFR, as well as consolidation with other therapeutic 
strategies, are warranted in order to prolong progression free 
survival and efficacy of erlotinib and gefitinib in NSCLC.
Methods: We report the experience of the NYU Cancer Institute 
and Langone Medical Center of New York (USA) and the 
University Hospital Arnau de Vilanova of Lleida (Spain) applying 
salvage radiation over solitary focus of disease progression in 5 
patients with metastatic NSCLC to bypass the eventual acquired 
resistance to erlotinib or gefitinib.
Results and Conclusion: Table 1 shows characteristics of 
our patients and results. Progression was further avoided 
in all the cases with no apparent additional toxicity. TKI-
EGFR administration was maintained, and progression free 
survival was increased 41 to 146%, suggesting prolongation of 
therapeutic benefit from these agents. CONCLUSION: Salvage 
radiation over solitary focus of disease progression is feasible 
and should be considered in selected NSCLC patients treated 
with TKI-EGFR. 
Disclosure: No significant relationships.
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P1.22: HERALD: A PHASE 1B/2 TRIAL OF HER3 INHIBITOR U3-
1287 IN COMBINATION WITH ERLOTINIB IN PATIENTS WITH 
ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
Joachim Von Pawel1, Jennifer Tseng2, Mircea Dediu3, Christian 
Schumann4, Catherine Copigneaux5, Robert A. Beckman5  
1Asklepios Fachkliniken München-Gauting, Gauting/GERMANY, 2MD 
Anderson Cancer Center Orlando, Orlando/UNITED STATES OF AMERICA, 
3Institute Of Oncology Bucharest, Bucharest/ROMANIA, 4Innere Medizin Ii, 
Sektion Pneumologie, Universitätsklinikum Ulm, Ulm/GERMANY, 5Daiichi 
Sankyo Pharma Development, Edison/UNITED STATES OF AMERICA
Background: Second- or third-line treatment with an EGFR 
tyrosine kinase inhibitor (TKI) is widely accepted as a standard 
option in advanced NSCLC; disease stabilization is expected in 
up to 45% of patients. However, all cases eventually develop 
therapeutic resistance. HER3 is a key dimerization partner of 
EGFR family members, and signaling through its dimers may 
play a role in EGFR TKI resistance. Thus, simultaneous inhibition 
of HER3/EGFR may be beneficial. U3-1287 is a fully human 
anti-HER3 monoclonal antibody with synergistic anticancer 
activity in combination with anti-EGFR inhibitors in preclinical 
models. The phase 1b/2 HERALD trial is investigating U3-1287 
in combination with erlotinib in advanced NSCLC patients after 
failure of ≥1 prior chemotherapy. Interim results are reported as 
of February 16, 2012.
Methods: Eligible patients had EGFR treatment-naïve stage 
IIIB/IV NSCLC that progressed on ≥1 prior chemotherapy. In 
the open-label, dose de-escalating, phase 1b portion, patients 
received erlotinib 150 mg/day orally and U3-1287 18 mg/kg 
intravenously Q3W; as no DLTs were reported, dose was not de-
escalated, and this regimen is the recommended phase 2 dose. 
The phase 2 portion of the study is a randomized, placebo-
controlled, double-blind study assessing the efficacy and safety 
of U3-1287 combined with erlotinib relative to erlotinib alone. It 
is a 3-arm study of 150 mg/day erlotinib with U3-1287 low-dose 
(18 mg/kg loading dose followed by 9 mg/kg Q3W; based on PK 
simulation, this dose will produce trough blood levels ≥10-fold 
greater than those associated with maximal efficacy in mice), 
high-dose (18 mg/kg Q3W; to test if higher concentrations lead 
to more homogenous large tumor penetration), or placebo. 
Study end points include adverse event (AE) incidence, 
pharmacokinetics, human antihuman antibody (HAHA) 
formation, tumor response, and progression-free survival. 
Results and Conclusion: The phase 1b portion of the trial 
enrolled seven patients (four male; median age [range], 68 
years [48−78]). AEs grade ≥3 occurred in two patients; none 
were related to U3-1287. Three patients had four serious 
AEs: grade 3 pain (unrelated to study treatment), grade 3 
dehydration (erlotinib-related), and grade 1 decreased appetite 
(erlotinib- and U3-1287-related) and grade 1 pyrexia (unrelated) 
in one patient. The only U3-1287–related AE reported in ≥2 
patients was decreased appetite (2 patients). All patients tested 
negative for HAHA formation. No response was recorded; stable 
disease was noted in four patients (83, 87, 90, and 117 days). 
In the phase 2 portion, 109 patients (62 male; median age 
[range], 64 years [35−83]) have received study treatment as of 
February 16. Seventy-eight patients (72%) experienced an AE 
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during treatment; of these, 27 (35%) experienced AEs with a 
worst grade ≥3. Seven deaths were reported, all unrelated to 
study treatment. Most frequent AEs reported were diarrhea 
(42.2%), rash (40.4%), nausea (20.2%), decreased appetite 
(13.8%), vomiting (12.8%), and fatigue (10.1%). Twenty-eight 
patients (26%) experienced a serious AE; the most common 
were dyspnea (3 patients), diarrhea (3), respiratory failure 
(2), abdominal pain (2), vomiting (2), pain (2), and general 
physical health deterioration (2). Treatment remains blinded. 
Results to date indicate that toxicity associated with U3-1287 in 
combination with erlotinib is manageable. 
Disclosure: CC and RB: stockholders and full-time employees 
of Daiichi Sankyo Pharmaceutical Development. RB: stockholder 
in Johnson & Johnson corporation. MD: served in advisor board 
committees, received speaker fees from Hoffmann LaRoche. 
JVP, TS, CS: none.
POSTER SESSION 1 - July 26, 2012 09:00 – 17:00
Advanced NSCLC
P1.23: PHASE 1 SAFETY AND PHARMACOKINETIC (PK) STUDY OF 
VELIPARIB IN COMBINATION WITH WHOLE BRAIN RADIATION 
THERAPY (WBRT) IN PATIENTS (PTS) WITH BRAIN METASTASES
Minesh P. Mehta1, Walter J. Curran2, Ding Wang3, Fen Wang4, 
Lawrence Kleinberg5, Anthony Brade6, Nael Mostafa7, 
Xiangdong Zhou7, Jiang Qian7, Terri Leahy7, Bhardwaj Desai7, 
Vincent Giranda7  
1Northwestern University, Chicago/UNITED STATES OF AMERICA, 2Winship 
Cancer Institute Of Emory University, Atlanta/UNITED STATES OF AMERICA, 
3Henry Ford Hospital, Detroit/UNITED STATES OF AMERICA, 4Kansas 
University Medical Center, Kansas City/UNITED STATES OF AMERICA, 5Johns 
Hopkins University, Baltimore/UNITED STATES OF AMERICA, 6Princess 
Margaret Hospital, Toronto/CANADA, 7Abbott Laboratories, Abbott Park/
UNITED STATES OF AMERICA
Background: Veliparib is an oral PARP-1 and -2 inhibitor that 
enhances the antitumor activity of DNA damaging agents 
including radiation therapy in vivo (e.g colon carcinoma and 
NSCLC). In pre-clinical models, veliparib crosses the blood-
brain barrier. This ongoing phase 1 dose-escalation study 
evaluates the safety, PK, and provides preliminary antitumor 
activity of veliparib in combination with WBRT in pts with brain 
metastases (NCT00649207).
Methods: Pts with brain metastases (including leptomeningeal) 
from primary non-CNS metastatic solid tumors (except germ 
cell cancer), adequate organ function, and RPA Class 2 and 
Karnovsky performance status ≥70 were treated with WBRT 
(37.5 Gy in 15 fractions or 30 Gy in 10 fractions) QD and 
veliparib BID with daily WBRT, in escalating doses of 10, 20, 30, 
50, 100, 150, and 200 mg; the final WBRT fraction was followed 
by 1 extra day of veliparib. Safety, PK, and tumor response by 
RECIST were assessed.
Results and Conclusion: To date, 61 pts (M/F, 22/39; median 
age 57 y) have been treated. Baseline KPS was 70, 80, 90, and 
100 in 8.2, 31.1, 39.3 and 21.3% pts, respectively; primary 
tumor types were breast (n=20), NSCLC (n=22), melanoma 
(n=9), colorectal (n=2), and others (n=8); 73.8% pts had 
multiple lesions, and 18.0% had prior brain stereotactic 
radiosurgery. Grade 3/4 treatment-emergent adverse events 
(TEAEs; ≥5%) were fatigue (6.6%) and other TEAEs (≥20%) were 
fatigue (57.4%), headache (42.6%), nausea (39.3%), alopecia 
(26.2%), vomiting (23%), radiation skin injury (21.3%), and 
decreased appetite (22%). PK of veliparib was approximately 
dose-proportional, with oral clearance of 21.6 ± 14.2 L/h (mean 
± SD, n = 45), minimal drug accumulation at day 15, and no 
significant effect of food on bioavailability. Best tumor response 
was calculated using 41 pts who had measureable lesion(s) at 
baseline, had at least one post baseline tumor assessment, 
and had no leptomeningeal involvement (including intra and 
extra-cranial metastases). Best tumor response rate (CR or PR) 
and median survival time were 42.9% and 10 months (m) for 
NSCLC, and 52.9% and 12.5 m for breast cancer (excluding pts 
with leptomeningeal involvement [including intra and extra-
cranial metastases]). Addition of veliparib up to 200 mg BID was 
well tolerated with concurrent standard WBRT. Dose escalation 
is ongoing. The PK of veliparib was dose proportional with no 
food effect. These encouraging safety and preliminary efficacy 
data suggest that veliparib requires further evaluation as a 
radiosensitizer with WBRT, in patients with NSCLC and brain 
metastases in a randomized trial. 
Disclosure: Disclosures for M. Mehta: Employment: 
Pharmacyclics Honoraria: Merck, Grace, MDM,Prime Onc, 
Strategic, Edge, WebMD Consultant: Bayers, Elekta, Novartis, 
Quark, Tomotherapy, Vertex, BMS,USOnc Stock: Pharmacyclics, 
Colby, Accuray, Procertus, Stemina Disclo
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P1.24: LARGE CELL CARCINOMA [LCC] (CLASSICAL, LCC WITH 
NEUROENDOCRINE MORPHOLOGY [LCCNM], AND LARGE CELL 
NEUROENDOCRINE CARCINOMA [LCNEC]) AND SMALL CELL 
CARCINOMA [SCC] OF THE LUNG: SHOULD THEY BE TREATED 
EQUALLY IN ADVANCED STAGES?
Aldo L.A. Dettino1, Graziella Z.D. Molin1, Ulisses R. Nicolau1, 
Vladmir C.C.D. Lima1, Milena S. Tariki1, Helano C. Freitas1, 
Marcello F. Fanelli1, Fabio J. Haddad2, Renato D.L. Rozenowicz2, 
Marcus Vinicius B. Baranauskas2, Cynthia T. Osório3, Clóvis A.L. 
Pinto3, Jefferson L. Gross4  
1Oncologia Clínica, Hospital A. C. Camargo, Sao Paulo-sp/BRAZIL, 
2Núcleo De Cirurgia Do Tórax, Hospital A. C. Camargo, Sao Paulo/BRAZIL, 
3Anatomia Patológica, Hospital A C Camargo, Sao Paulo/BRAZIL, 4Núcleo 
De Pulmão E Tórax, Hospital A C Camargo, Sao Paulo-sp/BRAZIL
Background: Lung cancers have many subtypes, such as LCC, 
which may be divided in classical, LCCNM, and LCNEC. On the 
other hand, neuroendocrine lung tumors may be classified 
as typical and atypical carcinoids, LCNEC and SCC. They are 
different pathological lung cancer subtypes, but with some 
similarities. LCNEC is rare and also has a poor prognosis. The 
best diagnostic approach and systemic treatment in advanced 
stages for each of them remain to be defined.
Methods: In order to review and discuss different treatment 
approaches for LCC of the lung, we present a series of patients, 
describing clinical and treatment data, in addition to response 
rates and survival outcomes. Patients were followed and treated 
in: Centro Internacional de Pesquisa e Ensino (CIPE)/Hospital A. 
C. Camargo, Clínica D. Erlich, in Sao Paulo-SP, or Instituto de 
Oncologia de Jundiaí-SP; Brazil.
Results and Conclusion: The series of lung LCC is presented 
below, with clinical, treatment and outcome aspects. 
Case #1 – Male, 63y, LCNEC, pT3N1M0. Surgery (S), 
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Chemotherapy (CT): etoposide+cisplatin x1 - bradicardia 
grade (G) 3, irinotecan+carboplatin x 3; Radiotherapy (RT): 
adjuvant. Survival 7+ months (m). Case #2 – Male, 55y, 
LCCNM, pT2aN0M1 (peri-hepatic lymph nodes). S, CT: 
pemetrexed+cisplatin x 6, pemetrexed maintenance x 15 
– asthenia G2; susteined complete response (CR). Survival 
18+ m. Case #3 – Male, 71y, LCNEC, cT4N2M1 (bone). CT: 
etoposide+cisplatin x 2: PD; pemetrexed+carboplatin+bev
acizumab x 6 – myelotoxicity G4; partial response (PR), not 
sustained. Survival 9m. In conclusion, lung LCCs appear to 
be different, either in pathological or in clinical aspects. The 
best treatment approaches remain to be better studied and 
definied. Nonetheless, we believe that LCCNM should be treat 
as non-small cell lung cancer, and LCNEC (highly responsive to 
platinum-based CT) should be treated as SCC of the lung. 
Disclosure: No significant relationships.
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P1.25: INFLUENCE OF PALLIATIVE RADIOTHERAPY ON 
PROGNOSIS AND QUALITY OF LIFE FOR PATIENTS WITH STAGE 
IV NON-SMALL CELL LUNG CANCER
Jian Z. Cao  
Radiotherapy, Shanxi Tumor Hospital, Taiyuan/CHINA
Background: A retrospective analysis of palliative radiotherapy 
for stage IV non-small cell lung cancer prognosis and quality of 
life impact. 
Methods: Clinical data of 318 advanced patients of non-small 
cell lung cancer who received palliative radiation was collected 
from January,2000 to December, 2009,and the patients cannot 
endure or receive chemotherapy for all kinds of reasons.Survival 
analysis was performed by the K-M method, comparison among 
groups was performed by log-rank test and multivariate analysis 
was carried out with the Cox proportional hazard model. 
Results and Conclusion: 318 patients 1, 2-year survival 
rates, median survival time were 25.2%, 7.4%, 7 months. 
The response rate defined as palliation of stage IV NSCLC 
symptoms after palliative radiotherapy was 72.4% for cough, 
80.6% for thoracic pain, 88.1% for haemoptysis, 60.8% for 
dyspnoea, 19.2% for hoarseness, Metastatic bone pain and 
brain metastases have different signs and symptoms ease or 
even disappear: 76.8% for bone metastases, 75.7% for brain 
metastases. Univariate analysis showed: KPS , histological 
type, brain metastases, multi-organ metastasis, primary tumor 
radiation dose correlated with prognosis, multivariate analysis 
showed: KPS , multiple organ metastasis were independently 
associated with OS. Conclusions Palliative radiotherapy in the 
treatment of stage IV NSCLC played relieve symptoms, improve 
quality of life and prolong survival role. KPS , multiple organ 
metastasis were independent prognostic factors. 
Disclosure: No significant relationships.
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P1.26: RACOTUMOMAB ADMINISTRATION IN PATIENTS WITH 
ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) IN 
PROGRESSION AFTER FIRST LINE THERAPY
Amparo Macías1, Sailly Alfonso2, Eduardo Santiesteban3, E 
Neninger4, Z Acosta5, Re Gómez6, Laura Ardigo6, Am Vázquez1, 
Tania Crombet1, Rolando Pérez1, Agustín Lage1  
1Center Of Molecular Immunology, Havana/CUBA, 2Oncology Unit, 
University Hospital “Celestino Hernandez Robau”, Santa Clara, Las Villas/
CUBA, 3Oncology Unit, “Jose Ramón Tabranes” Hospital, Matanzas/CUBA, 
4Oncology Unit, University Hospital Hermanos Almejeiras, Havana/CUBA, 
5Oncology Unit, General Hospital Saturnino Lora, Sto De Cuba/CUBA, 
6Clinical Research, Elea Laboratories/ARGENTINA
Background: Racotumomab is therapeutic vaccine that 
induces an immune response against NeuGc-containing 
gangliosides, sulfatides and other antigens expressed in 
several human tumors but not in normal tissues. Previous trials 
have demonstrated low toxicity, high immunogenicity and 
survival benefit in advanced NSCLC when Racotumomab was 
administered in patients with objective response (partial or 
complete response or stable disease) to first line therapy. 
Methods: An open, non- randomized, population- based 
study was performed in patients with recurrent and advanced 
stages (IIIB/ IV) of NSCLC after completion of first-line onco-
specific treatment (surgery, chemotherapy and/or radiotherapy) 
as per the NCCN Oncology Therapeutic Guidelines who were 
vaccinated with Racotumomab. At inclusion patients presented 
progressive disease (PD) according to Recist. 89 patients were 
in stage IIIB, 71 were in stage IV (88.8%) and 20 patients 
(11.1%) presented with recurrent disease. For most patients 
prior chemotherapy was 4 to 6 cycles of cisplatin/vinblastin. 
Vaccination consisted of an induction period of 5 intradermic 
doses of 1mg of Racotumomab/ aluminum hydroxide (1 every 
14 days), followed by a maintenance period of 1 dose every 28 
days. Vaccination continued until patient refusal or worsening of 
ECOG status. 
Results and Conclusion: 180 patients were included in an 
intent to treat (ITT) survival analysis (Kaplan Meier estimate), 
after at least 10 months of follow-up. Median survival was 
8.06 months. Long-term OS rate (%) at 24 months was: 21%. 
Per protocol population (PPP) survival analysis included only 
the 124 patients (68.8%) who received ≥ 5 doses of vaccine. 
Median survival was 12 months. Long –term OS rate (%) at 
24 months was 30%. Survival data of the 180 Racotumomab 
treated patients was compared with a control group of 85 
consecutive patients treated at the same institution by the 
same investigators, who did not receive second line therapy 
after disease progression. Median survival in the control group 
was 6.26 months (log rank test p= 0.011). Long term OS rate 
(%) at 24 months was only 7%. The most common adverse 
events were mild and moderate local reactions at the injection 
site (pain, erythema, induration) and flu-like symptoms, none 
unexpected. 
Our population based study with Racotumomab shows similar 
results to those previously reported in NSCLC clinical trials. 
Treatment was safe and showed a survival advantage in 
advanced NSCLC patients when Racotumomab was used as a 
second line therapy after disease progression. 
Disclosure: No significant relationships.
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P1.27: THE EFFECT OF WARFARIN ON SURVIVAL IN PATIENTS 
WITH LUNG CANCER
Abdullah Ciftci1, Gundeniz Altiay2  
1Respiratory Medicine, Trakya University Faculty Of Medicine/TURKEY, 
2Respiratory Medicine, Trakya University Faculty Of Medicine, Edİrne/
TURKEY
Background: To assess the effects on survival of the low dose 
warfarin in patients with lung cancer. 
Methods: In this single center, randomized study, patients with 
lung cancer were randomly assigned to warfarin or to control 
(no warfarin) in addition to their standard anticancer treatment. 
Warfarin was given orally starting on day 1 of chemotherapy at 
a dose of 5 mg/d to achieve a target interrnational normalized 
ratio (INR) of 1.5-2.5 for six months. 
Results and Conclusion: A total of 44 patients were allocated 
to warfarin group, and 47 were allocated to the control group. 
The overall median survival was statistically higher on the 
warfarin group (358 days, 95% CI 226-489 days), as compared 
with the control group (236 days, 95% CI 187-284 days) 
(p=0.03). There was no statistically significant difference in the 
response rates (complete+partial) between two groups (56.8 
percent in warfarin group vs. 36.1 percent in the control group, 
p=0.09). No significant difference between the warfarin group 
and the control group was detected in the rate of bleeding (15.9 
percent and 6.3 percent, respectively, p=0.18). Warfarin may 
be effective in improving survival without increasing the risk of 
bleeding in patients with lung cancer. 
Disclosure: No significant relationships.
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P1.28: QUALITY OF LIFE IN ADVANCED NSCLC IN OLDER PEOPLE 
TREATED WITH CHEMOTHERAPY
Norma G. Pilnik, Guillermo A. Cuello, Diego Carri, Jose L. 
Vanney Rachid  
Oncology, Hospital Transito, Argentina/ARGENTINA
Background: To study the most common toxicities resulting 
from treatment in elderly patients with cancer. To compare 
the level and types of toxicities. Evaluate its correlation with 
comorbidities present. To analyze survival and quality of life.
Methods: 148 lung cancer pts were included. Pts selection was 
conducted using General Geriatric Assessment. PS (Performance 
status), ADL (Activity of Daily Living) and IADL (Instrumental 
of Daily Living) was studied before and after treatment. 
Pts underwent type and number of chemotherapy cycles. 
Pts were divided in older and younger than 70. All pts had 
adequate cardiac, hepatic, renal and bone marrow functions. 
Comorbidities studied were: hypertension, diabetes, COLD, 
arrhythmia, coronary disease and digestive disease. Toxicities 
were studied following the WHO criteria and correlated 
according to age, ADL, IADL, PS, WL, comorbidities, and the 
use of more than 3 drugs (Polypharmacy), in addition to the 
treatment. QoL was assessed through the evolution of ADL, 
IADL and PS. Statistical Methods: Pearson´s Chi-Square, Kaplan 
Meier´s Survival tests.
Results and Conclusion: The most frequent toxicity level was 
bone marrow function. 47.3% received second-line therapy 
and only 61.4% received > 4 cycles. There were No relationship 
was found between toxicities and age, irrespective of type and 
level. Toxicity level was found to be higher in the patients who 
used more than 3 other medications p=0.006. No Statistically 
significant association was found between comorbidities and 
toxicity levels. There was improvement in Qol through ADL, 
PS, and IADL evolution after treatment p= 0.001. Conclusions: 
The toxicities is not more severe in older than 70 yrs. Age is 
not a contraindication to lung cancer treatment. Pts selection 
is very important to optimize the outcome. Pts in good 
general condition and with controlled comorbidities may 
receive Chemotherapy, if this treatment modality results in 
improvement of their QoL. IADL and nutritional status are an 
important issue to consider.
Disclosure: No significant relationships.
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P1.30: RADIOLOGICAL FINDING OF PULMONARY EMBOLISMS 
(PE) BY MULTIDETECTOR COMPUTED TOMOGRAPHY (MDCT): 
RETROSPECTIVE MONOCENTRIC STUDY IN PATIENTS WITH 
ADVANCED NON-SMALL CELL LUNG CANCER
Enrica Capelletto1, Federica Solitro2, Simonetta Rapetti1, Luana 
Focaraccio1, Silvia Novello1, Andrea Veltri2  
1Department Of Clinical And Biological Sciences, Orbassano/ITALY, 
2Radiology Department, Orbassano/ITALY
Background: Thrombotic risk in cancer patients is increased 
of 2-7 fold and cancer-associated venous thromboembolism 
(VTE) is one of the leading cause of death for these patients. 
Incidence of VTE is equal to 1 event per 110-120 patients with 
cancer and most of pulmonary embolisms (PE) occur during 
the first year after diagnosis. Cancer patients with VTE have 
a 2.2-fold increase in mortality and lung cancer, considered 
worldwide the leading cause of cancer-related death, is the 
second tumor type with the highest incidence of VTE. Sistemic 
treatments represent the therapy of choice for advanced non-
small cell lung cancer (NSCLC) patients, which account nearly 
85% of all lung cancer cases. Considering that chemotherapy 
is associated with a 6 times increased risk of VTE and that 
biological agents, especially antiangiogenetic agents, determine 
an additional risk, the aim of the present study is to evaluate, 
after radiological retrospective imaging evaluation, the real 
incidence of PE in selected cohorts of patients with advanced 
NSCLC and the impact of PE on survival. 
Methods: This retrospective monocentric study enrolled 141 
patients with advanced NSCLC, diagnosed between June 2007 
and June 2008, and between January 2010 and December 2010 
(Table 1). Most of patients of both groups received at least a 
platinum-based chemotherapy; patients treated during their 
clinical history with biological agents were respectively 74.1% 
and 43.3%, with antiangiogenetic agents 39.5% and 21.7%, 
while 46.9% and 20.0% of patients was involved in double-
blind clinical trials with biological drugs compared to placebo. 
Two different radiologists retrospectively reviewed 460 thoracic 
contrast-enhanced MDCT studies, looking for PE and reaching a 
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consensus for each one. 
Results and Conclusion: Prevalence of PE corresponded to 
13.6% in the 2007-2008 cohort and to 15.0% in the other one. 
Survival analisis, conducted according to Kaplan Meier method, 
didn’t show any statistically significant differences in terms 
of OS and TTP in the 2007-2008 cohort. In the 2010 cohort, 
Kaplan Meier curves showed a statistically significant difference 
in terms of TTP in favor of patients who never developed PE, 
p-value=0.003. Similar results were observed at the subgroup 
analysis, performed considering as stratification factors the 
use of biological agents, p-value=0.007, and of antiangiogenic 
drugs, p-value=0.010. The higher incidence of PE in the 
2010 cohort, despite a lower exposure to biological and 
antiangiogenic agents, could result from a greater thrombogenic 
action of these drugs, but also a higher prevalence of 
comorbidities predisposing to VTE. In this cohort, descriptive 
analysis was confirmed by survival data. This underlines the 
necessity of further evaluations to clarify the role of these drugs 
as predisposing factors for PE. 
Disclosure: No significant relationships.
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P1.32: ELECTROCARDIOGRAM QTC PROLONGATION IN 
PATIENTS WITH LUNG CANCER UNDER CHEMOTHERAPY 
TREATMENT
Patricia Panchuk1, Lorena L. Lainati1, Mariano Vidal1, Fernando 
Lopez Piñero1, Alejandra Campos2, Guillermo Keller2, Guillermo 
Di Girolamo2, Claudia I. Bagnes2  
1Oncology, Hospital Enrique Tornu, Ciudad Autónoma De Buenos Aires/
ARGENTINA, 2Pharmacology, Facultad De Medicina,Universidad De Buenos 
Aires, Ciudad Autónoma De Buenos Aires/ARGENTINA
Background: Electrocardiogram QTc interval prolongation 
associated with cancer chemotherapy is a frequent event. 
The objective of this study was explored the frequency of QTc 
prolongation episodes previous and post-chemotherapy cycle 
in patients with lung cancer, comparing these findings with 
those obtained from patients treated from other malignant 
neoplasms.
Methods: We included patients consecutively admitted to 
chemotherapy cycles at one oncology specialized service at 
a general hospital. An electrocardiogram was performed at 
baseline, and pre- and after- each chemotherapy infusion. QT 
interval between Q wave onset and end of the T wave on the 
electrocardiogram was quantify in milliseconds and corrected 
(QTc) according to Bazzet formula. A delta of at least 20 msec 
from the baseline QTc measurement and/or a QTc duration over 
440 msec in men or 460 msec in women were considered as 
QTc prolongations for the research purposes.
Results and Conclusion: A total of 198 cycles were studied, 
involving a total of 60 patients (50% female; age: 63.1+12.5 
yr; 24 of them with lung cancer at stages IIIb-IV). Mean of 
all pre-cycle QTc lengths: 430.1+27.1msec; Mean of all post-
cycles QTc length: 437.7+40.6 msec. Mean first pre-cycle QTc 
length: 426.7+28.2 msec; mean first post-cycle QTc length: 
444.3+64.9 msec (p=0.056). Post first cycle mean QTc length 
was 15.7 msec longer in patients with pulmonary cancer when 
compared with patients with other neoplasms (being slightly 
longer for non lung cancer patients at pre-cycle). Patients with 
non-pulmonary cancer entered into a 29.8% of their cycles with 
a QTc prolongation (generally considered as slight); for patients 
with pulmonary cancer, this proportion reached 37% of the 
cycles. Postcycle QTc prolongation was registered in 37.5% of 
cycles in non-lung cancer patients and in 42.6% of cycles with 
pulmonary cancer. Almost 26% of patients with lung cancer 
presented prolonged pre and post cycle QTc lengths. Precycle 
prolongations were strong predictors of postcycle increments in 
QTc lengths. In conclusion, QTc prolongation is a frequent event 
in lung cancer (both pre and post-chemotherapy administration)
Disclosure: No significant relationships.
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P1.33: ADVANCED SARCOMATOID CARCINOMA OF THE LUNG:  
A CASE REPORT AND LITERATURE REVIEW
Fernanda C. Bes, Gilberto De Castro Junior, Paulo M.G. Hoff  
Centro De Oncologia, Hospital Sírio-Libanês, São Paulo/BRAZIL
Background: Sarcomatoid carcinoma (SC) of the lung is a rare 
and aggressive malignancy, composed of both epithelial and 
mesenchimal-derived cells. It accounts for about 0.1% to 0.4% 
of all lung carcinomas and five different subtypes are described 
(WHO 2004). As to specific systemic treatment, there is little 
information available in the literature. Here we present the 
results of a literature review and also describe the outcomes of 
a patient with metastatic SC of the lung treated in our Hospital. 
Methods: A literature search was conducted using the key 
words “sarcomatoid carcinoma” and “lung” in PUBMED 
database, in English, Spanish and Portuguese, limiting to 
studies in humans and adults. A total of 22 articles were 
retrieved and 16 were the focus of this review. Those six articles 
not analyzed were excluded either due to the absence of clinical 
data or because they contained only diagnostic pathological 
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features. 
Results and Conclusion: Case report: A 67-year-old male with 
a history of heavy smoking and alcohol intake sought medical 
help after 2 months of fever, dry cough and weight loss. A 
6.3-cm cavitated mass in the left superior lobe with extensive 
contact with the descending aorta was seen in CT scan, with 
metastasis in the left adrenal gland. SC was diagnosed, staged 
as T4 N2 M1. Patient was treated with pemetrexed-cisplatin, 
and died of progressive disease after two cycles. Results: 352 
cases were reviewed, and both adeno- and squamous cell were 
described as epithelial components. Most patients (pts) were 
current or ex-smokers (212 out of 240 pts with available data, 
88%), with predominance of males (280 pts, 80%) and median 
age 61.5 y. Overall, most pts presented with locally advanced 
or metastatic disease at diagnosis, with large and cavitated 
tumors. In rare cases of pts submitted to surgery with curative 
intent, adjuvant cisplatin-based chemotherapy did not seem 
to have impact on overall survival. No patient presented major 
tumor responses with classic platinum-containing regimens. 
Conclusions: SC is a rare entity, frequently associated with poor 
response to platinum-containing doublets. There is a clear need 
of a better understanding of this disease. Global, multicenter 
clinical trials should be designed in order to develop specific 
strategies to overcome difficulties in the management of this 
challenging rare entity. 
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P1.34: RETROSPECTIVE ANALYSIS OF NON-SMALL CELL LUNG 
CANCER PATIENTS WITH BRAIN METASTASIS TREATED IN A 
BRAZILIAN CENTER
Clarissa Baldotto, Luiz Henrique De Lima Araujo, Mauro Zukin, 
Fernando M. Vieira, M G Lima, Rafaela C R P Helal, Jonas H 
Salem, Nelson Teich, Carlos Gil M. Ferreira  
Clínicas Oncológicas Integradas, Rio De Janeiro/BRAZIL
Background: The presence of brain metastasis (BM) is an 
important prognostic factor in non-small cell lung cancer 
(NSCLC) patients, frequently limiting therapeutic options. With 
emerging new therapies for this disease, a better understanding 
of this high-risk population becomes increasingly important. 
This study aimed to evaluate clinical characteristics and 
outcomes of NSCLC patients harboring BM, treated in a private 
oncology center in Brazil (Clínicas Oncológicas Integradas - 
COI).
Methods: A retrospective review of NSCLC patients medical 
records was performed between 1999 and 2010, and all 
patients with a confirmed diagnosis of BM were selected for 
analysis.
Results and Conclusion: Results: A total of 446 patients 
with NSCLC were included, and 73 patients had BM (16,4%) 
at diagnosis or follow-up. Most of them had non-squamous 
histology (68%) and were male (65.8%). Approximately 54.8% 
of patients were smokers or former smokers. Median age of the 
entire population was 65 years. (CI95% 27-92). Most patients 
who developed BM were younger than 65 years-old (69.9%)
Only 9 patients (12.3%) were submitted to BM ressection, and 
74% received palliative brain radiotherapy. Median overall 
survival was 13.8 months (m) (CI95% 13.6-22.7) for patients 
with BM, compared to 19.8m (CI95% 15.5-24.2) for non BM 
patients (p<0,0001). Median survival after the diagnosis of 
BM was only 7.3 m (CI 95% 3.0-11.6). Age < 65 y (OR=2.2; 
p<0,0001) and non-squanous histology (OR=1.25; p=0,047) 
were independent risk factors for BM development.
Conclusion: Our results are similar to previous published data, 
corroborating that this specific population is younger and 
carries a dismal prognosis.
Disclosure: No significant relationships.
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P1.35: PANEL OF SERUM BIOMARKERS MAY PREDICT BENEFIT 
FROM BEVACIZUMAB (BEV) IN ADVANCED NSCLC PATIENTS
Eduardo Braun1, Mary Jo Fidler1, Sanjib Basu1, Anjali Gargaram2, 
Kelly Walters2, Cristina Fhied2, Jeffrey A. Borgia2, Philip D. 
Bonomi1  
1Division Of Oncology, Rush University Medical Center, Chicago/UNITED 
STATES OF AMERICA, 2Division Of Biochemistry, Rush University Medical 
Center, Chicago/UNITED STATES OF AMERICA
Background: BEV has produced modest benefits in patients 
(PTS) with advanced NSCLC. Identification of positive predictors 
for BEV would have important implications for individual PTS 
and health care costs. 
Methods: We performed a prospective exploratory analysis to 
identify serum biomarkers as predictors of improved outcomes 
with BEV. Pre treatment sera were collected from 93 pts prior to 
initiation of first line treatment for advanced NSCLC. Treatment 
drugs, including BEV, were prescribed according to treating 
physician’s discretion. Seventy two serum biomarkers, relevant 
to angiogenesis and tumor progression, were recorded using 
Luminex immunobead platform. Serum levels were correlated 
with progression free survival (PFS) and overall survival (OS) 
and compared between patient treated with or without BEV 
containing regimens, BEV + and BEV- groups respectively. Log-
rank and interaction p value tests were used to identify markers 
associated with longer PFS and OS in the BEV+ group but not in 
BEV- group.
Results and Conclusion: Characteristics for each group were: 
BEV+ (n=43, median age 65 y/o, 72% smokers, 60% females, 
100% non-squamous). BEV– (n=50, median age 64 y/o, 84% 
smokers, 50% female, 70 % non-squamous). The BEV+ group 
had longer PFS (5.8 vs. 3.0 mos, log-rank p= 0.039) and OS 
(13.1 vs. 8.5 mos, log-rank p =0.11) when compared to the 
BEV- group. High serum levels of these markers resulted in a 
differential decreased hazard in the BEV+ group: PDGF-AB/BB 
(interaction p <0.01 for PFS, p=0.04 for OS), FGF (interaction 
p=0.15 for PFS, p<0.04 for OS), tenascin-c (interaction p=0.18 
for PFS, p=0.04 for OS), RANTES (interaction p=0.04 for PFS, 
p=0.6 for OS), epiregulin (interaction p=0.31 for PFS, p=0.04 for 
OS) and anti-HGF (interaction p=0.18 for PFS, p=0.03 for OS). 
In the BEV+ group higher levels of PDGF-AB/BB were associated 
with a better outcome (log-rank p=0.05 and p=0.01 for PFS 
and OS respectively). We did not find significant correlations 
between serum levels of VEGF, anti-VEGF or VEGFR and 
benefit from BEV. This exploratory analysis suggests that these 
biomarkers may have predictive value for BEV in NSCLC PTS and 
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should be considered for further studies.
Disclosure: Dr. Philip Bonomi - Advisory role/Research 
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P1.36: THE INNOVATIVE METHOD USING CIRCULATING TUMOR 
CELLS FOR PREDICTION OF THE EFFECT OF THE INDUCTION 
THERAPY TO LOCALLY ADVANCED NON-SMALL CELL LUNG 
CANCER
Shintaro Tarumi, Yoshitaka Kasai, Natsumi Matsuura, Soosong 
Chang, Masashi Gotoh, Tetsuhiko Go, Shinya Ishikawa, Hiroyasu 
Yokomise  
General Thoracic,Breast And Endocrinological Surgery, Kagawa University, 
Kagawa/JAPAN
Background: While there is not an established standard 
therapy for locally advanced non-small cell lung cancer (NSCLC). 
Favorable prognosis has been reported in NSCLC patients 
who underwent induction chemoradiotherapy followed by 
surgery and subsequently achieved pathological complete 
response (CR). However, pathological therapeutic response 
is not sufficiently predictable before surgery at present, even 
with diagnostic imaging modalities, such as 18F-FDG PET/CT 
or re-mediastinoscopy. We confirmed that circulating tumor 
cells (CTCs) are more frequently detected in pulmonary venous 
blood than in peripheral blood in patients with NSCLC. Since 
CR refers to a condition in which no pathologically viable 
tumor cells remain, we assumed that CTCs are undetectable in 
patients who achieved CR in pulmonary venous blood. In order 
to assess whether CTCs are predictive of pathological response 
after induction chemoradiotherapy. We measured the number 
of CTCs in peripheral blood (p-CTCs) and in pulmonary venous 
blood (v-CTCs) and examined the relationship with histological 
response.
Methods: All patients were treated our institution from 
December 2010 to January 2012. The 9 patients who underwent 
induction chemoradiotherapy followed by surgery (I group), and 
the 6 patients who underwent surgery alone (S group). At the 
surgery, peripheral blood and pulmonary venous blood from the 
involved lobe were collected (7.5 mL each) for CTCs counting. 
CTCs were isolated using the CellSearch System (Veridex LLC). 
The result of two or more CTCs was judged positive. Correlation 
between the results of CTC count and pathological response 
was analyzed.
Results and Conclusion: All the patients of I group were 
clinical stage 3A. Pathological therapeutic response was CR in 
4 patients and partial response (PR) in 5 patients. Two patients 
were each at clinical 1A and 1B and 1 patient was each at 2A and 
2B in S group. All patients in I and S groups were negative for 
p-CTCs. Five patients in I group were positive for v-CTCs (mean: 
57.8 cells). All these 5 patients showed PR. The remaining 4 
patients who achieved CR were negative for v-CTCs. There 
was a significant difference in the numbers of v-CTCs between 
cases with PR and those with CR (p=0.012, Mann-Whitney’s U 
test). All 6 patients in S group were positive for v-CTCs (mean: 
207.5 cells), and the difference from I group was significant 
(p=0.038). CONCLUSION: All cases with CR were negative for 
v-CTCs (not more than 1 cell), and a significant difference was 
observed, though the sample size was limited. In addition, all 
patients who did not receive induction therapy were positive 
for v-CTCs regardless of disease stage. Status of v-CTCs seems 
to accurately reflect CR, and pathological response may be 
predictable through measurement of v-CTCs. While sampling of 
pulmonary venous blood is not easy at present, a new means 
of sampling other than surgery, should it become available, 
will enable preoperative check of CR after induction therapy. It 
may be able to verify for the efficacy of surgery after induction 
chemoradiotherapy in the treatment of locally advanced NSCLC.
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P1.39: TARGET THERAPIES AS A WAY TO ACHIEVE COMPLETE 
RESPONSE IN SQUAMOUS CELL LUNG CANCER
Graziela Z. Dal Molin, Ulisses R. Nicolau, Marcello F. Fanelli, 
Ricardo C. Fogaroli, Douglas G. Castro, Antonio H.J.F. Campos, 
Clóvis A.L. Pinto, Luiz Gustavo S. Berriel, Fabio J. Haddad, Aldo 
L.A. Dettino  
Centro Internacional De Pesquisa Clínica Do Hospital Ac Camargo/ 
Fundação Antônio Prudente, Hospital Ac Camargo/BRAZIL
Background: The development of new strategies for the 
treatment of squamous cell lung cancer did not occur in the 
same speed when compared to other histologies. The use of 
platinum-containing doublets resulted in better outcomes. One 
strategy to improve response rate is the addition of targeted 
drugs to the cytotoxic chemoterapy. The FLEX chemoterapy 
regimen was associated with improved survival in NSCLC, 
including squamous cell lung cancer. 
Methods: To describe the case of a patient who benefited 
of the addition of Cetuximab to chemotherapy, obtaining a 
pathological complete response that was kept.
Results and Conclusion: A 69-years old female patient was 
diagnosed with a tongue squamous cell carcinoma, cT2N2M0, 
in 2001 and treated with chemotherapy and radiotherapy. 
In 2007, a squamous cell NSCLC was diagnosed in the right 
upper lung lobe and staged as cT2N2M0. She was treated with 
neoadjuvant chemotherapy based on Cisplatin and Gencitabine 
followed by surgery, with complete pathological response 
(ypT0N0M0). Four years later, she developed a mediastinal 
linfonodal relapse in multiple echelon, diagnosed by positron 
emission tomography (PET-CT). A percutaneus CT-guided 
biopsy was displaying a squamous cell carcinoma. Radiotherapy 
was contraindicated due to the total cumulative dose in the low 
cervical region. She started treatment with Carboplatin AUC x 
5 D1, Vinorelbine 25mg/m² D1 and D8, Cetuximab 400mg/m², 
(starting dose) and then 250mg/m² weekly, in 21-days cycles.
She developed neutropenia and thrombocytopenia resulting in 
delays after the first cycle. It was opted to use filgrastim from 
D9 to D13 after the second cycle and to reduce Vinorelbine dose 
to 20mg/m² from fourth cycle on. After the third cycle, a PETCT 
showed no evidence of disease. The patient completed a total 
of six cycles and started the maintenance phase with Cetuximab 
250mg/m² weekly. A PETCT was realized two months after 
the sixth cycle and the complete metabolic response was 
maintained. Future researches are necessary on squamous cell 
NSCLC to enable an treatment individualized fashion , based 
on the use of biomarkers that can allow the use of targeted 
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therapy, as also to permit an personalized medicine with 
predictive and prognostic factors and eventual improvement in 
response rate and survival. 
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P1.40: RESTROSPECTIVE COMPARATIVE  STUDY  OF  
CARBOPLATIN/PEMETREXED/BEVACIZUMAB  AND 
PEMETREXED/CARBOPLATIN AS  FIRST  LINE  TREATMENT  IN 
PATIENTS  WITH  ADVANCED NSCLC
Manuel E. Magallanes1, Angelica C. Cadena2, Daniel Mendoza3, 
Fernando P. Zincer4, Yolanda L. Bautista2 
1Medical Oncology, Hospital Central Militar, Mexico Distrito Federal/
MEXICO, 2Oncologia Medica, Instituto Mexicano Seguro Social/MEXICO, 
3Medical Oncology, Instituto Nacional De Enfermedades Respiratorias 
(Iner)/MEXICO, 4Medical Oncology, Hospital Central Militar/MEXICO
Background: Studies E4599, AVAIL and SAIL showed 
that adding bevacizumab to the doublet platinum-based 
chemotherapy as first-line NSCLC patients with adenocarcinoma 
lineage increased the response rate, progression-free survival 
and overall survival. The Pemetrexed is an antimetabolite 
whose use in first line NSCLC was confirmed from the 
study published by Giorgio Scagliotti in 2008 and which 
demonstrated an increase in overall survival of patients with 
pulmonary adenocarcinoma treated with Pemetrexed / cisplatin 
vs gemcitabine / cisplatin as first-line chemotherapy (12.6 vs 
10.9 months). The combination of pemetrexed / carboplatin 
/ bevacizumab based on previous findings it is possible and 
has been tested in phase II studies (Patel, ASCO 2008) which 
showed an increase in progression-free survival to 14.1 months 
/ 7.8m months patients using the combination of pemetrexed 
/ carboplatin / bevacizumab vs pemetrexed / carboplatin, in 
patients with lung adenocarcinoma. AVAPERL study shows a 
significant increase in progression-free survival to 10.2 months 
in patients receiving pemetrexed / carboplatin / bevacizumab vs 
Pemetrexed / carboplatin / placebo. 
Methods: In the medical oncology department of the Central 
Military Hospital of Mexico retrospective evaluation was 
conducted on the records of patients who were treated for 
NSCLC adenocarcinomas between 2008 and 2011, for those 
who use the combination of Pemetrexed / Carboplatin / 
Bevacizumab and Pemetrexed/carboplatin. The primary 
objectives of this study are an analysis of descriptive statistics 
on the following variables: progression-free interval, response 
rate , number of cycles received, toxicity, race, diagnosis and 
smoking history.
Results and Conclusion: Data were obtained from a review 
of thirty patients with lung adenocarcinoma stage IIIb and IV 
treated between the years 2008-2011 with the schemes of 
Pemetrexed / Carboplatin / Bevacizumab and Pemetrexed / 
carboplatin with the following results:
In this case series shows that adding bevacizumab to first-line 
treatment with chemotherapy in NSCLC based on Pemetrexed 
/ carboplatin / bevacizumab in non selected patients results in 
PFS(8.5m vs 8.9m) with respect to the first-line chemotherapy 
based on Pemetrexed / carboplatin. In patients with smoker 
history the PFS was (10.2m Vs 8.1m) in favor of the combination 
with Pemetrexed/carboplatin/bevacizumab respect 
Pemetrexed/carboplatin. In Non smokers patients the PFS 
was (9.5mVs 8.1m) in favor of pemetrexed/carboplatin respect 
Pemetrexed/carboplatin/bevacizumab. In terms of response the 
Smoker group had a superior response with the combination 
of Pemetrexed/carboplatin/bevacizumab (PR+SD=66.6% 
Vs 33.4%)respect Pemetrexed/carboplatin - In turn, the 
hematologic and non-haematological toxicity was higher in the 
PCB arm vs. PC. There were no grade IV adverse events in this 
series of cases as well as bleeding events or deaths related to 
treatment. CONCLUSIONS: This retrospective study presents 
data suggesting that the benefit of adding bevacizumab 
to the combination of pemetrexed / carboplatin should be 
individualized, taking into account factors such as smoking 
history of patients. Add bevacizumab showed the greatest 
efficacy in the subgroup of patients with lung adenocarcinoma 
and smoking history regarding subgroup of nonsmoking patients 
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P1.41: LOW DOSE ERLOTINIB AS FIRST LINE TREATMENT IN 
METASTATIC LUNG ADENOCARCINOMA WITH EGFR MUTATION
Rodrigo Ascui1, Osvaldo Arén1, Jorge Arancibia1, Cristina 
Fernandez2, Humberto Cerda1, Patricia Banchero1, Marcela 
Carcamo3, Claudia Bustamante4  
1Servicio De Oncología Médica-Sección Oncología Torácica, Instituto 
Nacional Del Cáncer, Santiago/CHILE, 2Servicio De Anatomía Patológica, 
Instituto Nacional Del Cancer, Santiago/CHILE, 3Estadistica Médica, 
Instituto Nacional Del Cancer, Santiago/CHILE, 4Servicio De Anatomia 
Patologica, Instituto Nacional Del Cancer, Santiago/CHILE
Background: Patients with metastatic adenocarcinoma with 
EGFR mutation must receive first line treatment with tirosine 
kinase inhibitors. Standard dose of erlotinib in this indication 
is 150 mg/day. Our clinical experience shows that tolerability 
of this dose is poor in chilean patients, putting compliance at 
risk. Evidence from a small trial performed in EGFR mutated cell 
lines and seven patients suggests that erlotinib doses as low as 
25mg/day can have significant efficacy.
Methods: A subgroup of 12 patients with metastatic EGFR 
mutated adenocarcinoma were treated with erlotinib 75 mg/
day. Erlotinib tolerability and overall survival of this group of 
patients is described.
Results and Conclusion: Results: 10/12 subjects had exon 19 
EGFR mutation and the rest exon 21 mutation. The survival 
curve of these patients is attached. Regarding tolerability, 3/12 
patients experienced grade 1 cutaneous rash, 2/12 patients 
experienced grade 1 diarrhea. No other adverse events were 
described. Compliance with treatment was 100%.
Conclusion: Considering the limitation of being a retrospective 
study performed in a small number of patients, we consider 
erlotinib 75 mg/day may be a therapeutic alternative for 
patients that cannot be treated with the standard 150 mg/day 
dose either due to unacceptable toxicity or unavailability due to 
cost.
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P1.42: MANAGEMENT OF PATIENTS WITH ADVANCED NON 
SMALL CELL LUNG CANCER PRESENTING TO A DEDICATED 
RAPID ACCESS LUNG CANCER CLINIC
Logeswaran Selvarajah, Ahmadfawwaz Mohd Sharkar, Siobhan 
Toner, Janet Clince, Eleanor Dunican, Margaret Triggs, Regina 
Mcquillan, Ross Morgan, Oscar S. Breathnach  
Department Of Respiratory Medicine And Thoracic Oncology, Beaumont 
Hospital Dublin, Dublin/IRELAND
Background: A dedicated Rapid Access Lung Cancer clinic 
was initiated in 2008 in Beaumont Hospital Dublin with the 
purpose of expediting diagnosis and treatment in patients 
suspected of having lung malignancies. Suspected patients are 
assessed and managed within 2 weeks of referral by general 
practitioners, radiologists or other hospital based clinicians. 
Approximately, over one third of patients presenting to the 
clinic have a diagnosis of lung cancer, with non small cell 
cancer lung cancer (NSCLC) making up the highest proportion1. 
Currently, the standard treatment for advanced NSCLC (Stage 
IIIB/IV) is chemotherapy or palliative symptomatic care where 
aggressive interventions are not possible2. The first 500 patients 
presenting to the clinic were assessed with the aim of assessing 
the management of patients with advanced NSCLC. 
Methods: Data of the first 500 patients presenting to the 
Rapid Access Lung Cancer Clinic was collected retrospectively. 
A database was established based on collation of information 
from patient records, electronic storage systems, intranetwork 
hospital databases, pathological reports and from clinical notes 
of the Lung Cancer Multi Disciplinary Team. The parameters 
analysed include patient demographics, disease profile and 
treatment modalities. The data was analyzed using standard 
descriptive statistics with SPSS.
Results and Conclusion: Of the five hundred patients that 
presented to the Rapid Access Lung Cancer Clinic, 201 (40.2%) 
had malignant disease and were referred for discussion at the 
Lung Cancer Multidisciplinary Meeting. Of those with malignant 
disease, 172 (85.6%) patients were diagnosed with primary 
lung malignancies. 145 (84.3%) patients were diagnosed with 
NSCLC with the remaining 27 (15.7%) being diagnosed with 
small cell lung cancer (SCLC). Out of those with NSCLC, 60 
patients were diagnosed with advanced disease (34.9%). Of 
patients diagnosed with advanced NSCLC, about half (46.7%) 
of the patients received active treatment (chemotherapy). 
Of the patients managed at our centre, 18 (85.7%) had one 
line of treatment while 3 (14.3%) had two lines. Double agent 
chemotherapy were administered in 75% of the cases while 
single agent was used in 25%. The other half (53.3%) of the 
cohort did not received chemotherapy due to various reasons 
mainly relating to low performance status (71.9%), patient’s 
preference (15.6%) and more rapid deterioration (12.5%). Most 
of the patients with advanced NSCLC (80%) evaluated had 
inpatients assessment by the palliative care service. This study 
suggests that approximately half of the patients diagnosed with 
advanced NSCLC received active therapy with chemotherapy. 
These findings pose significant implications for the management 
of advanced NSCLC and warrant further consideration of the 
expansion of palliative care services.
1Dunican E, Uzbeck M, Clince J, Toner S, Royston D, Logan MP, et al. 
‘Outcomes of patients presenting to a dedicated rapid access lung cancer 
clinic.’, Ir Med J. 2011 Oct; 104(9), pp. 265-8. 2Armstrong J, Breathnach O, 
Carney D, Eakin R, Grogan L, McDonnell T, et al. ‘Guidelines For Clinical 
Management of Lung Cancer.’. Ireland: Ir Med J; 2004 Feb [cited 2012 Mar 
24]. Available from http://www.imj.ie/Archive/Lung_Cancer_Guidelines.pdf
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P1.43: DELAY IN CHEMOTHERAPY TREATMENT AND ITS 
RELATIONSHIP WITH SURVIVAL IN PATIENTS WITH ADVANCED 
NSCLC
Eduardo A. Richardet1, Nicolas Castagneris2, Martin Richardet1, 
Laura Perelli1, Matias Molina1  
1Ionc/ARGENTINA, 2Ionc, Cordoba/ARGENTINA
Background: The impact of delayed chemotherapy in overall 
survival of patients with advanced NSCLC is uncertain. Several 
recently published trials proposed poorer PS as the main cause 
of worse outcomes in those who initiate chemotherapy earlier. 
Our goal is to assess whether the delay affects the results, and 
to test the former hypothesis in our population.
Methods: We prospectively evaluated 150 patients diagnosed 
with advanced stage NSCLC. They were included in three 
different groups according to the time between diagnosis and 
first infusion of chemotherapy. In group 1 it spent less than a 
month. In the second group, one to two months and in group 
three, it took more than two months. Chemotherapy regimens 
were platinum based doublets. The OS was evaluated by 
Kaplan-Meier curves and compared by the log rank test
Group 1 Group 2 Group 3 p 
Age 69 67 67 NS 
Sex Male / Fem 75% 25% 84% 16% 79% 21% NS 
Tobacco YES / NO 80% 20% 81% 19% 90% 10% NS 
Hemoptysis YES / NO 25% 75% 21% 79% 30% 70% NS 
PS 0-1 vs. 2 82% 18% 69% 31% 88% 12% NS
Results and Conclusion: The three groups are well balanced 
with respect to known prognostic factors. In the first group, 
patients had a median survival of 8.24 months (n = 96). Group 
2, 9.40 months (n = 32) and those in group 3 lived on average 
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14.95 months (n = 33). The test of interaction between the 
three groups did not reach statistical significance (p = 0.13). 
When comparing group 1 vs. group 3, the difference was 
statistically significant (p = 0.049) In our population, those 
patients who began chemotherapy treatment earlier had lower 
overall survival. This compares to recent international published 
trials. However, their hypothesis is discarded, as no differences 
were found in the three groups regarding performance status. 
This deserves further research, to find a cientific-founded 
explanation 
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P1.44: CLINICOPATHOLOGICAL INCIDENCE, SIGNIFICANCE, AND 
SURVIVAL OUTCOMES OF EML4-ALK TRANSLOCATION IN LUNG 
CANCER
Natalia V. Guggisberg 
Translational Lab, Calgary/CANADA
Background: Tumor budding is morphologically defined as 
infiltration by small clusters of cancer cells. The term tumor 
budding has been applied to single cells or small clusters 
of up to four cells within the stromal tissue at the invasive 
margin of tumor. Furthermore, the study (Yamaguchi Y., et 
al.) identified that tumor budding as a distinct morphologic 
feature that has biologic and prognostic significance; moreover, 
the presence was identified as a significant predictor of an 
unfavorable outcome. Recent studies also recognize the role of 
microenvironment in cancer, and tumor microenvironment is 
evaluated in our study. It was reported (Dacic S.et al, 2010) that 
the intensity of tumor-infiltrating lymphocytes is a predictor 
of EGFR mutations. It was shown that only stromal CD4+ 
tumor-infiltrating lymphocytes are associated with a favorable 
prognosis in non-small cell lung carcinomas (Wakabayashi O., 
et al. 2003). This is further supported by evidence (Hiraoka et 
al. 2006) that only concurrent infiltration by CD8+ and CD4+ T 
lymphocytes in the tumor epithelial cells is a good prognostic 
indicator. However, the infiltration of tumor inflammatory cells 
in ALK positive and ALK negative lung cancer cases have never 
been evaluated. 
Methods: Methodology We are investigating the relationship 
between tumor budding and clinicopathologic parameters 
of non-small cell carcinomas of the lung and the prognostic 
significance of tumor budding and lymphocyte and 
macrophages infiltration by reviewing the cases of ALK positive 
and ALK negative retrospective patients with non-small cell 
carcinomas of the lung. To semiquantify budding, a field in 
which budding intensity is maximal is selected on the slide, 
and the number of budding in that field is quantified. The most 
representative tumor areas are selected and marked on the H&E 
stained slide for construction of microarrays. Survival outcomes 
is correlated with the T cell lymphocyte status. The evaluation 
of CD4, CD 8, CD31, CD68 immune markers is evaluated by 
immunohistochemistry. The grade of the immune cell infiltrate, 
i.e. low vs. high is evaluated. Foci of tumor budding are 
evaluated and intensity of lymphocytic response at the tumor 
invasive front is assessed. Analysis of the data and survival 
outcomes is correlated with ALK mutational status. 
Results and Conclusion: Knowledge of the type of tumor-
infiltrating inflammatory cells may open a new avenue for 
possible immunotherapeutic interventions that may potentially 
enhance a clinically desirable response to targeted therapies 
and outcome for lung cancer patients. This investigation of 
tumor budding and the incidence of ALK mutations in non-small 
cell carcinomas could help to individualize treatment options for 
patients with lung cancer. 
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P1.45: SCLEROSING HEMANGIOMA OF LUNG: A CASE REPORT
Fernando Lopez Piñero1, Claudia I. Bagnes2, Lorena L. Lainati1, 
Patricia Panchuk1, Mariano Vidal1, Gustavo Bondulich3, Analia 
Pedernera4  
1Oncology, Hospital Enrique Tornu, Ciudad Autónoma De Buenos Aires/
ARGENTINA, 2Pharmacology, Facultad De Medicina,Universidad De Buenos 
Aires, Ciudad Autónoma De Buenos Aires/ARGENTINA, 3Surgery, Hospital 
Enrique Tornu, Ciudad Autonoma De Buenos Aires/ARGENTINA, 4Pathology, 
Hospital Enrique Tornu, Ciudad Autonoma De Buenos Aires/ARGENTINA
Background: Sclerosing Hemangioma of the lung is a infrequent 
bening neoplasm. Usually presents as solitary pulmonary nodule 
well defined, homogeneus, affecting more frequently female, 
with complex histology may suggest a number of malignancies. 
Methods: Methods: We report a case: female patient 60 years 
old with a family history of Colonic cancer. In an incidental chest 
X-ray exam, a right basal solitary nodular lesion was detected 
(may 2010). CT scan, bronchoscopy and bone scintigraphy were 
performed. 
Results and Conclusion: CTscan showed an irregular nodular 
lesion consistent with primary lesion . No mediastinal nodes 
were detected. Negative total body bone scan; normal 
spirometry. Bronchoscopy: no evidence of endoluminal lesions 
til 4th order bronchiole; no evidence of tuberculosis. Bronchial 
brushing reported atypical cells of undefined morphology.
In November 2010, surgical intervention was decided (right 
lateral thoracotomy). Intraoperative biopsy showed: atypical 
cells consistent with Adenocarcinoma. It was decided to 
perform right lower lobectomy with lymph node sampling. The 
final histopathological diagnosis was: Sclerosing hemangioma of 
the lung (with routine techniques and inmunohistochemistry).
After 16 monthsfollow-up period the patient condition is 
satisfactory. Conclusion: Being a tumor of very low frecuency, 
ussually presented as a basal, homogeneus solitary lesion, 
ussualy detected in an incidental manner, sometimes 
presenting respiratory symptoms (eg: hemoptysis), suggesting 
malignant neoplastic disease, we discuss this case as an 
infrecuent differential diagnosis within the field of lung tumoral 
disease as an Adenocarcinoma (Bronchioloalveolar carcinoma). 
Disclosure: No significant relationships.
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P1.46: DIAGNOSIS OF PLEURAL DISEASES USING 
INMUNOHISTOCHEMISTRY (IH) ON CELULAR BLOCK (CB) IN 
ALCOHOL-PRESERVED MALIGNANT PLEURAL EFFUSION: A 
DESCRIPTIVE STUDY
Paula Barcos1, Cristina Fernandez2, Ivan Gallegos3, Sandra 
Zapata2  
1Hospital Clinico Universidad De Chile, Santiago/CHILE, 2Instituto Nacional 
Del Torax/CHILE, 3Anatomia Patológica, Hospital Clinico Universidad De 
Chile/CHILE
Background: The celular block (CB) is a less invasive technique 
than surgical pleural biopsy (SPB) for the malignant pleural 
efussion diagnosis. The immunohistochemistry (IH) could 
improve the diagnostic performance of CB and reduce futile 
diagnostic surgery. Several studies refer that alcohol-preserved 
samples are not useful to perform IH.However with new 
antybodies and the improvement of antigen retrieval we can 
perform diagnostic IH markers in alcohol preserves samples 
with a good diagnostic result.
Methods: All patients with pleural effusion evaluated by 
pleurocentesis with CB and SPB between 2009 and 2011 at the 
Instituto Nacional del Tórax (INT) where included in this study. 
Histologic and cytologic diagnostic was made to every SPB and 
CB by two different pathologist. IH to CB and SPB samples was 
performed with antibodies MOC-31, Calretinin and D-240. The 
pathologist who performed IH for CB was blind to final SPB 
diagnosis.
Results and Conclusion: 38 patients were included in 
this study. Six mesotheliomas, 22 adenocarcinomas, 1 
adenocarcinoma with reactive mesothelial hyperplasia, and 2 
signet ring adenocarcinomas, 4 carcinomas NOS, 3 epithelioid 
malignant tumors unable to diferenciate between mesothelioma 
and adenocarcinoma. Mesotheliomas expressed calretinin in 
5 of 6 cases (83%) of SPB and 4 of 6 (63%) of CB. MOC-31 was 
negative in 5 of six (83%) of the cases of PB and 6 of 6 (100%) in 
CB. D-240 was observed in 5 of 6 (83%) of the cases of SPB and 
4 of 6 (66%) of CB. In adenocarcinomas, Calretinin was negative 
in all 22 cases (100%) of SPB and CB. MOC-31 was positive in 
19 of 22 (86%) in SPB and 17 of 22 (77%) in CB. D-240 was 
negative in 100% of the cases of SPB and CB. Conclusion: The 
use of IH in CB samples is a possible and a promising diagnostic 
tool. There is acceptable agreement between IH results of CB 
and SPB. The IH in CB samples can improve the diagnostic 
performance in patiens with malignant pleural effusion.
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P1.47: EGFR ACTIVATING MUTATIONS IN NSCLC: IMPORTANCE 
OF ROUTINE TESTING
Tiago K. Takahashi, Ibere C. Soares, Andrea M. Marini, Milena P. 
Mak, Carlos H. Teixeira, Felipe S.R. Roitberg, Teresa Y. Takagaki, 
Renata E. Martins, Cristiane Mesquita, Paulo M.G. Hoff, Gilberto 
Castro Jr.  
Clinical Oncology, Instituto Do Câncer Do Estado De São Paulo, Sao Paulo/
BRAZIL
Background: EGFR activating mutations in NSCLC confer 
better prognosis and are also predictive of response to both 
chemotherapy and EGFR-tyrosine kinase inhibitors. Therefore, 
EGFR genotyping in NSCLC patients (pts) is very helpful in 
treatment decision. Here we report the first 25 pts whose 
tumors samples were tested for EGFR activating mutations in 
our Institution. 
Methods: It is an observational study on all consecutively 
tested NSCLC samples from pts treated at ICESP. Briefly, all 
samples were formalin-fixed and paraffin-embedded. Tumor 
areas were selected and macrodissected, followed by whole 
DNA extraction and amplification by PCR. DNA sequencing 
(exons 18, 19, 20 and 21) was performed by Sanger´s 
methodology. Frequencies were compared by Fisher´s exact 
test. 
Results and Conclusion: Results: 25 tumor samples were 
tested from Aug/2011 up to now: 20 pts were caucasian, 13 
were male, 14 ex-smoker, 10 never smoker; 15 pts ECOG-PS 0-1 
and 5 PS 2. Regarding histologic subtype, 22 were classified 
as adenocarcinoma and 2 SCC. Staging: 3 IIIA, 2 IIIB and 20 
IV. Activating mutations were detected in 6 pts (24%): 4 in 
exon 19 (del 19), 1 in exon 21 (L858R) and in 1 pt two mutations 
were found (T790M and L858R). The frequency of these 
activating mutations was not related to gender (p=0.378), race 
(p=0.540) or smoking habits (p=0.350). In a short follow-up of 
6 mo., no deaths occurred in pts whose samples were positive 
for activating mutations. Conclusions: In this very selected 
population, the frequency of EGFR activating mutations was 
24%, with no correlation with gender, race or smoking habits. 
This reinforces the importance of testing EGFR activating 
mutations in all pts with lung adenocarcinoma.
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P1.48: FREQUENCY OF ALK TRANSLOCATIONS IN 8221 NON-
SMALL CELL LUNG CANCER SAMPLES
Kenneth J. Bloom, Paul Choppa  
Pathology, Clarient, A Ge Healthcare Company, Aliso Viejo/UNITED STATES 
OF AMERICA
Background: The anaplastic lymphoma kinase (ALK) gene codes 
for a transmembrane receptor tyrosine kinase (RTK) in the 
insulin receptor superfamily. It has been identified as the fusion 
partner in a number of different malignancies and has long been 
suspected as a driver oncogene in these conditions. Although 
a number of studies have been conducted, the frequency of 
EML4-ALK in NSCLC ranges from 2-7% likely due to variability of 
patient selection and testing platforms. Crizotinib was recently 
approved for the treatment of ALK positive NSCLC patients as 
determined by the presence of an ALK gene rearrangement 
based on a companion diagnostic FISH assay. We assessed a 
large series of patients to determine the positivity rate of this 
assay in a US based population. 
Methods: 8221 consecutive formalin fixed paraffin embedded 
non-small cell lung cancer samples sent to our laboratory for 
determination of ALK rearrangement status were assessed using 
the Abbott LSI ALK break apart rearrangement FISH probe. Fifty 
tumor cells were enumerated for the presence of a break apart 
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signal which was considered as present when at least one set of 
orange and green signals were 2 or more signal diameters apart 
or when a single orange signal without a corresponding green 
signal was observed in more than 15% of the tumor cells.
Results and Conclusion: Of the 8221 samples tested, 201 
(2.44%) samples demonstrated an ALK rearrangement and 
8020 had no detectable alteration. The Abbott LSI ALK break 
apart FISH probe has excellent performance characteristics 
with a failure/suboptimal hybridization rate of approximately 
1.5% in our hands. Although the ALK break apart probe does 
not specifically identify EML4 as the ALK fusion partner, the 
frequency of ALK rearrangements was 2.44% in our series of 
NSCLC patients. This number agrees with the expected rates 
based on previous studies and helps define the positivity rate in 
a US based population. 
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P1.49: EGFR MUTATION RATES IN 21757 CONSECUTIVE NON-
SMALL CELL LUNG CANCER SAMPLES
Kenneth J. Bloom, Paul Choppa  
Pathology, Clarient, A Ge Healthcare Company, Aliso Viejo/UNITED STATES 
OF AMERICA
Background: Non-small cell lung cancer (NSCLC) is the leading 
cause of cancer-related deaths worldwide. Two-thirds of 
patients present with advanced disease and have an average 
survival of less than 1 year with standard chemotherapy. Studies 
have demonstrated that exon 19 or L858R substitution in the 
EGFR gene are the most powerful predictive biomarkers in 
patients treated with erlotinib or gefitinib. This has led to the 
recommendation that EGFR mutational status be evaluated 
prior to initiating chemotherapy. We sought to determine the 
frequency and distribution of EGFR mutations in our laboratory 
over the past several years.
Methods: From June 2009 to October 2011 we have evaluated 
the mutational status of EGFR in 18246 formalin fixed paraffin 
embedded non-small cell lung cancer samples using an allele 
specific PCR procedure that is capable of detecting 29 of the 
most prevalent mutations in exons 18-21 of EGFR, (QIAGEN EGFR 
PCR kit). The assay uses a real-time PCR platform and is capable 
of detecting mutations at a sensitivity of 1-5% in a background 
of non-mutated alleles.
Results and Conclusion: Mutations were identified in 2877 
(13.2%) of NSCLC samples tested. Of the 2877 samples with a 
detectable mutation 1479 (51.4%) harbored exon 19 deletions, 
978 (34%) were L858R, 99 (3.4%) were mutations in codon 
719, 95 (3.3%) were insertions in exon 20, 95(3.3%) were 
L861Q, 30 (1.04%) were S768I, 25 (0.87%) were T790M, 
22 (0.76%) were L858R + T790M, 22 (0.76%) were S768I + 
G719X, 8 (0.28%) were L858R + S768I, 7 (0.24%) were T790M 
+ G719X, 7 (0.24%) were L861Q + G719X, 4 (0.14%) were del 
exon 19 + T790M, 3 (0.1%) were del exon 19 + L858R, 2 (0.07%) 
were T790M + L861Q and 1 (0.03%) was L861Q + S768I Analysis 
of over 21000 consecutive non-small lung cancer specimens 
sent to our laboratory for evaluation of EGFR mutation status 
demonstrated that 13.2% harbored an EGFR mutation as 
detected by our allele specific PCR procedure. Approximately 
half, (51.4%) harbored an exon 19 deletion and about one 
third (34%) demonstrated the L858R substitution, while 2.6% 
revealed multiple mutations in the EGFR gene. This represents 
the largest analysis of EGFR mutational status in a US based 
population to date. 
Disclosure: No significant relationships.
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P2.01: COMPARISON OF CLINICAL OUTCOMES FOR PATIENTS 
WITH CLINICAL N0 AND PATHOLOGIC N2 NON-SMALL CELL 
LUNG CANCER AFTER THORACOSCOPIC LOBECTOMY AND OPEN 
LOBECTOMY: A RETROSPECTIVE ANALYSIS OF 76 PATIENTS
Yun Li, Jun Wang  
Department Of Thoracic Surgery, People’s Hospital Of Peking University, 
Beijing/CHINA
Background: Video-assisted thoracoscopic surgery for 
lobectomy has been gradually accepted as a viable alternative 
for the treatment of non-small cell lung cancer since it was 
first introduced in 1995. It has been touted to provide intra-
operative safety and superior outcomes as compared with 
open thoracotomy for patients with early-stage NSCLC . Due 
to the limitation of preoperative clinical examinations, about 
10-20% NSCLC patients who were diagnosed with clinical N0 
were confirmed as having pathologic N2 (cN0-pN2) during or 
after operation. It remains unclear whether intra-operative 
lymph node sampling reveals pN2 during VATS lobectomy. Is it 
necessary to convert from VATS to thoracotomy? Here we try to 
compare clinical outcomes between thoracoscopic lobectomy 
and open thoracotomy for the treatment of patients with cN0-
pN2 non-small cell lung cancer (NSCLC).
Methods: Medical records of 182 cN0 patients (including 29 
pN2) underwent VATS lobectomy between September 2006 
and December 2009, and 204 cN0 patients (including 47 pN2) 
who underwent open thoracotomy between July 2000 and 
December 2009 were reviewed retrospectively. Pre- and intra-
operative status and post-operative survival and recurrence of 
the patients between the two groups were compared.
Results and Conclusion: Results: There was no difference in 
age, sex, and preoperative pulmonary function, complications 
and clinical staging between two groups. The operation time 
and blood loss of VATS group was significantly lower than those 
of the open thoracotomy group. The number of dissected 
mediastinal lymph node (LN) stations was 3.3±1.1 in VATS 
group vs 3.3±1.3 in open thoracotomy group, and the total 
number of dissected mediastinal LN was 12.7±8.9 in VATS 
group vs 10.5±7.2 in open group. The 1- and 3-year disease-
free-survival rate was 82.6% in VATS group vs 72.0% in open 
group, and 49.3% in VATS group vs 51.3% in open thoracotomy 
group (p=0.996), respectively. The 1- and 3-year survival 
rate was 84.9% in VATS group vs 71.2% in open group, and 
64.0% vs 42.7% in thoracotomy group (p=0.121), respectively. 
Conclusions: This study has demonstrated that VATS lobectomy 
is comparable with open thoracotomy in both safety and 
curability for the treatment of cN0-pN2 NSLCL, without 
necessity of conversion to open surgery. 
Disclosure: No significant relationships.
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P2.02: EXPERIENCE OF COMPLETELY VIDEO-ASSISTED 
THORACOSCOPIC SLEEVE LOBECTOMY
Yun Li, Jianfeng Li, Jun Wang  
Department Of Thoracic Surgery, People’s Hospital Of Peking University, 
Beijing/CHINA
Background: Sleeve bronchial reconstruction was once seen 
as the relative contraindications of VATs procedure. With the 
technique of thoracoscopic lobectomy and accumulation of 
large number of cases, surgeons begin the attempt of bronchial 
reconstruction endoscopiclly. In 2002, Luigi Santambrogio 
reported the world’s first completely thoracoscopic sleeve 
lobectomy, but because of this procedure required extremely 
high ttechnology and operation skills, so it developed slowly 
and were not popular.Here we summarize 8 cases of non-small 
cell lung cancer (NSCLC) that has accepted completely video-
assisted thoracoscopic sleeve lobectomy in People’s Hospital of 
Peking University in china, to explore the safety, effectiveness 
indications and experience of this procedure.
Methods: Between Sep 2011 and Mar 2012, Medical records 
of 8 cases of non-small cell lung cancer that has accepted 
complete thoracoscopic sleeve lobectomy were reviewed 
(7 male, 1 female). Median patient age was 62.4 years. And 
median maximal diameter of solid tumors was 2.3 cm. This 
group consisted of 5 cases of Right upper lobe sleeve lobectomy 
, 2 case of left lower lobe sleeve lobectomy and 1 case of left 
upper lobe sleeve lobectomy. The operation procedure was 
completely VATs anatomic sleeve lobectomy combined with 
systematic lymph node resection (at least 3 groups of lymph 
nodes in the mediastinum area). All procedure were underwent 
under general anesthesia with double-lumen endotracheal 
intubation. The patient was placed Lateral decubitus position. 
Three incision were made at 7th intercostal space on the 
median axillary line, 4th intercostal space anterior axillary 
line and 7th intercostal space subscapularis line. Bronchial 
were anastomosed combine with simple continuous suture 
anastomosis of membranous part of bronchus and simple 
interrupted suture anastomosis of cartilaginous part of 
bronchus, and then covered by surrounding tissue with blood 
supply.
Results and Conclusion: [Results] All procedures were carried 
out smoothly without serious complication. The median 
operative time was 240min median, the median bronchial 
anastomosis time was 45min, the median blood loss was 
200ml, and median number of resected lymph nodes was 
19.8. There were no conversion to open thoracotomy. Post 
operative show Pathology squamous cell carcinoma in 7 cases 
and adenocarcinoma in 1 case. pTNM staging show 1 case 
of T1aN0M0, 4 cases of T1bN0M0, 2 case of T1bN1M0 and 1 
case of T1bN2M0. There was 1 case of slight post operative 
complication. The median postoperative chest tube drainage 
duration was 7.0 d, and median postoperative hospital stay 
was 9.0 d. All patients were well during the followed up for 
2-7 months. [Conclusion] Completely thoracoscopic sleeve 
lobectomy was a safe and effective surgical procedure for 
patients with non-small cell lung cancer; the operative incision 
placed at 4th intercostal space anterior on the axillary line 
was convenient for anastomosis; anastomosis combine with 
simple continuous suture anastomosis of membranous part 
of bronchus and simple interrupted suture anastomosis of 
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cartilaginous part of bronchus was a fast and secure mode; 
keeping azygos vein does not affect the anastomosis.
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P2.03: SYSTEMATIC LYMPH NODES DISSECTION IN TOTAL 
VIDEO-ASSISTED THORACIC LOBECTOMY USING VESSEL 
SEALING SYSTEM 
Yoshio Tsunezuka 
Department Of General Thoracic Surgery, Ishikawa Prefectural Central 
Hospital, Kanazawa/JAPAN
Background: We had reported that the Ligasure-V (LSV), 
electrothermal bipolar vessel sealer, was safe and useful in 
sealing of pulmonary artery and systematic lymph nodes 
dissection (Interact Cardiovasc Thorac Surg. 2010:229-33).  
A novel instrument, Ligasure-Blunt Tip (LSBT) was introduced 
for lung cancer surgery, we compared Ligasure-V with Ligasure-
Blunt tip to avoid complications and to shorten the time 
required for the dissection of the superior mediastinal lymph 
nodes. 
Methods: Forty-one patients with lung cancer were assessed 
and studied. All patients were performed totally thoracoscopic 
major lung resection and right superior mediastinal lymph 
nodes dissection using bipolar vessel sealers, LSV(n=24) or 
LSBT(n=17). No patient needed conversion to open surgery. 
Retrospectively, we examined all recorded operation DVD 
and the operation time of right superior mediastinal lymph 
nodes dissection and other parameters likes of postoperative 
complications. 
Results and Conclusion: The lymph nodes dissection time was 
significantly shorter in the LSBT group than in the LSV group 
(unpaired t-test:P = 0.037, 1191 +/- 196 vs 1318 +/- 244 sec. 
F-study: p=0.148). Postoperative complications and median 
number of lymph nodes removed (17.5 vs 17 open) were similar 
in the 2 groups. No other parameters showed any significant 
differences between the two groups. Ligasure-Blunt Tip was 
safe and useful in lung cancer surgery. Ligasure-Blunt Tip is 
superior to Ligasure-V in terms of systematic lymph nodes 
dissection 
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P2.04: PROTEIN SIGNATURE FOR NON-SMALL CELL LUNG 
CANCER PROGNOSIS
Miao Cui1, Wei Liu2, David Zhang3  
1Pathology, Mount Sinai School Of Medicine, New York/UNITED STATES 
OF AMERICA, 2Departments Of Thoracic Surgery The First Hospital Of Jilin 
University/CHINA, 3Pathology, Mount Sinai School Of Medicine/UNITED 
STATES OF AMERICA
Background: Lung cancer is the leading cause of cancer deaths 
worldwide. Despite recent advancement in diagnostic testing, 
surgical techniques and the development of therapeutic agents, 
the overall 5-year survival remains low for advanced lung 
cancer. Current histopathological classification and TNM staging 
have limited accuracy in predicting survival and stratifying 
patients for appropriate treatment. Our hypothesis is that 
the dysregulated regulatory proteins can add additional value 
for more accurate classification and prognostication of non-
small lung cancer (NSCLC) since these proteins are critical in 
controlling cancer cell behaviors such as proliferation, invasion 
and metastasis.
Methods: The expression of 108 proteins and phosphoproteins 
in 30 paired NSCLC samples were assessed using Protein 
Pathway Array (PPA). The differentially expressed proteins were 
further confirmed using a tissue microarray (TMA) containing 
94 NSCLC samples and were correlated with clinical data and 
survival. We recently developed a powerful Protein Pathway 
Array (PPA) analysis that allows to identify the important, but 
low abundance proteins and phosphoproteins in NSCLC. The 
proteins included in the PPA analysis are those important in 
carcinogenesis including cell cycle regulation and proliferation, 
adhesion, migration, invasion, metastasis and angiogenesis.
Results and Conclusion: Twelve of 108 proteins 
(p-CREB(Ser133), p-ERK1/2(Thr202/Tyr204), Cyclin B1, 
p-PDK1(Ser241), CDK4, CDK2, HSP90, CDC2p34, β-catenin, 
EGFR, XIAP and PCNA) were selected to build the predictor 
to classify normal and tumor samples with 97% accuracy. 
Five proteins (CDC2p34, HSP90, XIAP, CDK4 and CREB) were 
confirmed to be differentially expressed between NSCLC (n=94) 
and benign lung tumor (n=19). Furthermore, over-expression 
of CDK4 and HSP90 in tumors correlated with a favorable 
overall survival in all NSCLC patients and the over-expression of 
p-CREB(Ser133) and CREB in NSCLC correlated with a favorable 
survival in smokers and those with squamous cell carcinoma, 
respectively. Finally, four proteins (CDK4, HSP90, p-CREB and 
CREB) were used to calculate the risk score of each individual 
patient with NSCLC to predict survival. Our data demonstrated 
a broad disturbance of regulatory proteins in NSCLC and some 
of these could be selected as clinically useful biomarkers for 
diagnosis, classification and prognosis.
Disclosure: No significant relationships.
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P2.05: GENOMICS MUTATIONS’ BASED ARTIFICIAL NEURAL 
NETWORK AND FIELD PROGRAMMABLE GATE ARRAY 
FRAMEWORK FOR LUNG CANCER DIAGNOSIS
Emmanuel Adetiba1, F A Ibikunle2, E F Adebiyi3  
1Department Of Electrical & Information Engineering,, Covenant 
University, College Of Science And Technology, Ota/NIGERIA, 2Electrical & 
Information Engineering Dept., Covenant University, College Of Science 
And Technology, Ota/NIGERIA, 3Department Of Computer & Information 
Sciences, Covenant University,College Of Science And Technology/NIGERIA
Background: Advances in Information and Communications 
Technology (ICT) supporting cancer research have accelerated 
the discoveries of new approaches for its diagnosis, prognosis 
and treatment. Sophisticated DNA sequencing has been used to 
study the whole genome sequence of different cancer tissues. 
The sequence information provides a detailed catalogue of the 
somatic mutations in the cancerous tissues. This provides a 
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good molecular and genetic understanding of cancer biology 
especially lung cancer.
In this work we utilized the genomes of Non-Small Cell Lung 
Cancer(NSCL) using Epidermal Growth Factor Receptor(EGFR) 
gene as a biomarker to produce training and testing datasets 
for an Artificial Neural Network(ANN) ensemble aimed at NSCL 
diagnosis electronically. Novel algorithms were developed 
and implemented in software for the pre-processing and 
features extraction stages while the ANN stage of the electronic 
diagnostic system was prototyped in hardware using Field 
Programmable Gate Array(FPGA) digital technology.
Methods: Some significant genes that have been identified in 
lung cancer formation and progression include FGFR1,BRCA1, 
INSR, EGFR, K-RAS and etc. In this study, Epidermal Growth 
Factor Receptor(EGFR) gene and the different mutations in 
this gene are used as biomakers for early detection of Non-
Small Cell Lung Cancer(NSCLC). We extracted records of 
NSCLC patients that suffered significant mutations in the TK 
domain of EGFR genes from public genomics databases. Seven 
different types of mutations were detected in the sample 
data which includes; microdeletion,missense, microindel, 
microinsertion, duplication, nonsense and missense(TBM). 
Among these, the two most common are the microdeletion 
and missense mutations and they represent between 85-87% 
of all EGFR TK domain mutations. We extracted deletions and 
missense mutation features from our sample data to build 
numeric mutation profiles for the patients. Our electronic 
diagnostic platform which was developed with Artificial Neural 
Network(ANN) is therefore based on the numeric patients’ 
mutation profiles. The phases for the system development are;
i.) data acquisition ii.) pre-processing iii.) features extraction 
iv.) ANN design, training, testing and validation. iv.) hardware 
prototyping with FPGA v.) performance evaluation
Results and Conclusion: We carried out five different 
experiments to train the ANN with hidden layer neuron ranging 
from 10 to 50 neurons.The best performance of 2.5169e-007 
mean square error(mse) at 23 epochs was obtained when 
50 hidden neurons were used to train the ANN at the fifth 
experiment. This confirms the validity of the hypothesis we 
formulated that the more the number of neurons in the hidden 
layer, the better the performance of the network. The confusion 
matrices showed various types of errors that occured for the 
trained network. 97.7% cases were correctly classified and 
2.3% cases were misclassified. These results show a very good 
recognition of the NSCLC by our electronics based diagnostic 
platform.
Disclosure: No significant relationships.
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P2.06: ROBOTIC STEREOTACTIC RADIOTHERAPY FOR EARLY 
STAGE LUNG CANCER: CLINICAL & DOSIMETRIC EVALUATIONS
Jean-Emmanuel Bibault, Bernard Prevost, Xavier Mirabel, 
Thomas Larcornerie, Eric Lartigau  
Academic Radiation Therapy Department, Oscar Lambret Comprehensive 
Cancer Center, Lille/FRANCE
Background: Stereotactic radiation therapy is a new field of 
treatment for early stage lung cancer occurring in medically 
inoperable patients. The CyberKnife system allows for real-time 
tumor tracking under free breathing conditions. It could reduce 
toxicity while maintaining the same efficacy. We report our 
initial experience with 51 patients treated with the fiducial-less 
Xsight Lung Tracking System® and with a follow-up of at least 3 
months, out of 241 patients treated with SBRT for lung cancer 
in our department. Potential dosimetric differences between 
the Ray-Tracing and the Monte-Carlo algorithms will also be 
presented. 
Methods: Patients were accrued after evaluation by thoracic 
surgeons and oncologists. Selection criteria were: single T1 or 
T2 pulmonary tumor, tumor size between 15 and 60 mm, N0 
and M0. Initial staging included CT-Scan with contrast agent 
and FDG-PET. Treatment were prescribed with Ray-Tracing 
(type A algorithm) and also calculated with Monte-Carlo (type 
B algorithm) to evaluate potential dosimetric differences. 
Response was evaluated with the modified RECIST criteria every 
3 months and toxicity with the CTCAE v4.0 grading scale. 
Results and Conclusion: 43 men (84%) and 8 women (16%) 
were treated for 25 T1 (49%) and 21 T2 (41%) lung cancer. 5 
pts (10%) were treated for a relapse after prior surgery (4%) 
or radiation therapy (6%). Median follow-up was 15 months 
(5-30). Median age was 69 (50-85). All pts were smokers. 
Median tumor size was 24 mm (15-70). Median delivered dose 
was 60 Gy (36-60 Gy) in 3 fractions. Local control rate was 
86%, including 16 complete responses, 16 partial responses 
& 12 stable diseases. 7 progressions were observed. 1 pt 
relapsed with mediastinal lymph nodes and 6 pts with distant 
metastases and subsequently received chemotherapy. Disease-
specific survival rate was 98% at 15 months. 7 grade 1 (14%) & 
two grade 2 (4%) radiation pneumonitis were found on CT-Scan 
at 3 months and disappeared on later controls. Dosimetric 
differences between the Ray-Tracing and the Monte-Carlo 
algorithms will be presented during the congress. Conclusion 
Local control rate was high for these patients, while toxicity 
remained low. This method could represent a completely non-
invasive curative treatment for inoperable patients. 
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P2.08: PHASE II TRIAL: CONCURRENT CHEMOTHERAPY AND 
RADIOTHERAPY WITH NITROGLYCERIN IN LOCALLY ADVANCED 
NON-SMALL CELL LUNG CANCER PATIENTS
Dolores De La Mata, Mónika Blake-Cerda, Jesús Zamora, Omar 
Pena, Diana Flores-Estrada, Jenny Turcott, Oscar Arrieta  
Radiation Oncology, Instituto Nacional De Cancerologia De Mexico, Mexico 
City/MEXICO
Background: The treatment of choice for locally advanced non 
small cell lung cancer (NSCLC) is concurrent chemoradiation 
(CRT). However, efforts to improve treatment results include 
targeted therapy and the use of radiosensitizers. Nitroglycerin 
(NTG), a nitric oxide (NO) donor agent, reduces expression of 
Hypoxia-Induced Factor, which is associated to both chemo and 
radio resistance.
Methods: This is phase II trial in patients with locally advanced 
NSCLC treated with chemotherapy (CT) based on Cisplatin and 
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Vinorelbin with NTG concurrent with radiation therapy. A 25 
mg NTG patch was administered to the patients during the first 
5 days of each induction treatment cycle and during chemo-
radiotherapy. Blood samples of VEGF were taken before any 
treatment and after two cycles of CT. The protocol is registered 
with ClinicalTrials.gov, number NCT00886405.
Results and Conclusion: 35 patients were enrolled in this trial. 
Median Follow up was 16.6 months (SD ±13.6). Mean age was of 
59.9 years (±10.8), 68.6% of the patients were smokers. ECOG 
status was 0 in 22.9%, 1 in 65.7% and 2 in 11.5%, respectively. 
Histopathology was adenocarcinoma in 68.6%, epidermoid 
in 17.1% and undifferentiated in 14.3%. Stage distribution 
was: IIIA- 57.6% and IIIB 42.5%. All patients completed CRT 
treatment and four underwent surgical treatment. Toxicity 
profile related to NTG was Grade I and II headache in 17.1%. 
Grade III and IV toxicities were esophagitis (17.1%), neutropenia 
(62.9%), and nausea (5.7%). Sixty Four per cent of patients 
achieved partial response after CT and 75.8% after CRT. PFS 
was 11.8 months (95%, IC 7.8-15.6) and OS was 42.9 months 
(95%IC 31.3-52.1). After two cycles of CT, plasma VEGF levels 
were significantly lower (median 132 vs. 53). No differences on 
PFS and OS were found between patients with a reduction ≥ 
93 pg/ml (median of differences between VEGFR before and 
after chemotherapy). Conclusions: The addition of NTG to 
induction CT, and concurrent CRT on locally advanced NSCLC 
patients seems to increase the response rate, PFS and OS with 
an acceptable toxicity profile. A prospective trial is warranted to 
confirm these findings.
Disclosure: No significant relationships.
POSTER SESSION 2 - July 27, 2012 09:00 – 17:00
Early Stage NSCLC (Stage I – III)
P2.09: LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER( 
NSCLC) IN THE ELDERLY: THE INCA EXPERIENCE
Pedro M. Domingues1, Ricardo Zylberberg2, Thalita D.M. 
Castro1, Clarissa Baldotto1, Luiz Henrique De Lima Araujo1  
1Medical Oncology Department, Thoracic Oncology Tumor Group And 
Clinical Research Coordination, Inca, Rio De Janeiro/BRAZIL, 2Department 
Thoracic Oncology, Inca, Rio De Janeiro/BRAZIL
Background: Combined chemoradiation (CRT) is the standard 
terapy in unresectable, locally advanced NSCLC. Nevertheless, 
the best approach in the eldery population is still poorly 
defined, since this subgroup was underrepresented in most 
clinical trials.
Methods: We retrospectively reviewed the medical charts 
of pacients with diagnosed stage III ( 6º AJCC), unresectable, 
NSCLC, treated at the Brasilian Nacional Cancer Institute ( 
INCA) between 2003 and 2005. Patients with malignant pleural 
effusion were excluded ( former “wet IIIB”). The primary 
outcome was overall survival( OS), measure from diagnosis 
until death. Prognostic factors were analyzed using log-rank 
and stepwise cox model. Palliative therapy (PT) included best 
supportive care, radiation terapy ( RT;<40Gy), and palliative 
chemoterapy. Among patients treated with radical RT,OS was 
measured from date of treatment beginning until death ( OST).
Results and Conclusion: One hundred fifteen patients were 
included. Median age was 71 years (range 65-83), 76% were 
male, 51% had squamous cell carcinoma, and 82% stage IIIB. 
Seventy percent of patients had more than 5% weight loss 
documented at the diagnosis, and most had performance 
status (PS) 0-1 (44%), while PS 2 and 3 were documented in 
29% and 26%, respectively. Ninety percent were current/
former-smokers, and Charlson index was 0 in 66% and 1-2 in 
34%. Thirty-six percent received PT, 32% exclusive RT (>40 
Gy), and 32% CRT (concomitant or sequential). Post-radiation 
surgery was not performed in our cohort. The median OS 
was 9.9 ms (95% CI, 7.2-12.6). Survival was significantly 
longer among patients with PS 0-1 (p<0.0001) and no 
weight loss (p=0.026), while histology (p=0.15), tumor stage 
(p=0.51), Charlson index (p=0.37), and age (p=0.54) were not 
prognostic factors. Patients treated with exclusive RT and CRT 
had better survival (median OS, 14.3 ms [95% CI, 11.7-16.9] 
and 17.0 ms [95% CI, 14.1-19.9], respectively) than patients 
receiving palliative therapy (median 4.1 ms [95% CI, 3.5-4.8]; 
p<0.0001). In the multivariate analysis, RT (HR 0.25 [95% CI, 
0.15-0.42]; p<0.0001) and CRT (HR 0.16 [95% CI, 0.09-0.27]; 
p<0.0001) were independently associated with better survival 
in comparison to PT. Among patients receiving radical RT, the 
addition of chemotherapy was associated with longer OST 
(median 14.1 ms [95% CI, 10.7-17.4] vs 10.7 ms [95% CI, 8.7-
12.6]; p=0.025). Elderly patients with locally advanced NSCLC 
derived significant survival benefit from radical RT and CRT, 
suggesting that age should not be a contraindication for these 
aggressive therapeutic strategies. In this setting, the highest 
survival was demonstrated in patients receiving a combination 
of CRT, either sequentially or concomitantly. Further prospective 
studies are encouraged to evaluate the best sequence and 
agents to be combined to RT in the elderly. 
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P2.10: SURGICAL MORTALITY IN RESECTIVE SURGERY OF 
LUNG CARCINOMAS AT A REFERAL PUBLIC HEALTH SYSTEM 
HOSPITAL
Nestor C. Spizzamiglio1, Javier E. Mendizábal1, Miguel Galmes1, 
Gustavo Jankilevich2, Karina O´Leary2, Federico F. Ferrer1 
1Hospital Durand, Victoria/ARGENTINA, 2Oncology, Hospital Carlos G 
Durand, Buenos Aires/ARGENTINA
Background: Surgical mortality (SM) is define as the death that 
occur during the first 30 days after surgery , even when the 
patient were out of hospital , or when it happened during the 
convalescence at hospital stay (no time limits).Our goa lis to 
analize the incidence of surgical mortality in patients operated 
with curative resective intention from a lung carcinoma in a 
referal public health system hospital.
Methods: During the period 1/1/1997 to 31/12/2011 109 
patients were operated consecutively from a lung carcinoma 
with resective curative intention. 64,2% were men (n=70). 
Mean age 57.15 years (95% CI 55,35-58,99). Histology types 
: adenocarcinomas (n=67), Squamus (n=28), carcinoids (n=10), 
por dif. carcinomas (n=2), SCLC (n=2). Stages: Ela 8, Elb 35, 
Ella 4, Ellb 20, Ellla 29, Elllb 7,E lV 4 and 2 localized (SCLC). 
Procedures: bilobectomies 7, lobectomies 66, neumonectomies 
18, sublobar resections 6, biopsies 12. 
Results and Conclusion: The SM Rate was 7,2% (n=8), 7 
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were men, ASA lll, heavy smokers at the time of surgery and 
6 of them had cardiovascular diseases (arterial hypertension, 
electrical disorders). Four of them died because of sepsis, 
one by intraoperative bleeding, one by posoperative bleeding 
and multiorgan failure, one by respiratory distress and the 
last because of heart failure after extracorporeal circulation. 
According the stage : Elb 1, Ellb 4, Ella 3. No one of them 
received induction therapy. Surgical procedure: lobectomies 5, 
neumonectomies 2, unresectable 1. Our Surgical Mortality Rate 
is higher than the published in the literature. We consider that 
this depends on several factors. The population of the Public 
Health System Hospitals use to have less resources tan the rest 
of the people ( socioeconomics ) and because of that they dont 
have periodical health controls, arriving in advanced stages of 
diseases (oncological, cardiovascular etc.). Many of the medical 
units in our hospital are assisted by residents that act not 
always under a staff supervision. The same surgical team (three 
of the authors ) in its extrahospitalry activity has a surgical 
mortality rate in accordance with the international literaure. 
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P2.11: COMPLIANCE, TOXICITY AND SUCCESSFULL GOALS IN 
ADJUVANT SETTING.RESULTS FROM PUBLIC REFERAL HOSPITAL
Karina O Leary, Edgar N. Olguin, Mariano Gallo Questa, Nestor 
Spizzamiglio, Miguel Galmes, Gustavo Jankilevich  
Oncology, Hospital Carlos G Durand, Buenos Aires/ARGENTINA
Background: Cisplatin based chemotherapy is the treatment 
of choice in the adjuvant setting of non small cell cancer 
(NSCLC) stages II-IIIA. Compliance, toxicity and follow up are 
issues of paramount importance. Series from Latinamerica 
were infrecuent. Objective: We report our experience with 
consecutive patients with NSCLC diagnosis and adjuvant 
treatment. Toxicity, compliance and follow up were the end 
points.
Methods: We report our experience with consecutive patients 
with NSCLC diagnosis and adjuvant treatment. Toxicity, 
compliance and follow up were the end points. The medical 
records of consecutive patients with NSCLC adjuvant treatment 
were reviewed.
Results and Conclusion: Records of twenty patients nine 
were reviewed (45%) were male and eleven (55%) female.
Stage IB one patient (5%), one patient was stage IIA (5%), 
9(45%) were IIB and 8 (40%) patients stage IIIA . Pathology 
was adenocarcinoma 15 patients (pts) (75%) and squamous 
cell carcinoma in five cases(25%).Perfomance Status at start 
of treatment were 0 in six pts, 1 twelve pts and 2 in two. All 
patients had accessibility (with or without insurance). The 
median days to start chemotherapy since surgery was 41 days 
(r.19-98 ).Regimes indicated were Cisplatin-Vinorelbine (70%), 
Cisplatin-VP-16 (20%), Carboplatin-Paclitaxel (10%).The median 
number of cycles were 4 (3-6). The Cisplatin-Vinorelbine 
regimen was completed in 75% of pts and related with more 
adverse events,others combo were completed with mild 
toxicity in 100% of cases. No Grade 5 toxicity were recorded. 
Toxicity was seen in 13 pts (65%), the toxicity more frequent 
was asthenia (7pts),neurotoxicity (5pts),pain at administration 
site (5pts) all with vinorelbine, febril neutropenia in 4 pts, 
trombocytopenia and neutropenia in 4 pts and anemia 3 pts. 
The pattern of recurrence were locoregional 3 pts (15%) and 
distant 8 pts (40%). Recurrence was in lung 3, bone 3, brain 
2, liver 2, multiple sites 4 pts.No second tumors were reported 
and two lung cancers with different histology were recorded 
at follow up in 2pts. (10%). Conclusions: Adjuvant treatment of 
NSCLC were feasible, with high compliance and mild toxicity in 
a public hospital. The multidisciplinary approach in the follow 
up and surveillance of adverse events is the target. 
Disclosure: No significant relationships.
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P2.12: PULMONARY RESECTIONS IN A TERITIARY CARE CENTRE- 
A PROSPECTIVE OBSERVATIONAL STUDY OF OUTCOME
Krishnamurthy Swamyvelu1, Vasu Reddy Challa2, Basavanna 
Goud Yg2, Poornima Rangappa2  
1Surgical Oncology, Kidwai Memorial Institute Of Oncology, Bangalore/
INDIA, 2Kidwai Memorial Institute Of Oncology/INDIA
Background: In order to assess short term outcomes and 
predictive factors for complications following pulmonary 
resections.
Methods: All patients who underwent pulmonary resections 
either for malignant or benign causes were included in the study 
prospectively from January 2011 to December 2011 in a single 
unit in a teritiary care cancer hospital, short term outcomes and 
predictive factors were analysed.
Results and Conclusion: Results: Twenty patients underwent 
pulmonary resections for malignant conditions and 8 
patients for benign conditions. The characteristics and the 
procedures performed were given in (Table 1). Three patients 
underwent lobectomy with chest wall excision and was 
reconstructed with mesh and bone cement in two patients 
and only mesh in one patient (Fig.1). Of 8 patients who 
underwent wedge resection; 7 for benign causes and one for 
metastatic gestational trophoblastic neoplasia. One patient 
with pulmonary tuberculosis and bronchiectasis underwent 
lobectomy. Six patients developed postoperative complications 
and were described in Table 2. Two patients had minimal air 
leak which settled on conservative management. One patient 
had prolonged ICU stay for more than one week because of 
pneumonia. Of the two patients who had undergone mesh 
and bone cement reconstruction one got infected for which 
mesh was removed on 35th postoperative day, thoracoplasty 
was done and later the wound was sutured secondarily. 
Predictive factors were analyzed for all patients and were 
analysed. Pulmonary complications occurred in patients with 
DLCO <60 % in 2 patients one had pneumonia and the other 
patient was on prolonged mechanical ventilation for 48 hrs 
and ICU care for 9 days. Four of the patients who developed 
complication had ECOG performance status of 3 and other two 
had ECOG performance status of two. Conclusion: DLCO is an 
independent predictor for postoperative complication apart 
from performance status, pulmonary function tests, smoking, 
diabetes mellitus and age. 
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P2.13: TAXANE CHEMORADIATION FOR STAGE III NON-SMALL 
CELL LUNG CANCER: NEW STUDY DESIGN BASED ON PRE-
CLINICAL AND CLINICAL OUTCOMES OF TWO PROSPECTIVE 
STUDIES
Yuhchyau Chen1, Michael Milano1, Deepinder Singh1, Hong 
Zhang1, Therese Smudzin1, Kishan J. Pandya2  
1Radiation Oncology, University Of Rochester, Rochester/UNITED STATES OF 
AMERICA, 2Medicine, University Of Rochester/UNITED STATES OF AMERICA
Background: Aggressive chemoradiotherapy (CRT) is the 
current treatment standard for stage III non-small cell lung 
cancer (NSCLC), but the outcome remains poor due to both 
high rates of local disease failure and high rates of distant 
metastasis. Large phase III studies of combined CRT have 
yielded an average local failure rate at 50% and an average 
distant failure rate at 80%. The interim analysis of the ongoing 
RTOG randomized phase III clinical trial (RTOG 0617) comparing 
high dose (74Gy) vs. standard dose (60Gy) radiation and 
concurrent chemotherapy with the intent to improve local 
cancer control failed to demonstrate the benefit of high dose 
chest radiation (RT). Thus the local disease control issue remains 
unresolved, and there remains no major breakthrough in the 
efficacy of treating distant metastasis.
Methods: At our institution, two prospective phase I/II clinical 
trials have been sequentially conducted using taxane-based 
CRT for stage III NSCLC. Both studies were designed using 
pre-clinical information of paclitaxel, docetaxel and radiation 
treatments to lung cancer cell lines. URCC1597 applied low dose 
paclitaxel 15 -20mg/m2 three times per week (M,W,F), and 
daily delayed RT given at least 4 hrs after paclitaxel infusion to 
64.5 Gy in 1.8 Gy daily fractions. URCC1500 applied one-cycle 
induction chemotherapy with docetaxel (75mg/m2) & cisplatin 
(75mg/m2), and rhG-CSF (150 mg/m2 days 2-10), followed by 
twice-weekly docetaxel at 12 mg/m2 (M,Th) and daily delayed 
RT to 64.5 Gy in 1.8 Gy daily fractions.
Results and Conclusion: Preclinical data from lung cancer 
cell lines showed that both paclitaxel and docetaxel had 
radiosensitizing effects, which was more pronounced with 
delayed radiation schedule after drug treatments. Docetaxel 
had much higher cytotoxic effects than paclitaxel when lung 
cancer cells were treated with drug alone. Pulsed low-dose 
paclitaxel CRT (URCC1597) for stage III NSCLC, yielded a 100% 
response rate, a 93% in-field tumor control, 75% chest disease 
control, and a median survival of 12 months. URCC 1500 yielded 
a response rate of 69%, a 55% in-filed tumor control, 25% 
chest disease control, and a median survival of 32 months. 
Hematologic and non-hematologic toxicities were very low in 
URCC1597, while high rates of grade 3 esophagitis was observed 
and led to dose reduction of the sensitizing docetaxel in URCC 
1500. Based on outcomes of pre-clinical and two clinical studies 
of taxane-based CRT trials, we conclude that the ideal and 
logical study design that will maximally target distant metastasis 
and local chest disease of stage III NSCL is one cycle induction 
docetaxel (75mg/m2)/cisplatin (75mg/m2) ± G-CSF followed by 
pulsed low dose paclitaxel (20mg/m2) chemoradiotherapy to 65 
Gy in 1.8 Gy daily fractions.
Disclosure: No significant relationships.
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P2.15: IMPACT OF SMOKING ON POSTOPERATIVE 
COMPLICATIONS OF SURGICAL RESECTION FOR LUNG CANCER
Ileana V. Palma, Silvia A. Quadrelli, Gustavo Lyons, Domingo 
Chimondeguy, Leonardo Pankl  
Thoracic Oncology Center, British Hospital Of Buenos Aires, Buenos Aires/
ARGENTINA
Background: Smoking is not only the most important risk 
factor identified for the development of lung cancer, but also for 
the genesis of many other diseases that cause a large increase 
in morbidity and mortality, such as COPD and atherosclerotic 
disease. It has been suggested that smoking per se increases 
the risk after surgery, possibly by increasing the overall 
inflammatory process. Objective: To analyze the influence of 
smoking on postoperative complications in patients with Non 
Small Cell Lung Cancer (NSCLC) undergoing a surgical procedure 
with diagnosis or curative intent. 
Methods: Retrospectively collected data were analysed, at a 
single center, on 593 patients undergoing lung resection for 
NSCLC between January 1986 and November 2011. Smokers 
were those who had smoked at least 100 cigarettes in their life. 
Results and Conclusion: Results: 593 patients were included 
(60.9 ± 10 year-old), reliable information about smoking 
was available in 564, 86.5% (487 patients) were smokers. 
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Smokers were, more often men (74.6 vs. 35.5%, p = 0.000), 
symptomatic (41.9 vs. 24.3%, p = 0.005) and had lower 
prevalence of previous malignancies (8.9 vs. 18.6%, p = 0.029) 
compared with non-smokers.
The frequency of presentation as SPN, right side, or the central 
location were not different, but smokers had significantly higher 
frequency of clinical N2 (10.8 vs. 2.7%, p = 0.029), prevalence 
of tumors larger than 3 cm (61.7 vs 44.6%, p = 0.009), and 
prevalence of squamous cell carcinomas (20.9% vs 6.6%, p = 
0.003). Resection was complete in a similar percentage (86.8 
vs. 91.8%, p = 0.231). The rate of postoperative complications 
(23.5 vs 21.9%, p = 0.758) or operative mortality (5.5 vs 5.3%, 
p = 0.920) were not different. However, when the period of the 
last 10 years was analysed, we observed a lower complication 
rate (15.6 vs. 29.4%, p = 0.001) and operative mortality (3.3 
vs 7.4%, p = 0.025) compared with patients undergoing lung 
resection before 2002. In the whole population (smokers 
and non-smokers) logistic regression identified age over 75 
years (OR 0.41 [95% CI, 0.20 to 0.81], p = 0.011), and surgery 
performed before 2002 (OR 2.14 [95% CI, 1.35 to 3.37], p = 
0.001) as factors independently associated with postoperative 
complications: Smoking was not an independent predictor (OR 
1.09 [95% CI, 0.55 to 2.15], p = 0.800). 
Conclusions: A history of smoking was not a risk factor for 
complications and operative mortality in our series. We believe 
that improvement in perioperative management during the last 
decade has been responsible of counterbalancing the potential 
adverse impact of smoking. 
Disclosure: No significant relationships.
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P2.16: PNEUMONECTOMY IN LUNG CANCER: ANALYSIS OF 
PREDICTIVE FACTORS OF POSTOPERATIVE MORBIDITY AND 
MORTALITY
Ileana V. Palma, Silvia A. Quadrelli, Gustavo Lyons, Domingo 
Chimondeguy, Leonardo Pankl  
Thoracic Oncology Center, British Hospital Of Buenos Aires, Buenos Aires/
ARGENTINA
Background: Complete surgical resection in patients with lung 
cancer non-small cell (NSCLC) remains the only potentially 
curative option. The surgical discussion on pneumonectomy 
has focused on the high postoperative morbidity and mortality 
rate and its possible impact on long-term survival. Objective: To 
analyse predictive factors of postoperative complications and 
mortality after pneumonectomy. 
Methods: Retrospectively collected data was analysed, at a 
single center, on 570 patients undergoing lung resection for 
NSCLC with curative intent between January 1986 and March 
2011. 
Results and Conclusion: Results: There were 66 
pneumonectomies. Most were men (74.2%) and less than 70 
years (97%). Smokers were 89.4%. The prevalence of previous 
malignancy was 4.7%, the frequency of presentation as SPN 
was 16.9%, right upper lobe location in 26.6%, 29.7% lower 
and 54.7% in middle lobe, and with involvement of bronchus 
7.9%.The clinical stages were IA 16.7%, IB 43.9%, and IIB 
39.4%.During surgery, the prevalence of tumors larger than 3 
cm was 85.7%, N2 disease 34.4%, pleural invasion 15.6% and 
regional involvement 51.6%.The prevalence of adenocarcinoma 
was 47%. Pneumonectomy was considered curative in 71.9% 
with a postoperative complication rate of 43.1% and 20.6% 
operative mortality.In 50.8% of patiemts, the pneumonectomy 
was performed on the right side, with an operative mortality 
of 24.2% (vs. 16.7% on the left side, p = 0.542).The median 
survival of stage I patients was not different compared to other 
surgical procedure (51.03 vs. 142.27, Kaplan-Meier log rank p 
= 0.912).We performed a multivariate analysis of postoperative 
morbidity and mortality: complete resection (OR 0.18, 95% CI 
0.04 to 0.75, p = 0.019) and curative resection (OR 0.15, 95% 
CI 0.04 to 0.58, p = 0.005) were protective factors; and age 
over 70 years old (OR 7.5, 95% CI 1.09 - 51.51, p = 0.04) and 
the presence of postoperative complications (OR 11.68, 95% CI 
2.31 - 59.03, p = 0.002) were predictors of mortality.
Conclusions: Pneumonectomy has high postoperative 
morbidity and mortality. The age over 70 years old and the 
presence of postoperative complications were predictor 
factors of mortality. In our center, we found no significant 
difference in median survival, neither operative mortality in 
right pneumonectomy. 
Disclosure: No significant relationships.
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P2.17: DOES AGE INCREASE POSTOPERATIVE MORBIDITY AND 
MORTALITY IN PULMONARY RESECTION IN LUNG CANCER?
Ileana V. Palma, Silvia A. Quadrelli, Gustavo Lyons, Domingo 
Chimondeguy, Leonardo Pankl  
Thoracic Oncology Center, British Hospital Of Buenos Aires, Buenos Aires/
ARGENTINA
Background: The diagnosis of non small Cell Lung Cancer 
(NSCLC) in elderly patients is increasing due to longer life 
expectancy. Although the surgery offers the best chance of cure 
in early stage; in the elderly, this is done with extreme caution 
because of the existance of high incidence of morbidity and 
mortality. Objective: to analyze the clinical characteristics, 
postoperative morbidity and mortality in patients over 75 years 
old diagnosed with NSCLC undergoing a surgical procedure with 
curative intent. 
Methods: Retrospectively collected data was analysed, at 
a single center, on 593 patients undergoing lung resection 
for NSCLC with curative intent between January 1986 and 
November 2011. They were divided into 2 groups: under 75 
(u75) and over 75 (o75). 
Results and Conclusion: Results: The o75 were 47 (8%), 
with mean age 78.2 ± 3.2 (vs. 59.49 ± 9.04), there was 
no differences in sex between groups (men 61.7 vs 68.8%, 
p = 0.315). The o75 had a higher prevalence of previous 
malignancies (20 vs. 9.4%, p = 0.068) and lower proportion of 
smokers (including ex-smokers) (72.3 vs. 82.4%, p = 0.038). 
The frequency of presentation as SPN (34 vs. 38.9%, p = 
0.537), right side (55.3 vs. 58.8%, p = 0.646), central location 
(25 vs. 26.3%, p = 1.000), asymptomatic (59.5 vs. 69%, p = 
0.253) or clinical suspicion of N2 (4.3 vs. 10.4%, p = 0.299) 
were not different. The rate of postoperative complications 
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(35.7% vs. 21.7% p = 0.053) or operative mortality (6.4 vs. 
4.8% p = 0.498) were not different; however, in o75 less 
pneumonectomies were performed (4.3 vs. 16.1%, p = 0.032) 
and had more days in hospital intensive care (3.13 ± 8.20 vs. 
1.43 ± 3.12, p = 0.003). The prevalence of tumors larger than 3 
cm. (71.4 vs. 58.1%, p = 0.103), the finding of N2 disease (18.6 
vs. 20.8%, p = 0.846), pleural invasion (5.5 vs. 19%, p = 0.335) 
or regional involvenment during surgery (42.5 vs. 31.3%, p = 
0.159) were not different.
Both groups had the same proportion of adenocarcinomas (68.1 
vs. 61.1 p = 0.434).
Surgery was considered curative in a similar percentage (89.1 vs. 
86.9%, p = 0.820). The median survival was not different 
between both groups (37.9 vs. 70 months Kaplan-Meier log 
rank p = 0.064). When logistic regression was performed to 
find risk factors independently associated with postoperative 
complications, the age over 75 persists in the multivariate 
analysis (OR 2.00 [95% CI 1.03 to 3.91], P = 0.041); however, 
this does not occur when analyzing postoperative mortality (OR 
1.23 [95% CI 0.35 to 4.27], P = 0.739). Conclusions: Our data 
shows that elderly patients do not have an increased morbidity 
and mortality after pulmonary resection, therefore should not 
be denied lung resection based on chronological age. 
Disclosure: No significant relationships.
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P2.18: IMPROVING OPERATIVE STANDARDS FOR LUNG CANCER 
BY AUDIT. WHY SOME PATIENTS DON’T GET THE BEST DEAL?
Laura Socci1, Marissa Hagan1, Sophie T Williams1, Munib Malik2, 
Eveline Internullo1, Antonio E Martin-Ucar1  
1Thoracic, Nottingham University Hospitals, Nottingham/UNITED 
KINGDOM, 2Anaesthesia, Nottingham University Hospitals/UNITED 
KINGDOM
Background: To audit anatomical resection and lymph node 
excision in patients undergoing lung cancer surgery according to 
the gold standards defined by the European Society of Thoracic 
Surgeons working group.
Methods: This is an analysis of all patients with primary lung 
cancer operated on by a single surgeon between July 2009 and 
December 2011. The patients are divided into 2 Groups: Initial 
Audit (100 patients, July 2009-October 2010) and Re-Audit (102 
patients, November 2010-December 2011) that completed our 
Cycle.
Rates of anatomical resection and lymph node excision were 
measured from data obtained from histo-pathology reports 
and a surgical database. Uni- and multi-variate analyses were 
performed to identify reasons associated with diversion from 
set standards.
Results and Conclusion: RESULTS: 202 patients [120 male and 
82 female, median age 70 (range 34-90) years] underwent 
surgery. Median PpoFEv1 was 58.2% (range 16 to 129). Median 
European Society Objective score (ESOS) was 5.4 (range 
0.1 to 37.4) for Mortality and 24.3 (range 5.2 to 51.7) for 
Complications. A total of 29 (14.4%) procedures were 
completed by VATS approach. Anatomical resections were 
performed in 92% cases (88% in the initial group and 94% 
after the initial Audit). At least 1, 2 and 3 N2 lymph node 
stations were obtained in 88%, 69% and 51% respectively.
On Multivariate Regression Analyses History of another 
malignancy (p=0.01), VATS approach (p=0.001) and high 
ESOS score (p=0.02) were associated with more use of non-
anatomical resections. Initial Audit group (p= 0.001) and VATS 
approach (p<0.001) were related to less complete mediastinal 
exploration on Logistic Regression.
CONCLUSION: Completing the Audit Cycle has helped to 
improve operative standards for lung cancer. Failure to perform 
extensive lymph node excision was unrelated to impaired 
spirometry, high ESOS score or advanced age. Our Audit 
demonstrates the need for attention to mediastinal lymph node 
dissection; specially during VATS lobectomies and might reflect 
the effects of a learning curve.
Disclosure: No significant relationships.
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P2.19: PRIMARY PLEUOPULMONARY SYNOVIAL SARCOMA: A 
RETROSPECTIVE CLINICO-PATHOLOGIC STUDY OF 21 CASES 
FROM A SINGLE INSTITUTION
Matteo Giaj Levra1, Silvia Novello1, Tiziana Vavalà1, Benedetta 
Crida1, Marina Longo1, Axel Le Cesne2  
1Department Of Clinical And Biological Sciences, Orbassano/ITALY, 2Institut 
Gustave Roussy, Villejuif/FRANCE
Background: Primary pleuropulmonary synovial sarcoma 
(PPSS) is a rare neoplasm well described in literature over the 
last years. It represents from 7 to 10% of soft tissue sarcoma, 
being the most common areas of occurrence the thigh, knee, 
shoulder, foot and upper extremities, while in rare cases it could 
be diagnosed in the chest wall, mediastinum, lung parenchyma, 
pleura or heart. The discovery of the pathognomonic t(x;18) 
chromosomal translocation has enabled the diagnosis of an 
increasing number of these tumors. 
Methods: This is a retrospective study of 21 consecutive 
patients (pts) with a diagnosis of primary PPSS treated or 
followed at the Institut Gustave Roussy (France) from 1998 to 
2010. The main objective of this study is to identify the different 
ways of diagnosis, management and treatment for rare a 
disease, for which there is not a standard of care. 
Results and Conclusion: Male/female ratio was 11/10, the 
median age 46 (range 16-72) with a median PS of 0 (1-2). Most 
commons symptoms were dyspnea, asthenia and cough, while 
in 4 cases the diagnosis was accidental. Tumors were localized 
in 12 cases in the lung, 6 were pleural, 2 mediastinal and in 
one case carinal. Six patients had synchronous metastases at 
diagnosis. Sixteen surgical interventions were performed: 11 
lobectomies, 3 pneumonectomies, 1 atypical resection and 1 
tracheal resection. A R0 resection has been achieved in 69% 
of the cases, while in the remaining there was evidence of a 
micro- or macroscopic residual (25% surgeries R1 and 6.25% 
R2). Neoplasms with monophasic component were the most 
prevalent (16/20, 80%) compared to those biphasic (4/20, 
20%), and in 83% of cases (15/18) the tumors were grade 3 
according to FNCLCC grading scale. Most of the neoplasm were 
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positive for the t(x,18) translocation (76.9%), and in 4 patients 
the fusion protein was searched (3 were positive for the SYT/
SSX2 fusion and only one for the SYT/SSX1). Seven patients 
received a doxorubicin-containing chemotherapy (CT) regimen 
in adjuvant setting and only four underwent radiotherapy. 
R0 patients had a better disease free (22.7 vs 11.7 months) 
and overall survival (37.3 vs 23.2 months) comparing with 
R1-R2 patients. Thirteen cases of relapse were observed with 
a median time of 15,7 months (range 4,7- 59,7 months), 8 
cases at thoracic level. Sixteen patients received a palliative 
chemotherapy. Seventeen (81%) died within 1 to 73 months 
(mean, 25 months), and 15 patients died within 5 years (71,4%). 
With a minimum follow-up With a minimum follow-up of 10 
months, at the time of analysis three pts (14,3%) were alive 
with no evidence of disease and one was alive with evidence of 
disease. PPSS is a rare subset of intrathoracic sarcoma, and its 
clinical features suggest a more aggressive behavior than the 
synovialsarcoma of other counterparts, possibly related to the 
difficulty in obtaining adequate surgical margins. Adjuvant and 
neoadjuvant therapies need to be discussed in multidisciplinary 
committee and are indicated in these unfavorable diseases. 
Disclosure: No significant relationships.
POSTER SESSION 2 - July 27, 2012 09:00 – 17:00
SCLC, Mesothelioma, Thymoma
P2.20: MALIGNANT PLEURAL MESOTHELIOMA AND ERCC1 
EXPRESSION
Cristina Fernandez1, Osvaldo Arén2, Rodrigo Ascui2, Jorge 
Arancibia2, Victor Zambrano3, Daniel Cancino3, Marcela 
Carcamo4, Mauricio Fica5, Claudia Bustamante1, Claudio Suarez5  
1Servicio De Anatomia Patologica, Instituto Nacional Del Cancer, Santiago/
CHILE, 2Servicio De Oncología Médica-Sección Oncología Torácica, Instituto 
Nacional Del Cáncer, Santiago/CHILE, 3Servicio De Radioterapia, Instituto 
Nacional Del Cancer, Santiago/CHILE, 4Estadistica Médica, Instituto 
Nacional Del Cancer, Santiago/CHILE, 5Cirugia Toracica, Clinica Santa 
Maria, Santiago/CHILE
Background: Advanced Malignant Pleural Mesothelioma (MPM) 
is a poor prognosis disease for which better treatment options 
and prognostic factors are urgently needed. Our study was 
to investigate the potential role of ERCC1 protein status as a 
prognostic factor in untreated patients with advanced MPM.
Methods: The study population consisted of 62 inoperable 
patients with advanced MPM enrolled betwen January 2003 and 
August 2010. None of the patients received chemotherapy due 
to non coverage by chilean public health system. All the patients 
received best supportive care. ERCC1 expression as a prognostic 
factor was evaluated by immunohistochemistry (IHC) on the 
formalin-fixed paraffin-embedded diagnostic biopsies.The 
tumor samples were separated according to this cutoff point 
into ERCC1-negative (H-score <= median) and ERCC1- positive 
(H-score> median) cases. 
Results and Conclusion: Results: The 62 patients had tumor 
tisssue available for IHC.There were 71% ERCC1 negative, and 
29% ERCC1 positive.There was no correlation between ERCC1 
status and survival. Conclusion: Even if the literature suggests 
that ERCC1 can be a predictive factor of response to platinum-
based chemotherapy, our retrospective study did not show 
ERRC1 expression to be an independent prognostic factor in 
untreated patients with advanced MPM. 
Disclosure: No significant relationships.
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P2.22: THORACIC E MEDIASTINAL PARAGANGLIOMA - A CASE 
REPORT
Romero Fenili1, Larissa D.S.H. Nunes2, Anderson Dietrich2, 
Frederico Di Giovanni1  
1Medicine, Furb, Blumenau/BRAZIL, 2Medicine, Furb/BRAZIL
Background: Paragangliomas are tumors that arise from 
the autonomic nervous system-associated paraganglia. 
These tumors can be hereditary cases and they are classified 
based on location and functioning character (catecholamine 
and serotonin secretors) and non-functioning character. 
Paraganglioma rarely occurs in the spinal canal and the 
extradural thoracic location is even less common. The treatment 
of choice is surgery when there is no metastasis. We report a 
case of a 36 year old woman with a thoracic paraganglioma. 
The patient first symptoms occurred in February 2010, when 
she presented shoulder and neck pain. At this time she 
was diagnosed as having stress. After that, she developed 
cough and posterior thoracic pain. Simultaneously, she 
presented progressive dysphagia and vomiting. In July 2011 
she looked for medical assistance. The chest x-ray showed 
an increase of cardiac and mediastinal areas. At this time the 
patient become with dyspnea and to become dysphonic. 
Transthoracic echocardiogram performed in August 2011 
demonstrated a low ejection fraction (57%) and a mass near 
pulmonary artery measuring 5.8x4.3cm with compression 
of pulmonary artery. CT done in August 2011 has shown 3 
heterogeneous masses with low density: one localized in 
anterior compartment of mediastinum sized 7.5x 4.0 cm, 
the other close to right pulmonary artery (3.0X2.5cm), and 
the third in left paravertebral region (6,1X3,4cm). All others 
thoracic structures seemed to be normal. First biopsy was 
performed in August 2011. The anatomy pathologic diagnosis 
was paraganglioma. A second biopsy showed the same 
diagnosis and the immunohistochemistry analisys has shown 
neuroendocrine low grade carcinoma. At this time it was 
indicated surgery treatment. The surgery occurred in December 
2011, when all but the lesion in contact with right pulmonary 
artery were submitted to excision. The postoperative evolution 
was favorable and the patient was dismissed from hospital 
within 7 days. The postoperative computed tomography control 
showed persistent mass at right pulmonary artery. Now there 
is a discussion about the next approach: radiotherapy or new 
attempt to surgical resection of the remain lesion? 
Methods: The study is a case report description study.
Results and Conclusion: In present case, we has shown a 
partial succesfull treatment of a thoracic paraganglioma by 
surgical treatment.
Disclosure: No significant relationships.
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P2.24: VATS PLEURECTOMY/DECORTICATION FOR PALLIATION 
OF MALIGNANT PLEURAL MESOTHELIOMA
Laura Socci1, Pamela Wake2, Munib Malik3, Eveline Internullo1, 
Antonio E Martin-Ucar1  
1Thoracic, Nottingham University Hospitals, Nottingham/UNITED 
KINGDOM, 2Anaesthesia, Nottingham University Hospitals, /UNITED 
KINGDOM, 3Nottingham University Hospitals/UNITED KINGDOM
Background: Surgery plays a role in the symptomatic 
management of Malignant Pleural Mesothelioma (MPM). We 
offer VATS debulking surgery to relieve symptoms in patients 
unsuitable for radical surgery. We present an operative video 
of the procedure. We aimed to assess the perioperative course 
and survival results of patients undergoing VATS Pleurectomy 
Decortication in the palliative management of MPM.
Methods: Over a 3-year period (2009-2011) 14 patients 
with MPM [13 male and one female, median age of 75 years 
(range 66-84) underwent VATS Pleurecomy Decortication with 
palliative intent under a single specialist surgeon. Indications 
for surgery were: Cytoreductive surgery as part of a randomised 
trial (n=3), elective debulking of trapped-lung síndrome (n=5) 
and Urgent inpatient surgery for malignant empiema, bleeding 
or dyspnea due to trapped-lung (n=6).
Median FEV1 was 52 (range 47 to 60) % predicted and patients 
had undergone a median of 2 (range 1-3) pleural invasive 
interventions prior to VATS debulking. The cell type was 
epitheloid and biphasic in 5 cases each and sarcomatoid in 4 
cases.
Results and Conclusion: RESULTS:There was one perioperative 
death(7%) after bronchopneumonia following decortication 
fr a malignant empiema. The procedure was converted into a 
limited thoracotomy in 4 cases (3 out of the 6 Urgent cases 
and 1 out of the 8 Elective cases). The median hospital stay 
and duration of intercostal drainage were 8 (range 3 to 26) and 
6 (range 2-51) days respectively. At a median follow-up of 16 
months the median surcival was 9 months.
CONCLUSION: VATS pleurectomy/decortication is a valid surgical 
alternative in patients with Malignant Pleural Mesothelioma 
that are not candidates for radical surgey with aceptable 
complications. Inpatient salvage surgery carries poorer 
prognosis.
Disclosure: No significant relationships.
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P2.25: USE OF BIOLOGICAL IMPLANTS FOR TISSUE 
RECONSTRUCTION AFTER THORACIC SURGERY FOR MALIGNACY
Laura Socci1, Anupama Barua1, Anna Raurell2, Munib Malik3, 
Eveline Internullo1, Antonio E Martin-Ucar1  
1Thoracic, Nottingham University Hospitals, Nottingham/UNITED KINGDOM, 
2Plastic Surgery, Nottingham University Hospitals/UNITED KINGDOM, 
3Anaesthesia, Nottingham University Hospitals/UNITED KINGDOM
Background: Synthetic materials have traditionally been used 
for tissue reconstruction in Thoracic Surgery. New biomaterials 
have been tested in other areas of surgery with good results. 
The aim of our study is to evaluate their use in extended 
thoracic surgery.
Methods: We reviewed all patients who underwent Thoracic 
Surgery requiring tissue reconstruction with bioprosthetic 
materials from August 2009 to January 2012. A total of 51 
consecutive patients [46 male and 5 female, median age 65 
(range 39-89) years] were included (42 elective admission and 
9 with a contaminated/infected environment). Operations 
involved radical pleurectomy/decortication for Mesothelioma 
(n=39) and extended operations for thoracic malignancies (n=12)
Results and Conclusion: Results: A total of 94 patches were 
used (median of 2 per patient, range 1-3). Median hospital 
stay was 12 (range 5-149) days. Three patients died during 
postoperative period (5.8%): pulmonary embolism 5 days after 
intrapericardial pneumonectomy with chest wall reconstruction, 
fatal pneumonia 26 days after radical pleurectomy/
decortication for mesothelioma, and bronchopleural fistula 11 
days after pneumonectomy with diaphragm and atrium excision 
for lung cancer after initial chemoradiotherapy. Six additional 
patients (10%) suffered majors complications: 3 required a 
reoperation (bleeding, tension pneumothorax, and release 
of a tight patch) and 2 patients suffered empyema treated 
conservatively. No other surgical exploration or removal of 
patches has been required for infection. Age, type of operation, 
number of patches, contaminated environment prior to surgery 
and emergency surgery did not increase postoperative dead, 
infection or complication rates. Conclusions: Our experience 
with the use of bioprosthetic patches for tissue reconstruction 
in Thoracic Surgery is proving satisfactory in extended/
complex procedures. The infection rates are low even when a 
proportion of procedures were performed under contaminated 
environments. Biological prosthesis should be part of the 
surgical options in Thoracic Surgery.
Disclosure: No significant relationships.
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P2.26: PRESERVING THE LUNG DURING RADICAL SURGERY FOR 
MESOTHELIOMA: QUALITY OF LIFE, SPIROMETRY AND LUNG 
VOLUME MEASUREMENTS
Laura Socci1, Debbie Raffle1, Anupama Barua1, Sandeep Tiwari2, 
Maruti Kumaran2, Antonio E Martin-Ucar1  
1Thoracic, Nottingham University Hospitals, Nottingham/UNITED 
KINGDOM, 2Radiology, Nottingham University Hospitals/UNITED KINGDOM
Background: To explore the changes in spirometry, lung volume 
measurements and quality of life after Radical Pleurectomy 
Decortication (RPD) for Malignant Pleural Mesothelioma (MPM)
Methods: Analysis of the changes in FEV1, Quality of Life 
(QoL)Questionnaires EORTC C30 and LC13, and volume 
measurements using CT scan software in the first 10 
consecutives patients [8 male and 2 female, median age 
62 (range 51 to 73 years] undergoing Radical Pleurectomy/
Decortication under a single surgeon from August 2009-March 
2010.
Results and Conclusion: Results: There were no perioperative 
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deaths and no admissions to Intensive Care. The median 
hospital stay was 12 (range 10 to 20) days. All patients 
responded to QoL questionnaires pre and postoperatively at 3 
month intervals. At median follow-up of 13 months (range 11 to 
17) months, 7 patients remain alive. Ct scan were performed 
within 3 months from surgery and 9 of 10 patients underwent 
spirometry 3 months after surgery. At a median follow-up of 
22 (range 14 to 25) months, the median survival is 20 (range 4 
to 22) months. The FEV1 was reduced after surgery 17% (range 
42% loss to 22% gain), but was not significant (p=0.5), and the 
lung volume changes ranged form loss of 57% to gain of 35% , 
but a the median change was only 1% (p=0.9).
QoL scores at 3, 6,9 and 12 months postoperatively showed no 
significant changes from preoperative responses. Conclusion: 
Preserving the lung parenchyma during Radical Surgery for MPM 
allows preservation of respiratory reserve and lung volumes. 
Some patients (the ones with a trapped-lung preoperatively) 
even improve their measurements. Patients reported 
preservation of QoL scores from 3 to 12 months.
Disclosure: No significant relationships.
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P2.27: FINAL RESULTS OF THE PHASE I COMPONENT OF A 
PHASE I/IIA STUDY OF CHEMOTHERAPY WITH BENDAMUSTINE 
AND IRINOTECAN (BI) FOLLOWED BY ETOPOSIDE/CARBOPLATIN 
(EC) IN UNTREATED PATIENTS (PTS) WITH EXTENSIVE SMALL 
CELL LUNG CANCER (E-SCLC)
Rodolfo E. Bordoni1, Francisco Robert2, Mansoor Saleh1, Pam 
Dixon2, Barbara Howell1  
1Medical Oncology, Georgia Cancer Specialist, Marietta/UNITED STATES OF 
AMERICA, 2Medical Oncology, University Of Alabama, Birmingham/UNITED 
STATES OF AMERICA
Background: First-line therapy (EC) for E-SCLC produces a 
progression-free (PFS) and overall survival (OS) of 4 and 9 
months, respectively. We evaluated safety and efficacy of a 
novel combination of BI followed by EC. Bendamustine and 
Irinotecan have single-agent activity in E-SCLC with tolerable 
toxicity.
Methods: This is a phase I/IIa study in untreated pts with 
E-SCLC, ECOG 0-2 and adequate organ function. Three dose 
levels (DL) of B (80, 100, and 120 mg/m2 - D1, 2) and I (150 mg/
m2 - D1) every 3 weeks [Regimen A] for 3 cycles, followed by 3 
cycles of E (100 mg/m2 - D1-3), and C (AUC 6, D1) [Regimen B] 
was evaluated in the phase I portion of the study. Regimen A 
dose limiting toxicity (DLT) and maximum tolerable dose (MTD) 
were evaluated in cycle 1 in 3-6 pts per dose level. Toxicity 
(CTCAE) was evaluated with CBC (weekly) and chemistry (every 
3 weeks) and response (RECIST) by imaging at the end of 
Regimen A and B.
Results and Conclusion: 15 pts in 3 cohorts (cohort 1 (n=3); 2 
(n=6); and 3 (n=6)) were enrolled in this phase I study. Baseline 
characteristics: median age 65 years, male 69%, increased LDH 
54%, low albumin 31%, 1 pt with brain metastases. Regimen A, 
cycle 1 DLTs: Grade 3 diarrhea (cohort 2) and Grade 3 diarrhea/
nausea/vomiting (cohort 3). Dose reduction was required in 2 
and 3 pts in regimen A and B, respectively. Objective responses 
were observed in all three cohorts. Response rate on regimen 
A ~ 71% (CR-0; PR-10; 1-early for evaluation). Best overall 
response rate (regimen A/B) ~ 71% (CR-1; PR-9; 1-early for 
evaluation. Time to progression: median ~ 7 months [95% CI 
(2.0; 7.00)]. OS: median ~ 10 months [95% CI (5.0; 11.0)]. To 
date we have enrolled 8:15 pts needed in the phase II portion 
of the trial. Efficacy is too early to report. AE’s to date: Grade 
3’s: nausea (cycle 1), neutropenia (cycle 1), weakness (cycle 
2), fatigue (cycle 20), hyponatremia (cycle 1), dehydration 
(cycle 1), diarrhea (cycle 1) and dyspnea (cycle 1). Grade 4’s: 
hyperuricemia, leukopenia (cycle 1). BI seems to be active and 
well tolerated in E-SCLC. DLTs were: diarrhea (n=11 [73%]; 
Grade 3 3:11)(cohort 2) and nausea, vomiting, diarrhea (cohort 
3) of regimen A. Overall grades 3/4 myelosuppression were not 
significant in regimen A. Other adverse events in regimen A 
included nausea/vomiting, fatigue, and hypokalemia. Objective 
responses were observed in all 3 cohorts; best RDIs for regimen 
A and B were seen in cohort 2. For the phase 2 component of 
the study our recommended dose of Bendamustine is 100mg/
m2 (d1, 2) plus Irinotecan 150mg/m2 (d-1). 
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P2.28: GENDER DIFFERENCES OF ESTROGEN RECEPTOR BETA 
EXPRESSION IN NON-SMALL CELL LUNG CANCER
Eugene A. Dudko1, Alexandra S. Shaturova1, Galina B. Smirnova1, 
Tatiana A. Bogush1, Boris E. Polotsky2, Sergey A. Tjulandin3, 
Mikhail I. Davydov2  
1Laboratory Of Medical Chemistry, N.N. Blokhin Russian Cancer Research 
Centre Of The Russian Academy Of Medical Sciences, Moscow/RUSSIAN 
FEDERATION, 2Department Of Surgery, N.N. Blokhin Russian Cancer 
Research Centre Of The Russian Academy Of Medical Sciences, Moscow/
RUSSIAN FEDERATION, 3Department Of Clinical Pharmacology And 
Chemotherapy, N.N. Blokhin Russian Cancer Research Centre Of The 
Russian Academy Of Medical Sciences, Moscow/RUSSIAN FEDERATION
Background: Important role of estrogens in occurrence and 
progression of non-small cell lung cancer (NSCLC) is recently 
shown. Estrogen receptor beta (ER beta) in the NSCLC tissue 
is a good prognostic marker and antiestrogen therapy target. 
We have supposed the level of ER beta expression in the tumor 
cells could be one of the reasons of gender differences in NSCLC 
progress. To check the supposition ER beta were quantitatively 
evaluated in NSCLC tissue – in the group of patients and 
separately in female and male. It was performed using 
immunofluorescence methodology developed by us.
Methods: NSCLC surgical specimens of 22 women and 79 
men were analyzed by flow cytometry. Single-cell suspensions 
were incubated with primary antibodies (anti-ER beta 14C8 
and isotype IgG2a, Abcam) overnight and with secondary 
FITC-conjugated antibody (F2772, Sigma) for 1.5 h. Mean 
cell fluorescence and number of stained cells were analyzed 
with WinMDI software and Kolmogorov-Smirnov statistical 
approach. ER beta expression intensity was estimated as ratio 
of the specific fluorescence to the isotypic one. MCF-7 cell 
culture was used as a reference for the control of antibody 
activity. Three indexes of ER beta expression level were used 
for the comparison: high – ER beta revealed more than in 50% 
of the cells; moderate – in 30-49%; low – less than in 30%. 
Two indexes of ER beta expression intensity were used: high 
– specific cell fluorescence is higher 2.0 times and more than 
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isotypic control; low – less than 2.0 times higher. 
Results and Conclusion: In all investigated patients ER beta 
was revealed in about 80% of cases. Low ER beta level was 
shown in 42%, high – in 30% and moderate – in 28% of 
patients. Low expression intensity – was revealed in 46%, 
high – in 54% of cases. In women as compared to men median 
of ER beta level was in about 1.4 fold higher (46±19.2% and 
34±16.8% respectively, p=0.01); but there was no significant 
difference in expression intensity (2.3±1.0 and 2.8±1.6, p=0.12). 
High ER beta level was revealed more frequently (p<0.05) in 
women (50% of patients) than in men (24% of patients). Low 
ER beta level was revealed more frequently in men than in 
women – in 19% and 63% of patients (p<0.05). Moderate ER 
beta level in women was the same as in men – in 32% and 
27% of cases (p>0.05). High ER beta expression intensity was 
revealed in 68% of women and 49% of men (p<0.05), and 
low – in 32% of women and 51% of men (p<0.05). NSCLC is 
characterized by high and moderate level of ER beta in about 
half of cases. Higher ER beta level in women than in men could 
be one of the reasons in gender differences of NSCLC disease 
progress. We believe that at least half of the NSCLC patients 
(more often – women) with tumor ER beta expression could 
benefit from adjuvant antiestrogen therapy similarly to breast 
cancer patients. ER beta has to be obligate marker among the 
other proteins studying in NSCLC patients. Supported by RFBR 
(N10-04-00551-a,N12-04-00028-a). 
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P2.29: REACTIVE OXYGEN SPECIES AS MAIN FACTORS 
CONDITIONING CELL DEATH IN RESPONSE TO ALA-
BASED PHOTODYNAMIC THERAPY IN HUMAN LUNG 
ADENOCARCINOMA SPHEROIDS
Julieta Teijo1, Berenice Diez1, Roberto Meiss2, Alcira Batlle3, 
Haydée Fukuda1  
1Cipyp-Conicet; Dto. Química Biológica Fceyn, Uba, Buenos Aires/ARGENTINA, 
2Instituto De Estudios Oncológicos, Academia Nacional De Medicina, Buenos 
Aires/ARGENTINA, 3Cipyp-Conicet, Buenos Aires/ARGENTINA
Background: Photodynamic therapy (PDT) is an approved 
anticancer treatment modality that eradicates tumor cells by 
the photochemical generation of reactive oxygen species (ROS) 
following absorption of visible light by a photosensitizer, which 
is selectively taken up by malignant cells. 5-Aminolevulinic 
acid (ALA) is the biological precursor of Protoporphyrin IX, 
the only endogenous photosensitizer. Multicellular spheroids 
(MCSs) are three-dimensional compact cellular aggregates that 
mimic micro-tumors with no vascular irrigation, representing 
a suitable model for the study of PDT-induced cell death, since 
tumor vasculature has a controversial role in tumor eradication 
by PDT. Previously, we found that cells cultured in MCSs appear 
to be more resistant to photodamage than cells cultured in 
monolayers, as the light dose yielding 50% cell death after PDT 
(LD50) determined by the MTT assay and the APH assay, was 
lower in cells growing in monolayers (7 min) than in spheroids 
(10 min). The aim of this study was to detect the limiting factors 
conditioning PDT efficacy in MCSs. 
Methods: ALA -PDT was performed in A549 human lung 
adenocarcinoma cells growing as monolayers or as MCSs. These 
were initiated by seeding 5x104 cells/ml on 3% agar:RPMI (1:1) 
coated wells and harvested after 7 days with periodic fresh 
medium renewal. Cells were incubated with 1 mM ALA for 3 h 
followed by irradiation with a bank of two fluorescent lamps 
(Osram L36W/10, 0,4 J/cm2) for different times and within 1 h 
analyzed for PDT-induced events. 
Results and Conclusion: Porphyrin synthesis was not 
significantly different between monolayers and MCS, neither 
quantitatively (monolayers: 0,109±0,1 pg/cell; MCSs: 0,09±0,1 
pg/cell) nor qualitatively, since PpIX fluorescence distribution 
was uniform along all sections of the spheroids analyzed 
under confocal microscopy. With normal PpIX synthesis and 
distribution, the limiting factor on PDT efficacy could be light 
penetration into the inner section of the MCSs. To this end, 
spheroids were trypsinized and cells counted for apoptosis by 
acridine orange/ethidium bromide staining and AnnexinV-FITC/
propidium iodide labelling. Results showed a higher percentage 
of viable cells when 20 min-irradiation PDT was performed on 
spheroids (66,57±6,5%) compared to monolayers (3,5±0,2%). 
Moreover, caspase-3 expression and cytochrome c release 
were also lower in MCSs. To visualize cell photodamage 
in intact spheroids, histological sections were stained for 
general morphology with hematoxylin/eosin, PAS staining for 
mucopolysaccharides, and Ki67 immunostaining as proliferation 
marker. Results showed that not only can light pass through the 
structure of the spheroid, but also that PDT can disrupt cellular 
morphology, secretory differentiation (which is consistent 
with the adenocarcinoma histology of the cell line) and cell 
proliferation. Another limiting factor on PDT efficacy could be 
a defective ROS production in MCSs, therefore, singlet oxygen 
(the main effector of PDT-induced cell damage) and superoxide 
anion generation were assessed by flow cytometry. It was found 
that both ROS production were significantly lower in MCSs (1O2: 
5,5±2,7%; O2-: 4,8±0,3%) compared to monolayers (1O2: 
83,5±1,9%; O2-: 70,6±8,1%) after 20 min PDT. These results 
indicate that oxygen availability and not porphyrin synthesis 
or light accessibility might be the conditioning factor for the 
differential response of MCSs to ALA-based PDT. 
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P2.30: TUMOR SUPPRESSOR FUS1 PROVIDES A MOLECULAR 
LINK BETWEEN INFLAMMATORY RESPONSE AND 
MITOCHONDRIAL HOMEOSTASIS
Roman Uzhachenko1, Natalia Issaeva2, Sergey Ivanov1, David 
Carbone2, Alla V. Ivanova1  
1Medicine, Division Of Hematology/Oncology, Vanderbilt University, 
Nashville/UNITED STATES OF AMERICA, 2Medicine, Division Of Hematology/
Oncology, Vanderbilt University/UNITED STATES OF AMERICA
Background: Fus1, a tumor suppressor on chromosome 
3p21.3, is down-regulated, mutated, or lost in the majority 
of inflammatory thoracic malignancies. Although its biological 
function remains unknown, mitochondrial localization suggests 
involvement of Fus1 in mitochondrial activities. Our earlier 
studies revealed the importance of Fus1 for immune system 
regulation and inflammation.
Methods: In this work, we investigated how Fus1 modulates 
inflammatory response and mitochondrial function on a mouse 
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model of asbestos-induced peritoneal inflammation.
Results and Conclusion: We found that peritoneal infiltrate 
in Fus1-/- mice even without asbestos contained an ~8-times 
higher proportion of granulocytes than Fus1+/+ mice pointing 
at ongoing chronic inflammation. Asbestos treatment results 
in a decrease of Fus1 expression in WT peritoneal immune cells 
suggesting that asbestos exposure may compromise the Fus1-
mediated inflammatory response. Indeed, disbalanced response 
in asbestos-treated Fus1-/- mice was apparent by the decreased 
immune organ weight and total protein concentration in 
peritoneal lavage alongside with the increased proportion of 
peritoneal macrophages. Fus1-/- mice showed augmented 
asbestos-induced activation of key inflammatory, anti-oxidant, 
and genotoxic stress response proteins ERK1/2, NFkB, SOD2, 
γH2AX, etc. Moreover, Fus1-/- mice showed altered dynamics 
of pro- and anti-inflammatory cytokine expression, such as 
Ifn-γ, Tnf-α, Il-1a, Il-1b, and Il-10. “Late” response cytokine 
Ccl5 was under-expressed in Fus1-/- immune cells at both basal 
and asbestos-activated states. Noteworthy, we observed a 
substantial asbestos-related difference in the size of CD3+CD4-
CD8- DN T cell subset that was expanded 4-fold in Fus1-/- mice. 
Finally, we demonstrated profound Fus1-dependent basal and 
asbestos-induced changes in major mitochondrial parameters 
(ROS production, mitochondrial potential, and UCP2 expression) 
in Fus1-/- immune cells and in Fus1-depleted cancer cells, thus 
confirming our hypothesis that Fus1 may establish its immune 
and tumor suppressive activities via regulation of mitochondrial 
homeostasis.
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P2.31: THE EFFECT OF GENDER ON RADIATION-INDUCED ACUTE 
LUNG INJURY IN A RAT MODEL
Zafer Kocak1, Burcu U. Bilal1, Rusen Cosar1, Semsi Altaner2, 
Alaattin Ozen1, Funda Cukurcayir1  
1Radiation Oncology, Trakya University Faculty Of Medicine, Edirne/
TURKEY, 2Pathology, Trakya University Faculty Of Medicine, Edirne/TURKEY
Background: There are very few studies investigating of sex-
specific differences in acute and late toxicity after radiotherapy 
in the literature. Our aim was to evaluate the effect of gender-
related difference on acute lung injury induced by radiation (RT) 
in male and female Wistar rats. 
Methods: Forty Wistar rats (Twenty male and twenty female) 
were divided into following groups: (1) control male - sham 
RT; (2) RT-male; (3) control female - sham RT; (4) RT-female. 
Radiation was delivered on a Linac unit using a single fraction 
of 10 Gy through an anterior portal covering the right lung in 
entirety. The rats underwent euthanasia at 6 weeks following 
radiation. The lungs were dissected and histopathological 
evaluation was performed. 
Results and Conclusion: The development of RT-induced 
changes was statistically higher in the RT-male and RT-female 
groups as compared to the control groups (RT-induced 
pneumonitis: RT-male and control male, p=0.004, RT-female 
and control female, p=0.01; Vasculitis: RT-male and control 
male, p=0.009, RT-female and control female, p=0.08). 
No significant difference between RT-male group and RT-
female group was detected in the development of RT-induced 
pneumonitis (60% vs. 50%, respectively, p=0.66) and vasculitis 
(80% vs. 70%, respectively, p=0.61).The data suggest that there 
are no gender-related differences in radiation-induced acute 
effects in the lung tissues of male and female rats. However, 
we believe that additional work is needed to better identify the 
influence of sex on RT-induced normal tissue injury. 
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P2.32: EGFR AND K-RAS MUTATIONS IN FIXED AND FRESH 
SPECIMENS FROM TRANSESOPHAGEAL ULTRASOUND-GUIDED 
FINE NEEDLE ASPIRATION (EUS-FNA) IN NSCLC PATIENTS
Paola Ulivi1, Micaela Romagnoli2, Elisa Chiadini1, Gian Luca 
Casoni2, Laura Capelli1, Carlo Gurioli2, Luca Saragoni3, 
Alessandra Dubini3, Dino Amadori4, Venerino Poletti2, Wainer 
Zoli1  
1Biosciences Laboratory, I.R.S.T., Meldola/ITALY, 2Thoracic Diseases, 
Morgagni-Pierantoni Hospital, Forlì/ITALY, 3Pathology Unit, Morgagni-
Pierantoni Hospital, Forlì/ITALY, 4Medical Oncology, I.R.S.T., Meldola/ITALY
Background: In Non Small Cell Lung Cancer (NSCLC) patients, 
somatic EGFR and k-ras mutations predict therapeutic 
effectiveness and resistance, respectively, to EGFR tyrosine 
kinase inhibitors (TKIs). Transesophageal ultrasound-guided 
fine needle aspiration (EUS-FNA) is a validated technique 
for diagnosis and staging of NSCLC. In the present study we 
compare the feasibility and reliability of EGFR and K-ras gene 
mutation analysis in fixed and fresh mediastinal lymph nodes 
and extra-lymphonodal samples obtained by EUS-FNA in 
patients suspicious for NSCLC. 
Methods: Thirty-six patients were selected for the EUS-FNA 
procedure. A rapid on-site cytological examination (ROSE) 
was performed to assess the suitability of the sample. When 
a sample was identified as metastatic at ROSE examination, 
fresh material was collected in hypertonic solution (9%) and 
sent for molecular analysis. When possible, a sample obtained 
from metastatic nodes was processed as a histology core 
(cell block). Fixed and stained cytological smears, which had 
undergone selection of the tumor cells, were also sent for 
molecular analysis. For each patient, DNA was extracted from 
both fresh samples and fixed cytological smears. Exons 18, 19, 
20 and 21 of EGFR and exon 2 of K-ras were amplified by PCR 
and mutation status was determined by direct sequencing and 
pyrosequencing analyses.
Results and Conclusion: All cases were eligible for analysis. 
NSCLC was diagnosed in 32 patients (25 adenocarcinomas 
and 7 squamous cell carcinomas) and 4 patients were free of 
malignancy. Of the 25 patients with adenocarcinoma, EGFR 
mutations were detected in 2 (8%) fresh tumor samples and in 
3 (12%) fixed cytological smears. K-ras mutations were detected 
in 8 (32%) fresh samples, and in 9 (36%) fixed cytological 
smears. In conclusion we have demonstrated that EUS/FNA 
samples are suitable to define tumor EGFR and K-ras mutation 
profiles aimed at a personalized treatment, and that the 
accurate selection and cleaning of tumoral cells is mandatory for 
an accurate analysis. To this purpose, fixed and stained samples 
are more reliable than fresh materials. 
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P2.33: POTENTIAL LOSS OF P53/P21 FUNCTION IN A MURINE 
LUNG ADENOCARCINOMA CELL LINE PREVENTS TGFβ1-
INDUCED DORMANCY DESPITE P38α/β ACTIVATION AND DEC2 
AND P27 INDUCTION
Maria Jose Carlini1, Paloma Bragado2, Paula F. Vazquez1, Elisa D. 
Bal De Kier Joffe1, Lydia I. Puricelli1, Julio Aguirre Ghiso2  
1Research Area - Cell Biology, Institute Of Oncology “Angel H. Roffo”, 
Buenos Aires/ARGENTINA, 2Department Of Medicine And Department 
Of Otolaryngology, Mount Sinai School Of Medicine, New York/UNITED 
STATES OF AMERICA
Background: Disseminated tumor cells can reside in target 
organs in a state of dormancy for prolonged periods before 
developing into overt lesions. Studies using the HEp3 model of 
head and neck squamous cell carcinoma (HNSCC) showed that 
a low ERK:p38 signaling ratio predicts for cellular dormancy. 
Further, p38 activation induces the expression of p53 and 
the tumor/metastasis suppressor BHLHB3/DEC2. Also, p53 
and DEC2 are positively regulated by transforming growth 
factor beta (TGFβ). Preliminary data studying the murine lung 
adenocarcinoma cell line LP07 suggested that TGFβ1 can only 
delay primary tumor growth with no effect on spontaneous 
metastasis development. This motivated us to test whether the 
effects of TGFβ1 signaling in this model might be short-circuited 
to prevent the activation of a tumor cell dormancy program as 
that described in HNSCC. 
Methods: TGFβ1 (4ng/ml), an inhibitor of TGFβ-receptor kinase 
activity (TβR inhibitor, 2µM) or a MEK1 inhibitor (10µM) were 
used for LP07 cell treatment. In overexpression experiments, 
constructs containing DEC2, a constitutive active mutant of p38 
(p38CA), or p53 were employed. Cell proliferation was assessed 
in vitro by manual cell counting and cell cycle distribution 
analysis; and in vivo by evaluating tumor growth. DEC2 mRNA 
expression was assessed by qPCR. Expression of downstream 
effectors of TGFβ1 and cell cycle regulatory proteins were 
assessed by western blot. 
Results and Conclusion: TGFβ1 mediated arrest in G0/G1 
phase of the cell cycle in LP07 cells, which was consistent with 
p27 upregulation. Concomitantly, TGFβ1 activated Smad2/3 
and inhibited proliferation, all these events blocked by a TβR 
inhibitor. Consistent with these data, LP07 cells exhibited a 
high ERK:p38 ratio that was lowered by TGFβ1, primarily due 
to a strong p38 activation. Accordingly, we observed in vivo 
growth inhibition of TGFβ1-pretreated cells upon subcutaneous 
implantation in syngeneic BALB/c mice. However, sustained 
in vivo growth arrest was not observed. We also found an 
increased level of DEC2 mRNA in TGFβ1-treated cells. LP07 cells 
overexpressing DEC2 or p38CA had increased p27 expression, 
suggesting that the p38->DEC2 pathway can be re-activated. 
Upon treatment of the cells with a MEK1 inhibitor, p27 was also 
upregulated and phospho-histone-H3 was downregulated. p53 
and p21 were refractory to modulation by these treatments, 
even following overexpression of p53. This suggests that 
p53 function might be disrupted and/or that p21 may be 
epigenetically silenced in this cell line. In conclusion, we have 
found that the LP07 cell line displays an ERK/p38 ratio and 
downstream signaling that predict for an efficient escape 
from dormancy. While the p38->DEC2-p27 pathway could be 
restored by establishing a low ERK/p38 signaling ratio, absence 
of functional p53 and p21 induction most likely explains why 
TGFβ1 only attenuates tumor growth. If p53 and p21 (also a 
target of DEC2) are silenced by DNA promoter methylation it is 
possible that restoration of p21 promoter sensitivity to DEC2 
using 5-Aza-C may allow for reprogramming LP07 cells into a 
prolonged dormant state.
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P2.34: ALTERED MRNAS EXPRESSION OF GENES INVOLVED IN 
CELLULAR IRON HOMEOSTASIS IN LUNG NON SMALL CELLS 
CARCINOMA
Marco Lo Iacono, Antonella Roetto, Valentina Monica, Martina 
Boero, Tiziana Vavalà, Silvia Saviozzi, Enrico Bracco, Silvia 
Novello, Mauro Papotti, Giorgio V. Scagliotti  
Clinical & Biological Sciences, University Of Turin, Orbassano/ITALY
Background: Iron is an essential element for cell proliferation 
and cell metabolism. The high proliferative rates in malignant 
cells are characterized by an increased requirement for iron. 
Recent study shows the association between tumors and 
altered cellular iron homeostasis. The transferrin receptor 
type 1 (TFRC), expressed on the cytoplasmatic membrane of 
human cells, is thought to play a crucial role in the control of 
cell growth mediated by iron. Abnormal expression of TFRC was 
identify in several tumors types, as carcinomas, sarcomas and 
some lymphomas and leukaemias. Furthermore, a correlation 
between lower intracellular iron content, due to decreased iron 
intake or high iron export, and patients favorable prognosis 
was recently identified in breast cancer. The purpose of the 
present study was to investigate the expression of some 
genes involved in cellular iron homeostasis in lung non small 
cells carcinoma (NSCLC) library. TFRC gene, that codifies for a 
protein involved in tranferrin dependent iron import, SLC40A1 
gene, that codifies for the only known iron exporter, and FTL, 
that produces the main intracellular iron storage protein were 
analyzed. Moreover, the correlation between these genes 
expression and clinico-pathological factors were performed. 
Methods: A real-time PCR analysis on matched cancer and 
corresponding normal tissues from 78 surgically resected 
patients has been performed. Expression levels of SLC40A1, 
TFRC, FTL and ESD as reference gene, were evaluated via SYBR 
technology with ABI PRISM 7900HT Sequence Detection System 
using specific primers. 
Results and Conclusion: TFRC & SLC40A1 genes modulation 
were significantly dysregulated in lung tumors respect to 
matched normal tissues. In particular, TFRC was up- (p=0.01, 
mean log2(FC)=1.07) while SLC40A1 was down-modulated 
(p=0.001, mean log2(FC)=-1.1). Moreover, TFRC up-modulation 
was significantly associated with moderately and poorly 
differentiated lung cancers (p=0.01), squamous carcinomas 
(p<<0.01) and in active smokers/early formers (p=0.03). No 
correlations with patients survival rate were identified. FTL was 
expressed at high levels respect of the other mRNAs evaluated 
in both tumors and normal lung tissues, its down-modulation 
in tumor samples was associated to squamous tumor subtype 
(p=0.02). Down modulation of FTL under log2(FC) -1 was 
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associated with poor patients prognosis (p=0.01) and it 
resulted to be an independent prognostic factor for patients 
overall survival (HR=2.5; 95% CI, 1.20 to 5.3, p=0.01). These 
results indicate that transcription alteration of genes involved 
in cellular iron homeostasis occurs in lung cancers and that it 
could contribute to the carcinogenesis and de-differentiation of 
lung cancers. Furthermore, the discrepancies identified for the 
expression of some genes between the lung tumors subtypes 
could reflect differences in cellular iron intake and could be 
useful to better define the molecular differences between lung 
cancer subtypes and/or to develop future patients personalized 
therapy. 
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P2.35: ROS1 FUSION GENES: POTENTIAL DRUG TARGETS IN 
NON-SMALL CELL LUNG CANCER
Kurtis D. Davies1, Anh T. Le1, Mariana F. Theodoro1, Margaret 
C. Skokan1, Dara L. Aisner2, Luigi M. Terracciano3, Matteo 
Incarbone4, Massimo Roncalli4, Federico Cappuzzo5, Ross D. 
Camidge1, Robert C. Doebele1, Marileila V. Garcia1  
1University Of Colorado School Of Medicine, Department Of Medicine, 
Aurora/UNITED STATES OF AMERICA, 2University Of Colorado School 
Of Medicine, Department Of Pathology/UNITED STATES OF AMERICA, 
3University Hospital Basel/SWITZERLAND, 4Istituto Clinico Humanitas, 
Rozzano, Italy/ITALY, 5Livorno Hospital, Livorno/ITALY
Background: Genomic rearrangements that fuse kinase 
domain-containing 3’ regions of tyrosine kinase genes with 
5’ regions of unrelated genes are well characterized in cancer. 
The resulting fusion proteins often drive proliferation and 
invasion of tumor cells and thus represent attractive targets 
for therapeutic intervention. One such kinase that has been 
demonstrated to be involved in various genomic rearrangement 
events in non-small cell lung cancer (NSCLC), glioblastoma, 
and cholangiocarcinoma is the ROS1 receptor tyrosine kinase. 
To date, seven different 5’ fusion partners for ROS1 have been 
identified.
Methods: In this study, we examined the frequency of ROS1 
gene rearrangement in a panel of 428 patient-derived NSCLC 
tumor samples using a break-apart FISH assay.
Results and Conclusion: We found that approximately 1.2% 
of samples were positive. In positive samples, the expression 
of the fusion gene and the identity of the fusion partner 
were examined. HCC78 is a NSCLC cell line that has been 
demonstrated by us and others to express the SLC34A2-ROS1 
gene fusion. In order to assess the cellular consequences of 
ROS1 inhibition, we treated HCC78 cells with two distinct small 
molecule kinase inhibitors that have activity against ROS1 
(crizotinib and TAE684). We found that both drugs inhibited 
proliferation of HCC78 cells, down-regulated signaling pathways 
known to control cellular growth and survival, and disrupted 
normal cell-cycle progression. Finally, we report clinical data 
from a NSCLC patient with a ROS1 gene rearrangement who 
demonstrated tumor shrinkage when treated with crizotinib. 
This patient’s tumor expressed the recently identified SDC4-
ROS1 fusion. In conclusion, genomic rearrangements involving 
the ROS1 receptor tyrosine kinase are present in a subset of 
NSCLC patients and drugs that target ROS1 may be an effective 
treatment strategy for these patients.
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P2.36: INTRAOPERATIVE BRONCHOSCOPIC COIL-MARKING, 
USING VIRTUAL BRONCHOSCOPIC NAVIGATION WITH 
ENDBRONCHIAL ULTRASOUND TO FACILITATE SMALL 
PERIPHERAL PULMONARY NODULE RESECTION
Masafumi Misawa1, Motoji Fukasawa2, Masaru Abe2, Hideki 
Makino1, Masahiro Aoshima1, Akihiko Takeshi2  
1Pulmonary Department, Kameda Medical Center, Kamogawa-city/JAPAN, 
2Thoracic Surgery Department, Kameda Medical Center/JAPAN
Background: In thoracoscopic surgery, the identification of a 
lesion during the operation is important. It had been reported 
that the lesions that have diameters of <10 mm and that are 
>5 mm from the pleura were very difficult to thoracoscopically 
detected. To facilitate marking and to reduce its complications, 
we performed thin bronchoscopic coil-marking using virtual 
bronchoscopic navigation (VBN) with endbronchial ultrasound 
before fluoroscopy-assisted thoracoscopic surgery for small 
pulmonary peripheral lesions. We then evaluated the feasibility, 
safety, and efficacy of this technique. 
Methods: Enrolled all subjects were consecutive patients with 
small pulmonary peripheral lesions (<15 mm) showing a CT 
scan-confirmed ground-glass opacity pattern who were referred 
to Kameda Medical Center for thoracoscopic surgery between 
June 2011 and March 2012. VB images to the planned marking 
sites near each lesion were produced from helical CT scan data. 
Based on these images, a thin bronchoscope was advanced to 
the target bronchus as far as possible in this pathway. Radial 
EBUS (R-EBUS) probe was then advanced to the target lesion 
under radiologic fluoroscopy guidance. After visualization of 
the lesion by R-EBUS, the probe was removed leaving the guide 
sheath in place, and platinum vascular coil was pushed to the 
target by guidewire and indwelling under fluoroscopy-assisted. 
Results and Conclusion: Our study included 4 patients (4 
females) with 4 lesions, mean age 69 years. The mean lesion 
size was 11.8mm in diameter. Pathologic studies revealed 
primary lung cancer in all lesions (papillary adenocarcinoma; 
1, bronchioloalveolar adenocarcinoma; 3), the bronchial 
branching patterns seen in VB images were highly consistent 
with those confirmed using the bronchoscope. Therefore, thin 
or ultrathin bronchoscope could be guided to a median of 
the fifth generation bronchi (range, fourth to sixth generation 
bronchi) toward the planned marking sites. Marking was 
achieved without causing complications in any of the patients. 
The median shortest distance between the coil-marker and 
the lesion was 3mm (within 5 mm in 4 lesions). In patients 
undergoing thoracoscopic surgery, all coil-marked sites were 
identified by intraoperative radiographic fluoroscopy, and all 
lesions were resected. This method can be readily performed 
without complications and is a useful marking method before 
fluoroscopy-assisted thoracoscopic surgery for small pulmonary 
peripheral lesions showing a CT scan-confirmed ground-glass 
opacity pattern. 
Disclosure: No significant relationships.
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P2.37: STENTING OF UPPER AIRWAYS IN PATIENTS WITH 
PRIMARY AND RECURRENT LUNG CANCER
Vladimir Anikin 
Thoracic Surgery, The Royal Brompton And Harefield Hospital Nhs 
Foundation Trust, Harefield Hospital, London/UNITED KINGDOM
Background: To evaluate the effectiveness of upper airway 
stenting in patients with primary and recurrent lung cancer. 
Methods: From May 2007 to March 2012 31 patients (15 males, 
mean age 67±10.6 years) with primary (27) and recurrent (4) 
lung cancer (NSCLC – in 25, small cell – in 4, other - in 2) 
had 33 episodes of upper airway stenting (Ultraflex, Boston 
Scientific) under GA with fluoroscopic control as part of 
oncological treatment. There were 18 unilateral (right – in 8, 
left – in 10), 7 – tracheal, 2 - tracheobronchial and 6 – bilateral 
procedures. Covered stents were used 5 times only. Seven 
patients had a concomitant procedure (chest drain insertion – in 
2, cryotherapy – in 2, empyema drainage – in 1, pleural biopsy – 
in 1 and oesophageal stent insertion – in 1) under the same GA. 
On 11 occasions the procedure was elective, on 19 urgent and 3 
times it was an emergency. 
Results and Conclusion: There was no intra-operative 
mortality. Two (6.4%) patients died in hospital prior to 
discharge, 19 discharged home and 12 were transferred to 
another hospital. Four patients required stent replacement or 
insertion of an additional stent during the follow up period. 
Tumour debulking with cryotherapy was required in 5 patients 
after stenting. Hospital stay ranged from 1 to 17 (mean – 4.2, 
median – 2) days. Hospital stay in patients with concomitant 
procedure ranged from 1 to 17 (mean – 7.8, median – 5) days. 
Total survival ranged from 2 to 590 (median – 55) days, in 
primary cancer subgroup – from 2 to 332 (median – 57) and in 
the recurrent subgroup – from 19 to 590 (median – 48) days. 
In urgent and emergency groups survival ranged from 2 to 332 
(median 54) and in the elective group – from 8 to 590 (median 
– 97) days. Survival in patients with concomitant procedure 
ranged from 14 to 453 (median – 55) and without concomitant 
procedure from 2 to 590 (median – 55) days. All patients 
reported significant improvement of distressing symptoms. 
Upper airway stenting is a rapid and effective technique of 
palliation in patients with tracheobronchial stenosis caused by 
primary and recurrent lung cancer. Survival is better in patients 
with elective endobronchial stent insertion. Concomitant 
procedure does not adversely influence survival. Stent occlusion 
may be controlled by repeat stenting or endobronchial 
cryotherapy. 
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P2.38: 18[F] FDG- PET/CT FUSIONS IMAGING IS SUPERIOR, 
CRYSTAL CLEAR AND PREDICTS SURVIVAL OF LUNG CANCER 
PATIENTS
Karan S. Peepre 
Nuclear Medicine Division,Radiotherapy Department, Gandhi Medical 
College, Bhopal/INDIA
Background: Lung cancer is the leading cause of cancer-
related deaths in men and women worldwide. It is the most 
common malignancy and has the highest cancer related death 
rate. Non-small cell lung carcinoma (NSCLC) accounts for 80% 
of cases and small cell lung cancer (SCLC) accounts for the 
remaining 20%.Approximately 75% of SCLC cases presents 
with disseminated disease. Lung cancers most commonly 
metastasize to the lymph nodes, bone, brain, adrenal glands, 
and liver. Positron Emission Tomography and Computer 
Tomography with 18(F)-labeled Fluoro-deoxyglucose (18F-FDG 
PET/CT) plays a clear role in lung cancer management. PET/CT 
is increasingly used in the diagnosis, staging and monitoring 
response to treatment. Evaluation of response to treatment 
include the clinical response for example; symptom reduction, 
improved quality of life, disease-free survival, progression-free 
survival, and overall survival, and imaging response with  
PET/CT. 
Methods: During the study period, 20 cases of lung cancer, 16 
(80%) male and 4 (20%) female with age ranges from 26 to 71 
years, were included and evaluated by PET/ CT. All the cases 
were diagnosed radiological and histopathologically,prior to this 
study. A standard dose of 10 mCi [370MBq] IV 18(F) FDG was 
injected to patients and after one hour, patients were taken 
for CT and PET examination. The SUVMax: > 2.5 is considered 
metabolically active.All the investigation(PET/CT) were reviewed 
in detail.
Results and Conclusion: The findings of PET / CT were 
reviewed and compared with other imaging (CT / MRI) and 
medical records, etc. During the interpretation of the PET/CT 
images, the findings were a focus / foci of markedly increased 
FDG uptakes in lung and metastasis in lymph nodes, brain, 
bones and adrenal glands. Of 20 cases, 15 (75%) were positive 
for primary cancer and metastasis in other organs, 5 (25%) 
were found normal in PET/CT. The organs involved in distant 
metastasis (n=15) in order of frequency were lymph nodes 6 
(40%), bone 3(20%), adrenal glands 3 (20%), pleural effusion 
1 (6.66%), liver 1 (6.66%), and lung metastasis in 1 (6.66%). 
13 of 15 of our patient had multiple organ involvements. 
PET/CT is superior, crystal clear and useful imaging method 
which predicts survival of lung cancer patients. It is useful for 
detecting lung cancers and distant metastases and contributes 
to a more accurate staging. 
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P2.39: THE SYMPTOM MANAGEMENT MODEL(SMS) TOOL 
FOR PREDICTION AND ASSESSMENT OF CERTAIN SYMPTOMS 
THAT AFFECT QUALITY OF LIFE OF PATIENTS WITH SMALL 
AND NON SMALL CELL LUNG CANCER CANDIDATES FOR 
RADIOCHEMOTHERAPY
Francesco Buda1, Oreste Bergamo2, Laura Pagani3, Giovanna 
Maria Celeste Massina4  
1Internal Medicine - Medical Oncology, City Of Udine Hospital, Udine/
ITALY, 2Dpt Internal Medicine-Service Of Pneumology And Respiratory 
Pathophysiology, Citi Of Udine Hospital, Udine/ITALY, 3Statistical Sciences, 
University Of Udine, Udine/ITALY, 4Oncologic Radiotherapy, University Of 
Messina, Messina/ITALY
Background: The communication of the diagnosis of cancer 
S148 Copyright © 2012 by the International Association for the Study of Lung Cancer
LALCA 2012 Abstracts Journal of Thoracic Oncology  •  Volume 7, Number 7, Supplement 2, July 2012
has a devastating impact on QL of the patient worsens in stages 
during treatment,stage of disease and the prospect of life and 
this is evident in patients with lung cancer.Therefore,predict and 
understand these factors.is fundamental to the team in order to 
implement care interventions and targeted support. 
Methods: The Symptom Management Model(SMM)was applied 
as the conceptual framework of the study, from December 
2007 - March 2011 after information and written informed 
consent,acceded to the study 40 patients(34 men, 6 women) 
mean age 64,2 years(±SD 6.42),median 64 years)with small 
and non small cell lung cancer(histologically confirmed and 
clinically staged)candidates for radiochemotherapy under 
the DH.To pts were delivered to the following evaluation 
questions:4DSQ,FACIT,VAPS,HAM-D,BSDS and IBCSG-QL.All 
questionnaires were completed and delivered.The data were 
analyzed with statistical methods using Stepwise Regression 
Statistic(SRS). 
Results and Conclusion: The predictive power was 82% 
of the variance(p<.01) indicating that the SMM is a useful 
guide for explaining and predicting quality of life of patients 
with lung cancer and for the clinical stage,are subjected to 
radiochemotherapy. The findings revealed that the mean 
scores of QL(X=66.43)was at the moderate level; significantly 
predictors were depression (p<.01), sleep disturbance (p<.01), 
fatigue(p<.01) and stage of disease (p<.01). Conclusion: 
pain,fatigue,and depression are complex affective,sensory,and 
cognitive phenomena and all of these symptoms, as well as 
sleep disturbances, are also in this type of patients known 
with lung cancer undergoing radiochemotherapy. Our results 
indicate that the questionnaires is a useful guide to explain 
and predict depression, sleep disturbance,fatigue and disease 
stage,parameters that would significantly QL
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P2.40: INCIDENCE OF PAIN IN CA. LUNG PATIENTS REFERRED TO 
PALLIATIVE CARE
Lingegowda K. Boregowda 
Palliative Medicine, Kidwai Memorial Institute Of Oncology, Bangalore/
INDIA
Background: Lung cancer being the major cancer in Men in 
the world, in developing country like India Ca. Lung constitutes 
7.1%(Men) and 2%(Women). Still majority of our patients 
present to hospital in an advanced stage. More than 80%will be 
having pain in this stage and they need only palliative care as 
there is no role for curative treatment.
Methods: METHOD: 446 patients were screened who were 
referred to palliative care department over a period of 3 months 
from all the departments. Total 38 patients with diagnosis of 
Ca. lung were referred from Surgical and Medical oncology.
Results and Conclusion: Results: 90% of patients had pain 
at the time of reporting to palliative care centre. Conclusion: 
Routine referral to Palliative care centre from the day of 
diagnosis solve many problems in ca Lung patients. Early 
referral will improve patients comfort from pain.
Disclosure: No significant relationships.
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P2.41: THE EFFICACY OF CT GUIDED PERCUTANEOUS 
CRYOABLATION IN LUNG CANCER
Lizhi Niu, Lihua He, Liang Zhou, Feng Mu, Haibo Li, Kecheng Xu  
Fuda Cancer Hospital, Guangzhou/CHINA
Background: Lung cancer has been the commonest cause 
of cancer death, with a very poor survival rate. By the time 
of diagnosis, most cases are at an advanced stage. In recent 
years, little progress has been in improving the quality of life 
of patients with advanced lung cancer. This has added to the 
importance of alleviating the symptoms and improving quality 
of life for patients with advanced stage, inoperable patients. 
While the possiblity of surgery has been limited, the other 
palliative measures must be considered.
Methods: From Jan 2002 to Apr 2006, 816 patients(568 male 
and 248 female) at an median age of 64±1.2 years old(range 
from 12 to 95 years old) with primary or metastatic lung cancer 
were treated with cryoablation, including 685 patients with 
primary lung cancer with 46 patients in stage I, 137 in stage II, 
296 in stage III and 206 in stage IV (small cell lung cancer n=51, 
non small cell lung cancer n=634, squamous carcinoma n=310, 
adenocarcinoma n=265, undifferentiated carcinoma n=40, 
alveolar cell carcinoma n=19) and 131 patients with metastatic 
lung cancer(breast n=45, colon n=42, prostate n=11, bone n=8, 
sarcoma n=2).. A total of 1139 cryoablations were done for 1014 
lesions, which with mean diameter of 6.3±0.4 cm (ranged from 
1.0 to 25.0cm). Cryocare Surgical System (CRYO-20 type) and 
cryo-probes with 1.7 mm or 2.0 mm in diameter were used in 
the present study. According to the size, shape and location 
of the lesion, 2-8 cryo-probes were inserted as following: 1-2 
cryo-probes for the tumor smaller than 2 cm in diameter, 2-4 
cryo-probes for tumor with 2-4 cm in diameter, and 5-8 cryo-
probes for tumor up to 5 cm or more. Freeze-thaw cycle was 
set as 15 min of freezing at -140±10oC with argon and 5 min of 
thawing at 15±5oC with helium. Three freeze-thaw cycles were 
performed during each cryoablation. Recheck CT or PET/CT 
and reappraise Karnofsky Performance Status (KPS) every 1-3 
monthes, and followed up every 3 months.
Results and Conclusion: There were 1006 lesions (68.3%) 
decreased in size, and with mean size reducing from 4.7±0.3 
cm to 3.5±0.4 cm in diameter, (CR+PR+SD) 91.2%. Tumor 
activity of all lesions decreased or deactivated. Paitents 
showed obvious improvement after treatment, with Karnofsky 
Performance Status (KPS) rising form 77.8±9.3 to 85.92±7.8 
(t=4.368, P=0.000). Among 202 patients with peripheral lung 
cancer and chest wall invasion who complained chest pain pre-
cryoablation, 40 patients (19.8%) showed complete pain relief 
after cryoablation and 124 patients (61.4%) showed partially 
pain relief, respectively. The overall survival rates were 70.2%% 
for 1-year and 54.1% for 2-year. The 1-year survival rate were 
100.0%, 93.5%, 84.1%, 57.6% and 49.0%, and 2-year survival 
rate were 100.00%, 81.36%, 71.27%, 48.19% and 38.48% 
for patients in stage I, stage II, stage III and stage IV of primary 
lung cancer and metastatic lung cancer, respectively. CT guided 
cryoablation showed some efficacy in controlling the progress 
of lung cancer and may contribute to pain relief and prolong 
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survival for lung cancer patients. KEYWORDS: Cryoablation, 
lung cancer, CT-guided, efficacy
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P2.42: ENOBOSARM IMPROVES PHYSICAL FUNCTION IN 
CANCER PATIENTS WITH < OR ≥ 5% WEIGHT LOSS IN A PHASE 
IIB TRIAL
Shontelle T. Dodson, Mary A. Johnston, Michael Hancock, 
Mitchell S. Steiner  
Gtx, Inc., Memphis/UNITED STATES OF AMERICA
Background: Although cachexia has been defined as >5% 
weight loss, limited data exists on the prevention and treatment 
of muscle wasting prior to a patient becoming cachectic. Cancer 
induced muscle wasting can begin early in the course of a 
patient’s malignancy resulting in decline in physical function 
and other detrimental clinical consequences including less 
tolerability to chemotherapy, worse outcomes, and shorter 
survival - underscoring the importance of diagnosing and 
treating this condition at an early stage. 
Methods: We conducted a randomized, double blind, placebo 
controlled, multi-center study to evaluate the effect of 
enobosarm on physical function and muscle wasting in cancer 
patients. Subjects (n=159) were randomized to oral enobosarm 
or placebo for 16 weeks. Subjects were males >45y and 
postmenopausal females, with ≥2% weight loss in the 6 months 
prior to randomization and diagnosed with NSCLC, colorectal 
cancer, non-Hodgkin’s lymphoma, chronic lymphocytic 
leukemia or breast cancer. We report on changes in physical 
function based on weight loss of < or ≥5% in the 6 months prior 
to randomization.
Results and Conclusion: Results: 103 subjects (MITT) had 
physical function assessed by stair climb at baseline and week 
16 with 24% losing <5% weight in the previous 6 months. 
Distribution of weight loss was similar across genders, however 
subjects with <5% weight loss were more likely to be ECOG=0 
(<5% loss: 46.2%; ≥5% loss: 35.8%). Subjects with ≥5% 
weight loss had worse physical function at baseline compared 
to those with <5% loss (P=0.048). A significant improvement 
in physical function was observed in subjects that received 
enobosarm regardless of baseline weight loss (<5% loss, 
P=0.041, ≥5% loss, P<0.001) while subjects that received 
placebo failed to improve. Conclusions: Enobosarm was 
generally well tolerated and showed a statistically significant 
improvement in physical function in cancer subjects regardless 
of baseline weight loss. These data provide evidence that 
enobosarm may play an important role in the management of 
cancer patients by not only treating, but also preventing further 
decline in physical function and muscle wasting before a patient 
becomes cachectic. 
Disclosure: I am an employee of GTx, Inc.
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P2.43: IN A PHASE IIB TRIAL IN CANCER PATIENTS WITH MUSCLE 
WASTING, ENOBOSARM IMPROVES PHYSICAL FUNCTION IN 
BOTH HYPOGONADAL AND EUGONADAL SUBJECTS
Shontelle T. Dodson1, Adrian Dobs2, Mary A. Johnston1, Michael 
Hancock1, Ronald A. Morton1, Mitchell S. Steiner1  
1Gtx, Inc., Memphis/UNITED STATES OF AMERICA, 2School Of Medicine 
Division Of Endocrinology And Metabolis, Johns Hopkins University, 
Baltimore/UNITED STATES OF AMERICA
Background: Hypogonadism has been associated with weight 
loss and poor outcomes in cancer patients. Up to 50% of males 
with advanced cancer are hypogonadal at presentation or 
during the course of treatment. Wasting in cancer patients has 
also been associated with a decline in physical function and 
performance status and has major public health significance. 
We conducted a Phase IIb, randomized, double blind, placebo 
controlled, multi-center study to evaluate the effect of 
enobosarm on muscle wasting and physical function in cancer 
patients. 
Methods: Patients (n=159) were randomized to oral enobosarm 
(1 or 3 mg) or placebo daily for 16 wks. Patients were males 
>45 y and postmenopausal females, had ≥2% weight loss 
in the 6 mths prior to randomization, BMI <35 and either 
NSCLC, colorectal cancer, non-Hodgkin’s lymphoma, chronic 
lymphocytic leukemia or breast cancer. We report on the 
incidence and impact of hypogonadism (T<300 ng/dL) in this 
population. 
Results and Conclusion: Baseline testosterone levels were 
available for 93 of 103 men. 60% of male patients were 
hypogonadal at randomization. Distribution of hypogonadism 
was similar across cancers; however hypogonadal men were 
less likely to complete the study. Baseline T levels were 
positively correlated with weight loss (r=0.32, P=0.002,) with 
hypogonadal men demonstrating greater weight loss in the 
previous six months (median, -9.5%). Baseline physical function 
as measured by stair climb power was higher among eugonadal 
males compared to hypogonadal males (84.5 watts vs 70.6 
watts; P=0.016). Enobosarm significantly improved physical 
function in this population regardless of baseline gonadal status 
(hypogonadal: 18.7%, P=0.0061; eugonadal: 13.2%, P=0.0032). 
The magnitude of improvement was greater in hypogonadal 
men. Conclusions Hypogonadism is common in male cancer 
patients and is correlated with weight loss and diminished 
physical function. In this randomized, placebo controlled trial, 
enobosarm improved physical function in both hypogonadal 
and eugonadal men despite poorer baseline physical function 
in hypogonadal patients. These data provide evidence that 
enobosarm may play an important role in the management of 
cancer related muscle wasting. 
Disclosure: I am an employee of GTx, Inc.
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P2.44: ASSESSMENT OF PAIN AND PULMONARY FUNCTION 
IN PATIENTS UNDERGOING THORACOTOMY BROAD AND 
MINIMALLY INVASIVE THORACOTOMY
Juliana D. Leandro1, Rogério Traballi2, Camila Guerra2, Tiaki 
Maki2, Adilson Antunes2  
1Fisioterapia, Unip, Sao Paulo/BRAZIL, 2Unip/BRAZIL
Background: In the diagnosis of lung tumors in common 
practice to total or partial resection of the lung tissue via 
thoracotomy in consist that large opening in the chest cavity 
for diagnostic or therapeutic purposes. However it is know 
that such a procedure because of the surgical procedure 
adopted, will cause acute pain and chronic long-term interfere 
significantly in their lung volumes and capacities. In order 
to prevent acute pain and respiratory change caused by 
thoracic interventions, new approaches are being practiced as 
thoracotomies minimally invasive. The advent of video-assisted 
surgery in the last two decades, the practice allowed access 
to the lower thoracic cavity resections and favored by many 
economic thoracotomies. This has reduced the incidence of 
postoperative pain and complications of lung function. AIM: 
the aim of this study was to compare pulmonary function and 
postoperative pain in patients undergoing thoracotomy broad 
and minimally invasive thoracotomy.
Methods: This study was conducted in a public hospital of São 
Paulo under the approval of the Ethics Committee in Research 
of Universidade Paulista- UNIP. Inclusion criteria were patients 
of both gender 45-65 years undergoing extensive thoracotomy 
and minimally invasive with a diagnosis of carcinoma of the 
lung base. For postoperative evaluation was used visual 
analogue scale (VAS) for pain and pulmonary function testing by 
spirometry on postoperative day 15.
Results and Conclusion: 15 days after the surgical procedures 
the patient underwent a minimally invasive thoracotomy were 
level of pain related to 2 and pulmonary functions test with 
14% reduction in forced vital capacity (FVC), 18% of forced 
expiratory volume in first second (FEV1) and 12% reduction 
in peak flow expiratory (PFE). Patients who underwent 
thoracotomy had ample level of pain equivalent to 6 with 32% 
reduction in FVC, 36%FEV1 and 28% en PFE. Both figures 
by visual analogue scale as well as the reduction shown by 
spirometry were statistically significant when compared 
between groups. CONCLUSION: Patients undergoing minimally 
invasive thoracotomies intensidde less pain in the postoperative 
period showed fewer change regarding their lung volumes and 
capacities. 
Disclosure: No significant relationships.
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P2.45: ASSESSMENT OF QUALITY OF LIFE IN PATIENTS 
WITH LUNGCANCER TREATED WITH CISPLATINUM-BASED 
CHEMOTERAPY: A PROSPECTIVE COHORT STUDY
Burcu Ozdemir1, Osman N. Hatipoglu2  
1Respiratory Medicine, Trakya University Faculty Of Medicine/TURKEY, 
2Respiratory Medicine, Trakya University Faculty Of Medicine, Edirne/TURKEY
Background: To assess the quality of life (QoL) over the 
chemotherapy cycles, patients’ survival, and a relationship 
between QoL and survival in patients with lung cancer given 
cisplatinum-based therapy. 
Methods: A total of 166 cases of lung cancer planned to get 
received cisplatinum-based regimen were enrolled into this 
prospective and cohort clinical study between March, 2004 
and September, 2006. Patients completed the Lung Cancer 
Symptom Scale (LCSS) at baseline and before each cycle. 
Adverse effects due to chemotherapy were scored according 
to the NCI CTC (National Cancer Institute Common Toxicity 
Criteria) after each cycle. Overall survival and days of hospital 
stay of all patients were recorded. 
Results and Conclusion: The mean baseline LCSS scores 
were 29.03 ± 19.72 in patients with non-small cell lung cancer 
(NSCLC, n=125) and 30.73 ± 22.66 in patients with small-cell 
lung cancer (SCLC, n=41) (p=0.80). In patients with NSCLC, no 
significant difference in the LCSS score between before and 
after each chemotherapy cycles was detected (p>0.05 for each 
cycles). In patients with SCLC, according to the assessment 
before 3rd cycle, the LCSS score improvement was detected 
significantly (p<0.05). The mean overall survival time was 
316 ± 25 days in patients with NSCLC and 415 ± 59 days in 
patients with SCLC. There was an association between the 
mean LCSS score and overall survival in patients with SCLC 
(p=0.00, r: 0.55) but this was not the case for patients with 
NSCLC (P=0.09, r: 0.12). The mean days of hospital stay was 
43 days (13.5 % of overall survival) for patients with NSCLC and 
47 days (11.3 % of overall survival) for patients with SCLC. The 
adverse events were observed in 6 (3.6%) patients. The most 
common side effects of chemotherapy were alopecia (96.7%), 
weakness (73.2%), nausea-vomiting (65.4%), and constipation 
(41.8%). The cisplatinum-based chemotherapy improve quality 
of life for patients with SCLC. However, for patients with NSCLC, 
chemotherapy may not have a positive effect on quality of 
life and larger studies are needed to assess the influence of 
chemotherapy on quality of life in this patients group. 
Disclosure: No significant relationships.
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P2.46: PATIENTS WITH LUNG CANCER PRESENTING WITH ACUTE 
ARTERIAL OCCLUSION
Turan Ege, Serhat Huseyin, Volkan Yuksel, Sahin Iscan, Ozcan 
Gur, Selami Gurkan, Suat Canbaz, Enver Duran  
Cardiovascular Surgery, Trakya University Faculty Of Medicine, Edirne/
TURKEY
Background: Although the close association between venous 
thromboembolism and malignancy established by research, 
there are only limited number of studies addressing the 
relationship between arterial embolism and malignancy. 
Furthermore, in the literature, very rare case of lung cancer 
presenting with acute arterial embolism have been reported. 
Here, we present our series of lung cancer presenting with 
acute arterial occlusion during the period of 13 years at our 
institution. 
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Methods: The patients who were operated for acute 
arterial occlusion between 1999 and 2012 were evaluated 
retrospectively. Doppler ultrasonography was performed in 
all patients presented with the symptoms of acute arterial 
occlusion, after the initial physical examination. Emergent 
surgery was performed as indicated. The patients who were 
diagnosed to have cancer at the time of the operation or during 
the follow up were identified. 
Results and Conclusion: In 883 patients who were operated 
for acute arterial occlusion, 33 patients (3.7%) were identified 
to have a malign neoplasm. Of these patients, 20 (69.6%) had 
a history of malignancy. For 13 patients (39.4%), acute arterial 
occlusion was the presenting sign of their malignant disease. Of 
these 13 patients, 5 had an arterial embolism occurring before 
the discovery of the lung primary. In these 5 patients, 4 of them 
had non-small cell lung cancer and 1 of them had small-cell lung 
cancer. Their age was varying from 60 to 84. All details of these 
5 patients will be presented and discussed. 
Disclosure: No significant relationships.
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P2.47: PHYSIOTHERAPY IN THE POSTOPERATIVE OF LUNG 
CANCER
Juliana D. Leandro, Tiaki Maki, Camila Guerra, Adilson Antunes, 
Rogério Traballi  
Fisioterapia, Unip, Sao Paulo/BRAZIL
Background: Lung cancer is a malign expansion and 
transformation of the lung tissue. It is the most lethal type of 
cancer in the whole world, responsible for 1,2 million deaths 
every year. Smoking habits are the main cause of the disease. 
The treatment depends specially on the type, “stage” and 
estadio (dispersion grade) of the cancer. Surgery, chemotherapy 
and radiotherapy are the most common treatments 
available. Usually after a lung surgery, patients are referred to 
physiotherapy practice in order to enhance the lung perfusion 
and ventilation ratio, conventionally with respiratory exercise 
support. OBJETIVE: To analyze the physiologic changes caused 
by respiratory exercise in patients submitted to segmentectomy 
for lung tumor 
Methods: 10 lung cancer patients with average age of 40 
years old were submitted to the protocol. PROCEDURE: Heart 
rate, respiratory rate and blood pressure were analyzed in all 
patients, before and after the application of the protocol. The 
protocol is based on the application of 5 sets of 10 repetitions 
of the following exercises: maximum inhalation held for six 
seconds, fractioned inhalation and exhalation. The results were 
statistically analyzed through test-t students. 
Results and Conclusion: The respiratory rate after the protocol 
decreased in 18,8% (from 19,6 ± 1,2 to 15,9 ± 1,5 rpm) (p < 
0,05), the heart rate had a non significative increase of 6,9% 
after the protocol (from 81,8 ± 5,0 to 87,5 ± 5,3 bpm) (p>0,05), 
the systolic blood pressure had a non significative increase of 
1,15% (from 130,5 ± 8,7 to 132 ± 9,8 mmHg) (p> 0,05) and the 
diastolic blood pressure had a non significative decrease of 
3,2% (from 76,5 ± 2,7 to 74 ± 2,6 mmHg) (p> 0.05). Conclusion 
The respiratory exercise when applied under a standard don’t 
present a significant interference on the vitals readings of a 
lung resected patient, however can be responsible for the 
adequation of the respiratory rate of those patients. 
Disclosure: No significant relationships.
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P2.48: SMOKING EFFECTS ON TOLERANCE TO PHYSICAL 
EXERCISE 
Juliana D. Leandro, Rogério Traballi  
Fisioterapia, Unip, Sao Paulo/BRAZIL
Background: Smoking is now worldwide considered a public 
health problem, which is responsible for the increased 
prevalence of lung cancer, chronic obstructive pulmonary 
diseases and coronary artery disease. Smoking is even more 
harmful when associated with a sedentary lifestyle, which is 
seen as a primary factor for cardiovascular disease. The six-
minute walk test is being used as an alternative to evaluate the 
physical capacity of patients with heart or lung disease. The 
test measures the distance a patient can walk on their own in a 
corridor for six minutes. Along with the test, the Borg scale was 
used, therefore the subjective perception of intensity of effort 
by the patient could be measured in numerical values (degree 
of fatigue), contributing greatly to the interpretation of results. 
OBJECTIVE: Investigate the effects on tolerance to physical 
exercise in sedentary young women. 
Methods: The evaluation of 40 sedentary women was divided 
into two groups: Control group (20 non-smokers) and Smoking 
group (20 smokers). Firstly, data was collected on respiratory 
rate, heart rate and blood pressure. In sequence, they took 
the six-minute walk test. Immediately after the test, the level 
of effort on the Borg scale was verified and the women were 
assessed again, according to the parameters mentioned above. 
The distance covered in the walking test was also measured. 
The data were analyzed using the “Student’s t test” 
Results and Conclusion: In the control group of nonsmokers, 
there was no statistically significant difference between the 
results of the pre-test and the test. Taking into consideration 
the distance traveled by these patients (628m), the difference 
was statistically greater than the distance traveled by the 
smoking group (536m). The smokers showed statistically 
significant difference for heart rate and respiratory rate in 
relation to its preliminary assessment. As for the Borg scale, 
this group had an average value of five, higher than the control 
group, whose average value was three. Conclusion After the six-
minute walk, there was a marked increase in respiratory rate, 
heart rate and feeling of tiredness in the smoking group. Also, 
the distance traveled by the smoking group was statistically 
lower than the distance traveled by the control group. 
Disclosure: No significant relationships.
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P2.49: HOW TO DISTINGUISH AN ACTIVE AIR LEAK FROM A 
PLEURAL SPACE EFFECT BY MEANS OF A DIGITAL CHEST DRAIN 
SYSTEM
Rita D.F. Marasco1, Cosimo Lequaglie2  
1Thoracic Surgery, I.R.C.C.S. - C.R.O.B. Basilicata Regional Cancer Institute, 
Rionero In Vulture/ITALY, 2Thoracic Surgery, I.R.C.C.S. - C.R.O.B., Rionero In 
Vulture/ITALY
Background: In this prospective study we aimed to recognize a 
pleural space effect, distinguishing it from an active air leak, by 
means of a digital chest drain system providing a continuous air 
flow and pleural pressures check.
Methods: Since March 2010 to October 2011, we employed 144 
digital drains for 125 patients undergone 138 thoracic surgical 
procedures.
Results and Conclusion: We observed: 18 active air leaks 
(12.5%), among which 4 prolonged (2.8%), all characterized 
by high differential pleural pressure, especially due to an 
increased mean expiratory pressure (>1 cmH2O) (p <0.0001), 
and significantly related to upper lobe resections (p: 0.00017), 
a chest tube removal time later than the fifth post-operative 
day (p <0.0001), an increasing pneumothorax after a one day 
provocative clamping (p <0.0001); three late air leaks (2.1%), 
all long lasting (p <0.0001), predicted by pressure curves 
divergency before the air flow appearance. Moreover, we 
reported 25 pleural space effects (17.4%), equally characterized 
by a high differential pleural pressure, but mainly due to a 
lower mean inspiratory pressure (<20 cmH2O) (p <0.0001), 
and especially related to surgical pleurodesis procedures (p: 
0.0003) and wide lung resections (p: 0.0002); none of these 
patients had an increasing pneumothorax after provocative 
clamping. Conclusions: A digital chest drain system ensuring a 
continuous air flow and pleural pressures measurement could 
clearly identify a pleural space effect, avoiding the frequent 
misinterpretation with an active air leak and allowing to safely 
remove a chest tube at the right time. 
Disclosure: No significant relationships.
Fig.1: Active air leak. The upper plot (yellow curve), showing air flows, clearly demonstrates an air leak; the lower plot, separately showing the expiratory 
pressure (“pe”, blue curve) and the inspiratory pressure (“pi”, azure curve), demonstrates an increasing pleural pressures span.
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Fig.2: Late air leak: a progressive pressure curves divergency anticipates 
the air leak appearance.In the lower plots we can observe an initial 
interspace between “pe” (blue curve) and “pi” (azure curve), then a 
pressure plateau, and finally a progressive curve divergency since the 2nd 
post-operative hour. a: the greenish-blue line illustrates the progressive 
increase of differential pressure (Δp=pe-pi) approximately from the 
2nd p.o. day.b: the yellow line shows air flows, revealing an air leakage 
reappearance, anticipated by the differential pressure increasing. 
Fig.3: a-b Pleural space effect: high differential pleural pressure without a 
significant air flow. In both illustrations, referring to a surgical pleurodesis, 
the lower plots separately show the expiratory (“pe”, blue curve) and 
inspiratory pressures (“pi”, azure curve), with a wide interspace. In “a”, 
the upper plot (greenish-blue line) summarizes a high differential pleural 
pressure (Δp=pe-pi). In “b”, the upper plot (yellow line) describes a 
sporadic, minimal air flow.
P2.49: 
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